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Abstract 
Cell adhesion molecules including leukocyte function associated antigen-1 (LFA-1) 
and intercellular adhesion molecule-1 (ICAM-1) play an important role in regulating 
inflammatory responses. For circulating leukocytes to enter inflamed tissue or 
peripheral lymphoid organs, the cells must adhere to and transmigrate between 
endothelial cells lining blood vessel wall by binding of LFA-1 on leukocytes to 
ICAM-1 on endothelial cells. In addition, interaction of LFA-1 expressed on T cells 
and ICAM-1 expressed on antigen presenting cells (APCs) is crucial for 
immunological synapse formation and hence T cell activation. Clustering of LFA-1 
and ICAM-1 by multivalent ligands increases binding avidity of these cell adhesion 
molecules. In this thesis, multivalent ICAM-1 or LFA-1 ligands were conjugated to 
the surface of polymeric nanoparticles (NPs) to target the clustering of these receptors 
and increase the avidity of binding to ICAM-1 or LFA-1. Polymeric nanoparticles 
possess some advantages over other multivalent ligands since drugs can be protected 
and released. This delivery system permits modification of the nanoparticle surface 
without compromising the activity of the drug carried.  
In chapter 2 of this thesis, a peptide ligand targeting ICAM-1 (cLABL) was 
conjugated to poly (DL-lactic-co-glycolic acid) (PLGA) nanoparticles. The cellular 
uptake of cLABL conjugated NPs (cLABL-NPs) by lung carcinoma epithelial cells 
upregulating ICAM-1 was significantly more rapid than control NPs. The specificity 
of ICAM-1 mediated internalization was confirmed by blocking the uptake of 
cLABL-NPs to ICAM-1 using free cLABL peptide. Cell studies suggested that 
cLABL-NPs targeted encapsulated doxorubicin to ICAM-1 expressing cells and 
iv 
 
provided sustained release of doxorubicin. In chapter 3, a peptide ligand targeting 
LFA-1 (cIBR) was conjugated to PLGA NPs to specifically target T cells expressing 
LFA-1. The specificity of NPs targeting LFA-1 was demonstrated by competitive 
inhibition using free cIBR peptide or by using the I domain of LFA-1 to inhibit the 
binding of cIBR-NPs. In addition, T-cell adhesion to epithelial cells was inhibited by 
cIBR-NPs. In chapter 4, nanoparticles capable of blocking LFA-1/ICAM-1 
interaction were then studied as inhibitors of T cell conjugation to DCs. LABL-NPs 
and cIBR-NPs rapidly bound to DCs and inhibited T cell conjugation to DCs to a 
greater extent than the free peptides, unconjugated NPs, anti-ICAM-1 antibodies and 
anti-LFA-1 antibodies. In addition, DCs treated with NPs or with cIBR-NPs 
stimulated the proliferation of T cells, but DCs treated with LABL-NPs did not 
stimulate T cell proliferation. LABL-NPs and cIBR-NPs also altered cytokine 
production compared to free ligands suggesting these NPs may offer a unique tool for 
shaping T cell response. In chapter 5, multivalent ligands having both ovalbumin 
(OVA) antigen and LABL peptide grafted to hyaluronic acid (HA) were found to 
bind professional APCs and may offer an alternative targeting approach for inducing 
immune tolerance. Collectively, results verified that cyclic and linear LABL and 
cIBR peptides can target NPs to ICAM-1 and LFA-1, respectively, to deliver 
encapsulated agent or to provide function as potent immune modulators.  
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Chapter 1 
Targeting T cell costimulation in autoimmune disease 
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1.1 Autoimmune disease  
Autoimmunity results from the breakdown of mechanisms controlling immune 
tolerance and the failure of the host immune system to distinguish self from non-self-
antigens. Autoimmunity produces an attack on self-cells and organs by 
autoantibodies and auto-reactive T cells. Central tolerance in primary lymphoid 
organs (thymus and bone marrow) provides the mechanism by which T cells and B 
cells are removed if they carry receptors that recognize self-antigens. For self-reactive 
T cells or B cells that escape from the thymus or bone marrow, there is a backup 
mechanism of „peripheral tolerance‟ that renders these cells inactive or anergic by 
several processes such as apoptosis or by the function of regulatory T cells.
1, 2
 Despite 
tight regulation, inappropriate humoral and cellular-mediated immune responses 
against self-antigens occasionally occur. Autoimmune reactions propagate a number 
of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, Graves' 
disease, Crohn‟s disease, lupus erythematosus and insulin-dependent diabetes 
mellitus. Autoimmune diseases are chronic inflammatory diseases assumed to arise 
from a combination of genetic traits, environmental factors and the breakdown of 
regulatory mechanisms.
1-5
Both humoral (autoantibodies) and cellular (autoreactive 
lymphocytes) responses mediate autoimmune diseases.  Some autoimmune diseases 
are mediated by cellular damage. Autoimmune diseases that are mediated by cellular 
damage occur when lymphocytes or antibodies bind to cell membrane antigens and 
stimulate cellular lysis and inflammatory response. Insulin-dependent diabetes 
mellitus is caused by the attack of auto-reactive T cells against insulin-producing 
cells (beta cells) in the pancreas. In multiple sclerosis, patients produce autoreactive T 
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cells that infiltrate brain tissue and cause inflammatory lesions along the myelin 
sheath of nerve fibers.
2
 Some autoimmune diseases are mediated by stimulating or 
blocking autoantibodies. In Graves‟ disease, autoantibodies are produced and bind to 
thyroid stimulating hormone (TSH) receptor without regulation, hence 
overstimulating the production of thyroid hormone. Myasthenia gravis is an 
autoimmune disease mediated by autoantibodies that block acetylcholine receptors on 
the motor end plate of muscles and inhibit the binding of acetylcholine to this 
receptor, hence weakening skeletal muscle. 
Current therapies for autoimmune diseases only reduce symptoms to provide 
an acceptable quality of life; for example, by general suppression of the immune 
system. The problem of using non-selective immunosuppressants, cytotoxic drugs or 
corticosteroids that threaten the overall immune response is that patients are then 
susceptible to opportunistic infections and other side effects.
6
 
Chronic inflammation is one target for autoimmune disease intervention.
5
 The 
inflammatory pathway involves several steps including leukocyte transmigration and 
cytokine production. Advances in discoveries of pathogenetic mechanisms of 
autoimmune diseases have contributed to the introduction of biologics as new 
therapies for autoimmune diseases. TNF- inhibitors (infliximab, etanercept, and 
adalimumab) have been used for treatment of rheumatoid arthritis, psoriasis and 
Crohn‟s disease.  There are several other cytokines that modulate inflammatory 
responses such as IL-1, IL-6, IL-17 and IL-23. The rationale behind attempts to block 
the biological effects of cytokines is that an imbalance of proinflammatory cytokines 
4 
 
and anti-inflammatory cytokines may be responsible for the induction of 
autoimmunity.
5
 
Besides inhibition of cytokine production or signaling, blockade of cell 
trafficking, B cell depletion and blocking of T cell activation are used as therapeutic 
intervention strategies. Tysabri® (natalizumab), an 41 integrin blocker, acts as an 
inhibitor of leukocyte extravasation and was approved for the treatment of multiple 
sclerosis. The drug was withdrawn later due to cases of opportunistic infections in the 
brain, but was later reintroduced to treat relapsing forms of multiple sclerosis. 
Rituximab, a monoclonal antibody against CD20 antigen presented on the surface of 
B cells, kills B cells via complement-mediated cytotoxicity, antibody-dependent 
cytotoxicity and apoptosis.
5 
In the United States, it has been approved for use in 
combination with methotrexate (MTX) for reducing symptoms in patients with 
rheumatoid arthritis who have had an inadequate response to one or more anti-TNF-
alpha therapies. 
1.2 T cell activation and costimulatory molecules 
In autoimmune diseases, T cell activation is initiated by presentation of self-antigen 
to T cells. Antigen presenting cells (APCs) capture self antigen and load it onto major 
histocompatibilty complex (MHC) class II. The antigen-primed APC then presents 
the self antigen to T cells which express T cell receptors that recognize self antigen.T 
cell activation requires two signals, the interaction of TCR on T cells and antigenic 
peptide-MHC complex on APCs (Signal 1) and a costimulatory signal (Signal 2), to 
promote T cell proliferation, cytokine secretion, and effector function.
 7, 8
 Signal 1, 
which imparts specificity to the immune response, must occur through the antigen 
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specific receptor of T cells. Signal 2, the costimulatory signal, is composed of several 
receptor/ligand interactions including the binding of CD28 on T cells and B7 on 
professional APC, and the binding of leukocyte function associated antigen-1 (LFA-
1) primarily on T cells and intercellular cell-adhesion molecule 1 (ICAM-1) primarily 
on APC.
9-11 
Activated T cells then either transmigrate to the tissue where antigen is 
located (beta cells in type I diabetes or CNS in multiple sclerosis) or T cells proceed 
to activate B cells to secrete antibodies (myasthenia gravis or systemic lupus 
erythematosis). The activation of T cells in the absence of the costimulatory signal 
can lead to T cell anergy and interrupt the immune response. Abatacept, a CTLA4-Ig 
fusion protein, blocks T cell costimulation and has been approved to treat rheumatoid 
arthritis and is now in clinical trials for other autoimmune diseases.
12
 
The costimulaltory signal is important in determining T cell activation since 
the TCR has low affinity for the antigen-peptide complex, has a small size hindering 
engagement, and is only present in small quantities.
6
 In the absence of the 
costimulatory signal, antigen-specific T cells fail to respond effectively and become 
anergic or die.Several costimulatory molecules have been identified and classified in 
families. Among these molecules, there are both stimulatory and inhibitory signals.  T 
cell costimulation plays an important role in the development of effective immune 
response including T cell proliferation, differentiation and survival (Table 1). 
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Table 1 Summary of costimulatory molecules 
Molecule Expression Ligands Expression Ligation to its receptor Drugs/mAb 
CD28 T cells
6,8
 CD80 (B7-1) 
 
 
 
 
 
CD86 (B7-2) 
Constitutively 
expressed on DCs 
and inducible on 
activated B cells 
and macrophages.
6
  
 
Constitutively 
expressed on 
monocytes, DCs 
and B cells and 
inducibly 
upregulated on both 
T cells and APCs.
6
 
- Enhance T cell 
proliferation and cytokine 
production through 
induction of IL-2 
production.
6 
- Promote T cell 
differentiation into IL-4 
producing T helper 2 cells.
6, 
13
  
-Stimulate B cells for 
antibody production.
8
  
- Augment the kinetics and 
level of expression of OX40, 
4-1BB and CD30.
6, 13, 14 
-Inhibition of CD28/B7 
reduces specific Ab 
production, prolongs the 
survival of organ transplants 
and inhibits autoimmune 
diabetes and lupus. 
-Abatacept (CTLA-4-Ig) targeting 
CD80/86 has been approved by 
FDA to use in RA. It is also in 
Phase I clinical trials in 
psoriasis.
15, 16
 
-Belatacept (CTLA-4-Ig) has a 
clinical indication in renal 
transplantation.
17, 18
  
-Galiximab is a chimeric antibody 
targeting CD80/86. It has clinical 
indications in Non-Hodgkin's B 
cell lymphoma (NHL)
9
, and 
psoriasis.
16
 It is now in Phase III 
clinical trials.  
PD-1 Activated T, B 
cells, 
monocytes and 
macrophages
20
 
 
PD-L1  
(B7-H1) 
 
PD-L2 
(B7-DC) 
-APC and 
nonhematopoietic 
cells
20
 
-Inducibly 
expressed on 
dendritic cells and 
macrophages
20
 
-Transmit signals that inhibit 
T cell and B cell activation.
20
 
 
-PD-L1 Ig fusion protein reduced 
clinical score in CIA mice model 
and prolonged graft survival in 
mice
20, 21
 
-Anti PD-1 antibody antagonists 
(MDX 1106, CT-011) are 
currently in Phase I/II clinical 
trials in melanoma.
22, 23
 
CTLA-4 
(CD152) 
Activated T 
cells
13
 
 
B7-1 (CD80) 
and  
B7-2 (CD86) 
T, B cells, 
macrophages, DCs, 
endothelial cells, 
epithelial cells and 
fibroblasts
13
 
-Transmits an inhibitory 
signal to T cells and inhibit 
T cell activation.
13
 
-Deplete the expression of 
IL-2 and IL-2R.
8
 
-CTLA-4 binds B7 with a 
much higher affinity than 
CD28.  
-Anti CTLA-4 mAb (Ipilimumab 
and tremelimumab) have clinical 
indications in melanoma and other 
tumors. They have been studied in 
Phase II/III clinical trials.
24-27
 
 ICOS Activated T 
cells
28
 
 
ICOSL 
(B7RP-1) 
Constitutively 
expressed as a 
monomer on B cell, 
dendritic cells, 
monocytes, 
endothelial cells, 
fibroblasts, 
epithelial cells
27
 
-Enhance T cell 
differentiation, cytokine 
production and survival.
28
 
 
Anti-ICOSL mAb antagonist has 
shown to reduce the severity of 
G6PI-induced arthritis
29
, reduce 
lethality and symptoms in 
GVHD.
30
  
-Anti ICOS mAbprolongs cardiac 
and bone marrow graft survival in 
mice.
31, 32
 
BTLA 
(CD272) 
B cells and 
inducible 
during 
activation of T 
cells.
33, 34
 
HVEM Naïve or resting T 
cells, NK cells, B 
cells and DCs, 
myeloid cells.
 31,32 
-Deliver the inhibitory signal 
of T cell activation.
32 
-Decrease IL-2 production
 32
 
Anti-BTLA in a combination with 
CTLA-4-Ig has shown efficacy in 
allograft rejection.
35, 36
 
CD40 B cells, 
monocytes, 
macrophages, 
DCs, platelets 
and inducibly 
expressed on 
non-
hematopoietic 
cells such as 
epithelial cells 
and 
fibroblasts.
37 
 
CD40L 
(CD154) 
Activated T cells, 
activated B cells 
and platelets.
37
 
-Promote B cell activation 
and DC maturation.
8
 
- Induce memory B cells 
maturation.
37, 38
 
CD40 ligation leads to the 
upregulation of B7-1 and 
B7-2 on APCs and enhances 
the ability of APCs to 
activate naïve T cells.
37, 38
 
-Dacetuzumab (anti-CD40 mAb) 
has clinical indications in multiple 
myeloma, Non-Hodgkin's 
lymphoma (Phase I)
39, 40
, diffuse 
large B-cell lymphoma (Phase II)
41
 
and CLL (Phase I).
42
 
- Anti-CD40L MAb has clinical 
indications in allograft rejection 
(Phase I/II).
43, 44
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OX40 
(CD134) 
Activated T 
cells.
14
 
 
OX40L 
(CD252) 
Professional APCs 
and can be induced 
on activated B 
cells, mature DCs 
and macrophages.
14 
 
-Promote T cell 
proliferation, differentiation, 
survival, differentiation, 
cytokine production and 
effector cell function of T 
cells.
14
 
-OX40-OX40L interactions 
additionally modulate the 
differentiation and activity 
of regulatory T cells (both 
suppress and promote 
proliferation of these cells).
14
 
-Anti OX40 and OX40L mAb 
agonists have shown benefits in 
cancer.
45-47
 
-Neutralizing anti OX40L 
ameliorated the severity of disease 
in EAE
48
, colitis
49
, arthritis
50
, 
asthma
51
, and diabetes 
52
 in vivo. 
 
GITR Naïve T cells 
and Treg. It is 
upregulated on 
effector T cell 
upon 
activation.
53
 
 
GITRL B cells, 
macrophages, DCs, 
endothelial cells 
and activated T 
cells.
53
 
-Suppress function of Treg.
54
 
-Activation of effector T 
cells and NK cells.
54
 
-Induce inflammatory 
activation of macrophage.
53
 
-Anti GITR mAb agonist induced 
potent antitumor immunity.
55, 56   
-GITR fusion protein binding to 
GITRL prolonged allograft 
survival and showed potential anti-
inflammatory properties in animal 
studies.
57, 58
 
-Neutralizing anti GITRL MAb 
protected the progression of 
diabetes.
59
  
CD27 Naïve T cells, 
B cells, NK 
cells, memory 
and antigen-
exposed T 
cells.
60, 61
 
CD70 Activated T cells 
and activated 
APCs.
60, 61
 
- Stimulate T cell activation 
and survival.
62
 
-Promote B cell activation 
and production of 
antibodies.
60
 
-Anti CD70 exhibited antitumor 
immunity in in vivo studies.
63, 64  
-Improved disease severity in 
inflammatory and autoimmune 
disease.
65, 66
  
LIGHT 
(TNFSF14) 
Activated T 
cells and 
immature 
DCs.
61, 67
 
HVEM T cells, B cells and 
NK cells.
61, 67
 
-Promote T cell 
proliferation, cytokine 
production, and activation of 
NF-B8 
-LTR–Ig fusion protein improved 
ACR scores in RA patients
68, 69 
 
and prolonged survival of GVHD 
mice
 70
 
-anti–HVEM mAb 
profoundly ameliorated GVHD in 
mice
71
 
-HVEM Ig fusion protein plus 
cyclosporine A prolonged allograft 
survival in mice.
72
 
4-1BB 
(CD137) 
Activated T 
cells and 
activated NK 
cells.
73-75
 
 
4-1BBL Activated DCs, B 
cells and 
macrophages.
73-75
 
-Provide costimulation of T 
cell activation and promote 
T cell survival.
73-75
 
-Anti 4-1BB MAb has clinical 
indication in cancers. It is now 
being studied in Phase II clinical 
trials.
76 
 
-Anti 4-1BBL attenuated acute 
rejection in rat liver 
transplantation.
77
 
 VLA-4 T cells, B cells, 
monocytes, NK 
cells, 
eosinophils, 
neutrophils and 
hematopoietic 
cells.
75
 
 
VCAM-1 
(CD106) and 
fibronectin 
Endothelial cells
75 
 
-Regulate adult 
hematopoiesis.
75
 
-Promote the adhesion of 
lymphocytes, monocytes, 
eosinophils, and basophils.
8  
 
 
-Natalizumab (anti VLA-4 
antagonist) was approved by FDA 
for the treatment of relapsing 
forms of multiple sclerosis (MS)
78
 
LFA-1 Leukocytes.
79 
 
 
ICAM-1 
(CD54) and 
ICAM-2 
(CD102) 
Vascular 
endothelium, 
macrophages and 
lymphocytes.
8
 
-Mediate adhesive 
interaction between T cell 
and APC in the 
immunological synapse and 
mediate leukocyte 
trafficking during 
inflammation.
79
 
-Efalizumab (anti LFA-1 mAb) 
was approved to use in psoriasis 
but withdrawn due to an increased 
risk of progressive multifocal 
leukoencephalopathy (PML).
80
 
-Anti ICAM-1 mAb were studied 
in clinical trials for Crohn‟s 
disease (Alicaforsen)
81 
and 
Ischemic stroke‟s disease 
(Enlimomab).
82
 None of them 
were continued in post marketing 
phase. 
Mac-1  Leukocytes 
79 
 
 
ICAM1 
(CD54) 
Vascular 
endothelium, 
macrophages, and 
lymphocytes.
8
 
-Mediate leukocyte 
trafficking during 
inflammation and 
contributes to leukocyte 
activation in immune 
responses.
79
 
-Anti-Mac-1 showed no effect in 
graft survival.
83
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1.2.1 Costimulatory molecules of the immunoglobulin superfamily 
CD28-B7 costimulatory pathway 
The interaction of CD28 on T cells and B7 family on APC provides a crucial positive 
costimulatory signal for T cell activation. CD28 is a disulfide linked homodimeric 
transmembrane member of Immunoglobulin superfamily constitutively expressed on 
CD4+ T cells and CD8+ T cells. The ligands for CD28 are B7-1 (CD80) and B7-2 
(CD86). They are constitutively expressed on DCs and induced on activated 
macrophages and activated B cells. Binding of CD28 and their ligands promotes 
proliferation of activated T cells and differentiation of T cells into T helper cells and 
enhances the production of antibodies by B cells.
8, 84
 
CTLA-4-B7 costimulatory pathway 
CTLA-4 (CD152) is structurally homologous to CD28. CTLA-4 is expressed on T 
cell membrane and binds to the same two ligands as CD28 (B7-1 and B7-2) with 
higher affinity. CTLA-4 is upregulated and activated after binding of CD28 and B7 
ligands and T cell activation and undetectable on resting T cells, whereas CD28 is 
expressed on both resting and activated cells.
2, 17
CTLA-4 has similar structure as 
CD28, but their functions are different. CD28-B7 interaction delivers a positive 
costimulatory signal to T cells, whereas CTLA-4-B7 interaction delivers an inhibitory 
signal to T cells resulting in the attenuation of T cell activation and proliferation. Due 
to the higher binding affinity to B7, the upregulated CTLA-4 competes for the B7-1 
or B7-2 ligands to turn off T cell activation and hence regulating the lymphocyte 
homeostasis.
84
 
Therapeutics targeting CD28-mediated costimulation 
9 
 
Abatacept (CTLA-4-Ig) is a fusion protein composed of the extracellular binding 
domain of CTLA-4 fused to an Fc domain of human IgG. It was developed to block 
the binding of CD28 to B7.
84
 Abatacept was approved for the treatment of moderate 
to severe rheumatoid arthritis (RA) in the case of inadequate response to anti-TNFα 
therapy.
84, 85
 A recent report, however, has shown that RA patients respond poorly to 
abatacept.
86
 Furthermore, abatacept was shown to lack efficacy in organ 
transplantation in non-human primates, which was suggested to be due to the lower 
avidity of abatacept to CD86 compared to CD80.
8
 For this reason, belatacept was 
developed. Belatacept is a second-generation CTLA-4-Ig, differing from abatacept 
only by 2 amino acids leading to a superior binding to CD80 (2 fold) and CD86 (4 
fold) compared to abatacept.
87
 Belatacept provided more potent immunosuppressive 
properties required for transplantation.
17
 Belatacept is intended to provide extended 
graft survival and is under currently continuing through clinical trials.  
PD-1-PD-L Costimulatory pathway 
Programmed death-1 (PD-1 or CD279) is an inhibitory costimulatory molecule.
88
 It is 
a member of the immunoglobulin superfamily expressed on activated T cells, B cells, 
monocytes, and macrophages.
89
 PD-1 binds PD-L1 (B7-H1) and PD-L2 (B7-DC). 
PD-L1 is expressed on B cells, DCs, and T cells including Treg. PD-L2 expression is 
limited to DCs and macrophages. Ligation of PD-1 on lymphocytes delivers a 
negative costimulatory signal to T cells and plays a critical role in the regulation of 
peripheral tolerance.
90-93
 Engagement of PD-1 by its ligands PDL-1 or PDL-2 blocks 
TCR signaling and transduces a signal that inhibits T and B cell proliferation, 
cytokine production and cytotoxicity of CD8+ T cells.
89, 93
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Therapeutic targeting of PD-1-PDL interactions 
An in vitro study has shown that PD-L1 Ig stimulated PD-1, thus inhibiting CD4+ 
and CD8+ T cell proliferation.
8
 PD-L1 Ig has been shown to ameliorate collagen-
induced arthritis (CIA) in the CIA mouse model as evaluated by clinical score and 
histology and reduce the production of inflammatory cytokines. These results 
suggested a beneficial effect of PD L1 Ig in this arthritis model via anti-inflammatory 
actions and inhibition of cell proliferation.
20 
PD-L1 Ig prolonged corneal allograft 
survival in mice by augmented ligation of the PD-1 negative costimulatory 
molecule.
21
  
ICOS-ICOSL costimulatory pathway 
Inducible costimulator (ICOS) is also a member of the immunoglobulin superfamily 
of costimulatory molecules. ICOS is induced after TCR engagement upon T cell 
activation. ICOSL (B7H) is constitutively expressed on DCs, monocytes, 
macrophages, B cells, endothelial cells, fibroblasts, and renal epithelial cells.
28
 ICOS 
has similar sequence with CD28 and CTLA-4. Unlike other costimulatory molecules 
such as CTLA-4, ICOS can be upregulated in the absence of CD28-B7 interaction.
6
 
ICOS promotes T cell differentiation and cytokine production.
8, 94
 ICOS can stimulate 
both Th1 and Th2 effector cytokine production, especially IL-4 and IL-10.
8, 94
 Since 
ICOS signaling does not sustain IL-2 production, it does not stimulate T cell clonal 
expansion.
95, 96
 
Therapeutic targeting of ICOS-ICOSL interactions 
The ICOS-ICOSL costimulatory pathway is crucial for T cell activation, 
differentiation and effector function. Anti-ICOS mAb treatment resulted in significant 
11 
 
inhibition of graft versus host disease (GVHD) and reduced the number of Ag-
specific T cells that reject the bone marrow graft.
32
 The blockade of ICOS-ICOSL 
was effective in prolonging cardiac and liver allograft survival.
8
 ICOS blockade also 
prevented development of spontaneous disease in pre-diabetic NOD mice.
97 
Transient 
blockade of ICOS/ICOSL interactions profoundly reduced the severity of glucose-6 
phosphate isomerase (G6PI) induced arthritis.
29
 These observations suggested that 
ICOS costimulation may be a beneficial therapeutic target for allograft 
transplantation and autoimmune diseases.
94
 
BTLA-HVEM costimulatory pathway 
B and T lymphocyte attenuator (BTLA or CD272) is an immunoglobulin-like 
molecule belonging to the immunoglobulin superfamily. BTLA is not expressed by 
naive T cells, but it is induced during activation and remains expressed on TH1 but 
not on TH2 cells.
34
 It is also constitutively and highly expressed on B cells. BTLA 
was identified as an inhibitory receptor with structural and functional similarities to 
CTLA-4 and PD-1.
98
 The engagement of BTLA and  herpes virus entry mediator 
(HVEM), which is a member of the TNF receptor (TNFR) superfamily delivers an 
inhibitory signal. BTLA interaction with HVEM impairs T cell activation resulting in 
decreased T cell proliferation and cytokine production.  
Therapeutic targeting of BTLA-HVEM interactions 
Blockade of BTLA-HVEM costimulation has been suggested that anti-BTLA mAb in 
a combination with CTLA-4-Ig can prolong cardiac allograft survival.
35
 In a different 
study, combination therapy between anti-BTLA mAb and CTLA-4-Ig induced donor-
specific tolerance in murine islet allograft.
36
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1.2.2 Costimulatory molecules of the TNF-TNFR family 
CD40-CD40L costimulatory pathway 
CD40 is constitutively expressed on B cells, dendritic cells, monocytes, platelets, and 
macrophages, and can be inducibly expressed on non-hematopoietic cells such as 
endothelial cells and fibroblasts in the presence of inflammation.
37
 Ligation of CD40 
and its subsequent signaling leads to activation of B cells, as well as activation and 
maturation of dendritic cells, priming of helper and cytotoxic T cells, and propagation 
of a variety of inflammatory reactions.
38
 The ligand for CD40 (CD40L or CD154), a 
member of the TNF family, is expressed on activated T cells, after stimulation by 
TCR-antigenic peptide/MHC complex engagement and signaling from CD28-B7 
interaction.
8
 Blockade of the CD40-CD40L pathway alone or together with the 
CD28-B7 pathway can lead to long-term allograft survival in animal transplantation 
models and can inhibit development of autoimmune diseases.
38
 
Therapeutic targeting of CD40-CD40L interactions 
Blocking the CD40-CD40L costimulatory pathway was examined by using anti-
CD40L mAb, which has shown promise in both rodent and non-human primate 
models.
99
 Anti-CD40L mAb can prevent acute allograft rejection and promote 
allograft and xeno-graft survivals in rodents and non-human primates.
8
 Although 
treatment with anti-CD40L mAb promoted long term allograft survival in 
experimental transplantation, clinical trials in autoimmune diseases and 
transplantation were halted due to unanticipated thromboembolic complications. This 
complication may be explained by the high expression of CD40L on platelets; 
however, observed stabilization of arterial thrombi were thought not to involve CD40 
13 
 
molecules.
99
 An anti-CD40 mAb has also been developed and was shown to block 
binding of CD154 and to inhibit CD154-induced B cell proliferation in vitro. Anti-
CD40 mAbs promoted moderate prolongation of graft survival when used alone. 
When combined with belatacept, anti-CD40 mAbs synergized the effect in 
prolonging graft survival in non human primate models of renal and islet 
transplantation.
99
 
OX40-OX40L costimulatory pathway 
OX40 (CD134) is predominantly expressed on activated T cells, but not naïve CD4+, 
CD8+ T cells, and memory T cells.
14
 Following activation, OX40L is induced on 
activated B cells and mature dendritic cells, endothelial cells and T cells. It is not 
expressed on resting APC. Expression of OX40 is delayed and decreased in the 
absence of CD28. OX40-positive T cells are found at the site of inflammation in 
experimental allergic encephalomyelitis (EAE), graft-vs-host disease (GVHD) and 
rheumatoid arthritis (RA).
100
 Targeting the OX40-OX40L interaction with anti-
OX40L mAb can delay disease progression in EAE, colitis, arthritis, asthma and 
diabetes.
48-52 
GITR-GITRL costimulatory pathway 
Glucocorticoid-induced TNFR-related gene (GITR or TNFRSF18) is a 
transmembrane protein of the TNFR superfamily. GITR is preferentially expressed 
by Treg and is also upregulated in conventional effector T cells upon activation.
57
 
GITR ligand (GITRL) is mainly expressed on B cells, macrophages, dendritic cells, 
endothelial cells, and activated T cells but not on resting T cells.
53, 57
 Binding of 
GITRL to its receptor is involved in the development of autoimmune or inflammatory 
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responses due to costimulation of effector T cells, inhibition of Treg cells, and 
activation of macrophages.
54
GITR fusion protein binding to GITRL prolonged 
allograft survival and showed potential anti-inflammatory properties in animal 
studies.
57, 58
 Neutralizing anti GITRL MAb protected the progression of diabetes.
59
 
1.2.3 Costimulatory molecules of the integrin family 
Leukocyte function associated antigen-1 (LFA-1) and Intercellular adhesion 
molecule-1 (ICAM-1) belong to the integrin family and immonuglobulin superfamily, 
respectively. They are critical costimulatory molecules since they mediate strong 
interaction and enhance T cell activation signaling.
101
 Binding of LFA-1 and ICAM-1 
stabilizes the interaction of TCR and MHC-peptide complex in immunological 
synapse.    
Therapeutic targeting for ICAM-1/LFA-1 mediated signaling 
The effect of anti-ICAM-1 mAb on preventing rejection was reported in a rat 
transplantation model.
102
 Intravenous administration of anti ICAM-1mAb alone could 
not prevent acute lung allograft rejection; however, combination with cyclosporine 
significantly reduced infiltration of leukocytes into the allograft.
102 
Anti ICAM-1 
mAb were studied in clinical trials for Crohn‟s disease (Alicaforsen) and Ischemic 
stroke‟s disease (Enlimomab). 81, 82 None of them were continued in post marketing 
phase. 
Anti-LFA-1 mAb (efalizumab) has been shown to be effective in reducing the 
severity of chronic psoriasis without lymphocyte depletion and prevented rejection in 
kidney transplantation. Recently, efalizumab was withdrawn from clinical use due to 
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concerns about the development of progressive multifocal myeloencephalopathy 
(PML) in several patients receiving the drug as treatment for psoriasis.
103
 In other 
studies, Posselt et al. described a novel immunosuppressive regimen using efalizumab 
which permitted long-term islet allograft survival while reducing the need for 
corticosteroids and calcineurin inhibitors (CNI).
104
 
1.3 Immunological synapse (IS) 
Immunological synapse is a specialized junction between cells, within which a 
variety of receptors and adhesion molecules engage their ligands on the apposed cell 
surface.
105
 One such junction occurs between T cells and APCs and includes the 
specific binding of antigenic peptide-MHC class II and TCR recognizing this 
particular antigen surrounded by a ring of LFA-1 and ICAM-1, among other 
receptor/ligand pairs.
105
 T cell activation requires sustained conjugate formation 
between T cells and APCs because the number of peptide-MHC complexes can be 
very low, in the range of 10 to 100 per APC, and because the interaction between the 
TCR and its ligand has low affinity.
106-108
 In the immunological synapse, the ligands 
and their receptors are arranged in an orderly manner to enhance binding specificity 
and to prolong the duration of signaling.
109
 Reports suggest that, T cell activation 
requires more than 1 hr which is mediated by the longevity of stabilized IS.
109
 The 
activation signals are sustained by localization of TCR and MHC complexes to the 
center of the IS.
107, 109
 Pairs of costimulatory receptors and their ligands also 
accumulate at the center of the IS while clusters of LFA-1 and ICAM-1 among others 
are localized to the peripheral ring of the IS.
110
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The surface proteins located within the immunological synapse on T cells 
include T cell receptors, costimulatory molecules CD2, CD28, CD40L, LFA-1, VLA-
4, ICAM-1, ICAM-3, and various cytokine and chemokine receptors.
111
 The 
immunological synapse on APCs contains surface proteins including CD80, CD86, 
CD40, ICAM-1, ICAM-3 and other surface and cytoplasmic proteins.
112
 The 
structure of the mature IS was described as a „bull‟s eye‟ arrangement with three 
distinct regions.
110
  The central region of the IS, called the central supramolecular 
activation cluster (cSMAC), contains TCR complexes interacting with peptide-MHC 
complexes as well as interactions of costimulatory molecules such as CD4, CD2, 
CD28 and CD40.
109-111, 113 The intermediate ring of the bull‟s eye, called the 
peripheral supramolecular activation cluster (pSMAC), contains complexes of 
integrin LFA-1 binding to ICAM-1 and the cytoskeletal protein talin, among 
others.
113
 The outermost region is the distal supramolecular activation cluster 
(dSMAC), containing CD45 and CD43.
110
 
After T cell and APC contact, the binding of TCR to peptide-MHC complexes 
leads to the formation of small TCR microclusters containing about 100 TCR/ MHC 
each, distributed in the periphery of the T cell-APC interface (dSMAC).
114, 115
 The 
increased density of TCR and MHC by forming microclusters facilitates the 
engagement of this low affinity pair. The segregated microclusters of LFA are also 
formed in d-SMAC.
116
 TCR and LFA-1 microclusters then translocate to pSMAC. 
After T cells begin to contract, TCR microclusters migrate towards the center region 
of the contact area (cSMAC), while integrin microclusters accumulate in a 
surrounding area (pSMAC).
106, 116-118
 At the center, TCR microclusters assemble to 
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form larger clusters and a stable cSMAC to sustain the activation signal.
119
 Similarly, 
MHC and ICAM-1 microclusters are also formed at the contact interface on the APC. 
cSMAC is surrounded by peripheral SMAC (pSMAC) containing adhesion molecules 
such as LFA-1 and ICAM-1. ICAM-1 on APCs forms oligomers that bind to LFA-1 
clusters on T cells.
111, 120
 The interactions of integrins and their ligands enable the 
formation of tight and prolonged contacts between T cells and APCs. The stable IS 
cannot be formed in the absence of integrins.
111
 
In addition to the formation of TCR clusters, clustering of costimulatory 
molecules and their ligands is also required for T cell activation to occur. The 
costimulatory molecules CD28 and CTLA-4 have been reported to accumulate in the 
cSMAC.
107
 The accumulation of CD28-B7 enhanced T cell response by modifying T 
cell signaling and stabilize the arrangement of immunological synapse.
110
 Other 
costimulatory receptor-ligand pairs, including PD-1-PD-L1/PD-L2, ICOS-ICOSL and 
CD40-CD40L were reported to localize and function in the cSMAC.
110
 CD28 and 
CTLA-4 are expressed as homodimers on the T cell surface with monovalent and 
bivalent binding capacities, respectively. B7-1 is also present on the surface as a 
homodimer, while B7-2 is monomeric.
114
 A homodimeric CTLA-4 molecule can bind 
two B7-1 molecules at low concentration of CTLA-4. At high concentration, CTLA-4 
can form an linear array of B7-1-CTLA-4 multimers containing 7-18 receptor-ligand 
pairs.
121
 At low concentration, one CD28 molecule can bind two molecules of B7-1. 
At high concentration, two molecules of CD28 can bind a dimer of B7-1 without 
forming a multimeric array.
121
 As a result of multimerization, CTLA-4 has 10-100 
fold higher binding avidity for B7 ligands than CD28.
114
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1.4 The importance of mutivalency of LFA-1 and ICAM-1 
LFA-1 mediates multiple events in the immune system, such as leukocyte 
trafficking, transmigration, and formation of the IS. Binding of LFA-1 to ICAM-1 is 
needed for the initiation and stabilization of T cell-APC conjugation. Avidity is the 
overall strength of cellular adhesive interactions resulting from the combination of 
both the affinity of individual receptor-ligand bonds and the total number of bonds 
formed (i.e., the valency of the interaction).
122
  The affinity of integrin is regulated by 
the alteration of integrin conformation, whereas valency regulation is mediated by 
changes in cell surface receptor diffusivity or density that alter the number of 
adhesive bonds that can form.
123
 The ligands of LFA-1 are members of the 
immunoglobulin superfamily known as intercellular adhesion molecules (ICAMs) 
expressed on APCs, endothelial cells and epithelial cells, and are inducible by 
inflammatory cytokines. 
LFA-1 on resting leukocytes circulating in the blood is normally inactive (i.e. 
a non-ligand-binding conformation). The conformational change of LFA-1 from low 
to high affinity state can be activated by several factors including the binding of other 
receptors on leukocytes, such as chemokine receptors, antigen-specific TCRs or B-
cell receptors (BCRs).
124
 The high affinity state of LFA-1 induces its ability to bind 
ICAMs. There are three different LFA-1 conformations that occur at different stages 
of activation.
124
 The low affinity conformation of LFA-1 is a bent form where the 
LFA-1 I domain is bent and close to cell membrane, whereas the extended form with 
a closed binding domain has an intermediate affinity, and the extended form in which 
the ligand-binding I-domain of is opened to bind domain 1 of ICAM-1 with the 
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highest  affinity.
79, 125 
Microclusters of LFA-1 on T cells are formed after initial 
multivalent binding of LFA-1 to ICAM-1.
67
 The interaction of intermediate affinity 
LFA-1 with ICAM-1 induces the high affinity conformation that stabilizes adhesion. 
Change in affinity is not the only means to regulate the binding of LFA-1. The 
dynamic adhesion of LFA-1 is also controlled by its avidity resulting from clustering, 
which is driven by outside-in signals from activated LFA-1 itself.
124
 
ICAM-1 is the primary ligand of LFA-1, expressed on both T cells and APCs. 
ICAM-1 on APC may act as a costimulatory receptor and receives signal that 
facilitates immune response .
120
 ICAM-1 is composed of five immunoglobulin-like 
domains. Oligomerization and clustering of ICAM-1 increase its ligand binding 
avidity by allowing the rebinding of receptors and ligands after dissociation, since 
monomeric adhesion molecules tend to have fast dissociation rates.
120
 The crystal 
structure analysis of ICAM-1 reveals that this molecule organizes into non-covalently 
linked homodimer via D4-D4 interaction on the cell surface, and two homodimers 
bind each other by using D1, resulting in W shaped tetramers.
120
 These tetramers can 
form linear arrays zigzagging between the T cell and APC.
120
 This linear structure 
can bend and close to form a peripheral ring in IS facilitating the adhesion between 
APC and T cells.
120
 The adhesion ring can be composed of thousands of circular 
LFA-1/ICAM-1 pairs and has a diameter of several microns.
120
 
1.5 Strategies and rational design of multivalent, targeted drug delivery system 
Targeted drug delivery is a strategy to preferentially increase the concentration of 
drug in the diseased cells relative to normal cells.
126
 This strategy results in an 
increased therapeutic efficacy and reduced side effects and toxicity of the targeted 
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drug.
126
 Targeted drug delivery often uses specific types of membrane-bound protein 
including surface antigens or cell surface receptors as a target. Tools for targeting 
specific cellular populations have been widely explored by using various targeting 
ligands including antibodies, aptamers, peptides, and small molecules.
127-130
 
High affinity binding and selectivity are important properties of targeted drug 
delivery systems.
100, 131, 132 
The ideal targeted delivery system should have a low 
affinity for its targeted receptor expressed in normal cells but high affinity to 
receptors on diseased or activated cells.
100 
However, high affinity delivery systems 
can have low specificity if the target receptors are expressed in both diseased and 
healthy cells.
100
 One active targeting method for cancer treatment focuses on 
transferrin and folate receptors that are upregulated in cancer cells. Ligands targeting 
transferrin receptor increased uptake of targeted nanoparticles by cancer cells; 
however, since these receptors are expressed to some degree on many types of normal 
cells, side effects may occur. An example of a more selective targeting strategy is the 
use of antibodies to target prostate-specific membrane antigen (PSMA) exclusively 
expressed on prostate cancer cells. Anti-PSMA conjugated dendrimers were found to 
bind preferentially to prostate adenocarcinoma, whereas the untargeted dendrimer did 
not. Furthermore, the targeted dendrimer did not bind to cells which do not express 
PSMA.
126
 
The specificity of targeting can also be improved if there are more ligands 
bound to target cells than to untargeted cells. The low affinity of ligand reduces 
specific binding in monovalent form but binding of ligand can be increased through 
multivalent presentation (higher avidity). Multivalent ligands consist of multiple 
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monomeric ligands attached to a single backbone carrier such as quantum dots, 
polymers, microparticles or nanoparticles, creating an array that can bind to multiple 
receptors simultaneously. Due to the multiple, simultaneous binding events, 
multimeric ligands often exhibit stronger binding compared to their corresponding 
monomers.
133
 Several investigators have designed delivery systems with multiple 
ligands to achieve more effective targeting through multivalent interaction.
133
 Studies 
have shown the enhanced binding avidities of biological multivalent inhibitors on the 
order of 1 to 9 orders of magnitude.
131
 However, the specificity of targeting can be 
achieved when ligands have low binding affinity For some ligands such as antibodies 
having high binding affinities, using multivalent interaction of multiple antibodies to 
increase binding specificity would be possible at much lower concentrations.
134
 
Many proteins that participate in multivalent interactions (e.g. cell adhesion) 
are oligomeric. One of the most studied members of this type of surface proteins is 
LFA-1 and ICAM-1. LFA-1 and ICAM-1 possess characteristics which can serve as a 
target for multivalent targeted drug delivery systems. First, LFA-1 and ICAM-1 on 
resting leukocytes, APC, endothelial and epithelial cells are normally inactive (i.e. a 
non-ligand binding conformation).Once triggered (e.g. by binding of TCR to MHC 
class II complex), molecules like LFA-1 change conformation to enhance binding to 
ICAM-1.
120
 Second, LFA-1 and ICAM-1 are upregulated on activated T cells and on 
endothelial cells in inflammatory diseases or autoimmune diseases. Third, both LFA-
1 and ICAM-1 ligand bindings are controlled by their avidities resulting from 
clustering.
120, 124
Cell adhesion mediated by ICAM-1 and LFA-1 involves multivalent 
interaction between these two molecules on opposing cells (APC and T cell).  
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In order to design a system that could specifically target the multivalent state 
of LFA-1 and ICAM-1 on activated T cells and APC populations, multiple copies of 
their ligands were conjugated to NPs to facilitate receptor binding through 
multivalent presentation. LFA-1 and ICAM-1 exhibit clustering during activation, 
which should promote the proper geometry for multivalent interaction of receptors 
with their ligands presented on NPs. Thus, this targeting strategy should yield a 
benefit when targeting receptor clusters. 
Besides increasing therapeutic efficacy and reducing side effects, 
internalization of targeted drug delivery system can also be critical. LFA-1 and 
ICAM-1 targeting offers the possibility of improved inhibition since receptor 
internalization is triggered by the multivalent engagement of ligands.
135
 The 
conjugation of LFA-1 and ICAM-1 ligands on NPs is, therefore, hypothesized to 
preferentially target specific immune cell populations, increase the binding avidity of 
these ligands to receptors, inhibit receptor signaling by blocking binding and reduce 
the number of surface receptors by facilitating the internalization of these receptors 
via endocytosis.   
The use of targeted nanoparticles (NPs) in drug delivery is expected to 
increase specificity of the encapsulated drugs and thus reduce side effects and 
decrease the dose of administration. In addition, encapsulation of drugs in NPs may 
increase the bioavailability of drug, offer sustained release, andprotect against 
degradation. Encapsulation of drug into NPs can also alter pharmacokinetics of the 
drug, while maintaining its pharmacological action.  
23 
 
In this thesis work, PLGA NPs targeting ICAM-1 (cLABL-NPs) were loaded 
with the anticancer drug, doxorubicin. Binding specificity to lung carcinoma 
epithelial cells was confirmed. Drug release and microscopy studies indicated that the 
cLABL-NPs sustained drug release and confirmed the localization of drug to the 
target site (chapter 2).  In chapter 3, an LFA-1 targeting peptide was conjugated to 
PLGA NPs to target T cells (cIBR-NPs). The results revealed that the binding of 
cIBR-NPs was specific to LFA-1 compared to untargeted NPs and binding was 
dependent on the surface ligand concentration. The internalization of cIBR-NPs was 
suggested by the reduced uptake of NPs at low temperature. In addition, cIBR-NPs 
were able to block the binding of T cells to lung epithelial cells. In chapter 4, cIBR-
NPs and LABL-NPs were found to shift immune cell responses when compared to 
monomeric ligands (free cIBR and LABL peptides). Finally, in chapter 5, the 
performance of hyaluronic acid as a multivalent nanomaterial for targeting DC and 
inhibiting T cell proliferation and proinflammatory cytokine expression (TNF- and 
IL-17) were reported.  
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2.1 Introduction 
Interaction of leukocyte function associated antigen-1 (LFA-1) and intercellular cell 
adhesion molecule-1 (ICAM-1) can play a critical role in tumor metastasis and 
progression.
1-6
 ICAM-1 is expressed on a variety of inflammatory and immune 
effector cells as well as endothelial cells, fibroblasts, and epithelial cells.
7
 ICAM-1 is 
also up-regulated on the surface of a variety of lymphomas, melanomas, renal, 
pancreatic, bladder and lung carcinomas and/or their local vascular network.
7
  The 
expression of ICAM-1 may be involved in the regulation of tumor susceptibility to 
the activity of defensive cells. The upregulation of ICAM-1 expression on some types 
of carcinomas such as melanomas and lung carcinomas may be followed by the 
extracellular release of soluble ICAM-1 (sICAM-1).
7
 The sICAM-1 could interfere 
with the interaction of surface ICAM-1 and immune cells such as natural killer (NK) 
cells or lymphocyte activated killer (LAK) cells by competition, leading to the 
reduction of cancer cell exposure to these protective cells.
7
 Shedding of sICAM-1 in 
the extracellular space has been proposed as one of the mechanisms that tumor cells 
use to escape cell-mediated cytotoxicity.
7
 
A cyclic peptide, cyclo-(1,12)-PenITDGEATDSGC (cLABL), derived from 
the I-domain of the αL-subunit of LFA-1 integrin has been shown to impair LFA-
1/ICAM-1 interaction by binding to the D1 domain of ICAM-1. This peptide 
specifically inhibited homotypic and heterotypic T-cell adhesion to epithelial and 
endothelial cell monolayers by disrupting the LFA-1/ICAM-1 interaction.
8-12
 In 
addition to its receptor binding characteristics, cLABL displayed receptor mediated 
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endocytosis, insinuating a possible use as a targeting moiety for intracellular drug 
delivery.
11
 Accordingly, cLABL conjugated nanoparticles were proposed to be a 
promising anti-cancer drug delivery system targeting ICAM-1. 
Recently, monoclonal antibodies have become crucial therapeutic agents 
against a wide range of cancers. However, autoimmune reactions and short half-lives 
are often encumbrances for immunotherapy using monoclonal antibodies.
13, 14
 
Peptides and small molecule inhibitors may offer similar therapeutic interventions by 
acting as a targeting ligand to proteins on the cell surface.
1
 Furthermore, in 
comparison to monoclonal antibodies, cyclic peptides have been shown to offer 
improved physicochemical stability and may even improve selectivity to the targeted 
site.
1, 6
 
The utmost ambition of pharmaceutical therapy is to deliver the drug carriers 
to a specific therapeutic site of action with a triggered or sustained drug release. 
Advantages of this modality could include a decrease in adverse effects, lower 
toxicity, an increase in the efficacy of the therapeutic agent and a reduction in the 
frequency of administration. Polymeric nanoparticles (NP) possess some advantages 
over other formulations in terms of stability and feasibility of modulating the drug 
release profile by controlling polymer degradation.
15, 16
 In addition, this delivery 
system permits functional group modification on the nanoparticle surface without 
compromising the activity of the drug carried.  
In this study, cLABL-conjugated poly (DL-lactic-co-glycolic acid) 
nanoparticles (cLABL-NP) targeting ICAM-1 on A549 lung epithelial cells have 
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been formulated and characterized. Binding and internalization studies have 
demonstrated that nanoparticles can be targeted to these epithelial cells via ICAM-1 
and can be internalized into the cells rapidly. The cellular internalization was 
confirmed by utilizing fluorescence markers and microscopy. Interestingly, the 
results indicated that cLABL-NP trafficked to lysosomes and escaped lysosomal 
sequestration. Targeting and drug release studies of nanoparticles encapsulating 
doxorubicin (DOX-NP) suggested that PLGA nanoparticles targeted by cLABL 
localized this drug within A549 cells to offer sustained release. The IC50 of 
nanoparticles encapsulating doxorubicin, both conjugated and not conjugated with 
peptide compared to that of free doxorubicin HCl were reported.  Ultimately, 
cLABL-nanoparticles may be aerosolized to provide a targeted anti-cancer drug 
delivery system directly to the pulmonary epithelium. 
2.2 Materials and Methods 
Materials 
Poly(DL-lactic-coglycolic acid) (50:50) with terminal carboxylate group (PLGA, 
inherent viscosity 0.22 dL/g, Mw ~ 20 kDa and 0.67dL/g, Mw ~90 kDa) was 
purchased from LACTEL Absorbable Polymers International (Pelham, AL, USA). 
Pluronic
®
F-127, Texas Red Dextran (10,000 Mw, lysine fixable) and 4',6-diamidino-
2-phenylindole, dilactate (DAPI, dilactate) were purchased from Invitrogen 
Molecular Probes, Inc. (Carlsbad, CA, USA). 1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride (EDC) and N-
hydroxysulfosuccinimide (sulfo-NHS) were purchased from Thermo Fisher Scientific 
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Inc. (Rockford, IL, USA) Coumarin-6 was obtained from Polysciences, Inc. 
(Warrington, PA, USA). Doxorubicin HCl for injection was provided by Novaplus 
(Irving, TX, USA). Dialysis membrane (MWCO 100,000) was purchased from 
Spectrum laboratory Products Inc. (Rancho Dominguez, CA, USA). F-12K medium 
and A549 cell line were obtained from American Type Culture Collection (Manassas, 
VA, USA). Recombinant, Human, Tumor Necrosis Factor- (TNF-) was purchased 
from Promega (Madison, WI, USA). Human Interferon gamma was purchased from 
Roche Diagnostics Corporation (Indianapolis, IN, USA), 3,3′,5,5′-
Tetramethylbenzidine (TMB) was obtained from Sigma (St. Louis, MO, USA). 
Monoclonal anti-human CD54 (ICAM-1) Domain D1 was purchased from Ancell 
(Bayport, MN, USA) and Horseradish Peroxidase-Conjugated Goat Anti-Mouse IgG 
was obtained from Cayman Chemical (Ann Arbor, MI, USA). CellTiter 96
®
 AQueous 
Non-Radioactive Cell Proliferation Assay (MTS) was purchased from Promega 
(Madison, WI, USA) 
Methods 
Pluronic
®
F-127 functional group modification 
Terminal hydroxyl groups on Pluronic
®
F-127-OH were converted to carboxyl groups 
according to the following procedure (16). Pluronic
®
F-127-OH (2 g)was dissolved in 
tetrahydrofuran (THF, 60 ml). Then 4-dimethylaminopyridine (DMAP, 98 mg), 
triethylamine (108 l) and succinic anhydride (800 mg) were added. The mixture was 
stirred for 48 hr at room temperature. The solution was dried by rotary evaporation, 
and, was then dissolved in carbon tetrachloride (30 ml).Theexcess succinic anhydride 
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was removed by filtration. The Pluronic
®
F-127-COOH was purified by precipitation 
with ice-cold diethylether. The product was identified by 
1
H NMR sepctroscopy 
(Bruker AVANCE 400 MHz spectrometer) and FTIR spectroscopy (ABB Bomem 
MB series). 
Preparation of PLGA nanoparticles encapsulating coumarin-6  
Nanoparticles encapsulating a fluorescence marker, coumarin-6, were formulated 
using a solvent displacement method.
15
 In brief, PLGA, inherent viscosity 0.22 dl/g 
or 0.67 dl/g) was dissolved in trifluoroethanol (TFE, 18 mg/ml) containing coumarin-
6 (95 g). The solution was slowly transferred to a water phase containing surfactant; 
0.1% Pluronic
®
F-127-COOH (35 ml) under mild stirring (250 rpm). The 
nanoparticles were spontaneously formed due to the rapid removal of TFE. Excess 
surfactant was removed by dialysis against a 0.2% mannitol solution for 48 hr.  
Preparation of PLGA nanoparticles encapsulating doxorubicin  
Doxorubicin HCl for injection (2 mg/ml) was lyophilized and neutralized using 
triethylamine (108 mol). The non-aqueous form of doxorubicin was extracted using 
methylene chloride and evaporated.
17
 In brief, PLGA (0.22 dl/g or 0.67 dl/g) in 
acetone solution (18 mg/ml) was mixed with 1.8 mg of the purified doxorubicin. The 
solution was infused (17.5 ml/hr) into 10 ml of 0.1% Pluronic
®
F-127-COOH (250 
rpm) to allow the formation of nanoparticles encapsulating doxorubicin (DOX-NP). 
Nanoparticles were collected by centrifugation (15,000 rpm, 40 min) and washed 
three times. The nanoparticles encapsulating doxorubicin conjugated with cLABL 
(cLABL-DOX-NP) was prepared using the method described above. The 
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encapsulation efficiency was determined by centrifugation (13,000 rpm, 40 min) of 
the DOX-NP or cLABL-DOX-NP suspension (200 l) by collecting the pellet and 
dissolving in DMSO (200 l). Doxorubicin content was analyzed by fluorescence 
spectroscopy (Spectramax M5, ex: 500 nm, em: 600 nm). 
Conjugation of cLABL peptide to PLGA-nanoparticles 
A Pluronic
®
F-127-COOH coated PLGA nanoparticles (1.5 mg/ml) suspension was 
buffered using 2-(N-morpholino)ethanesulfonic acid (MES) pH 6.5. Nanoparticles 
were then incubated with 100 mM 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride (EDC) and 50 mM N-hydroxysulfosuccinimide (sulfo-NHS) for 15 
min.
18
The activated carboxyl terminus of Pluronic
®
 F127-COOH on the surface of 
nanoparticles was allowed to react with the amino terminus of the cLABL peptide (80 
M) at least 6 hr at room temperature. Conjugated NP were collected by 
centrifugation (10,000 rpm, 10 min) and washed three times with purified water. Size 
and charge of NP and cLABL-NP were characterized using dynamic light scattering 
(ZetaPALS, Brookhaven instrument Inc.).  The amount of free cLABL after the 
reaction was quantified by gradient reversed phase HPLC (SHIMADZU) using a C18 
column. The HPLC consisted of SCL-10A SHIMADZU system controller, LC-10AT 
VP SHIMADZU liquid chromatograph, SIL-10A XL SHIMADZU autoinjecter set at 
10 l injection volume, DGU-14A SHIMADZU degasser, sample cooler, and SPD-
10A SHIMADZU UV-Vis detector (220 nm). The HPLC-UV system was controlled 
by a personal computer equipped with SHIMADZU class VP Software. All 
separations were carried out using a Vydac
® 
HPLC column Protein and Peptide C18 
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column. Gradient elution was carried out at constant flow of 1 ml/min, from 100% A 
to 0% A (corresponding to 0% B to 100% B) for 15 min, followed by an isocratic 
elution at 100% B for 3 min. Mobile phase compositions were (A) acetronitrile-water 
(5:95) with 0.1% TFA (B) acetonitrile–water (90:10, v/v) with 0.1% trifluoroacetic 
acid (TFA). At the end of each analysis, the cartridge was re-equilibrated at 1 ml/min 
flow rate for 13 min with A. The density of peptide on the surface of nanoparticles 
was calculated from the total surface area assuming a normal Guassian particle size 
distribution. 
Drug release study of nanoparticles encapsulating doxorubicin  
The release of doxorubicin from cLABL-DOX-NP or DOX-NP was investigated 
using 0.1M acetate buffer pH 4 and phosphate buffer pH 7.4 as dissolution media. 
One milliliter of DOX-NP (4 mg/ml) or five hundred microliters of cLABL-DOX-NP 
(4 mg/ml) were placed in the dialysis membrane (MwCO 10,000) immersed in 100 
ml and 50 ml of buffer solution, respectively and were shaken at 100 rpm, 37C.19 At 
predetermined time points, the dialysate was sampled and the amount of released 
doxorubicin was determined using fluorescence spectroscopy (ex; 500 nm, em; 600 
nm). 
Cytotoxicity assay 
The CellTiter 96
®
 AQueous Non-Radioactive Cell Proliferation Assay
(a)
 is a 
colorimetric method used to  determine the viability of cells in this cytotoxicity study. 
ICAM-1 up-regulated A549 cells (80,000 cells/ml) were incubated with cLABL-
DOX-NP or DOX-NP for 3 hr and then were washed three times with PBS. Cells 
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were incubated in cell culture medium for 20 hr to allow the sustained release of the 
drug. For a control experiment, cells were incubated with doxorubicin HCl for 20 hr. 
After incubation, cells were washed three times with PBS. The solution composed of 
tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium,  MTS and an electron coupling reagent (phenazine 
methosulfate; PMS) (20 l) was added into each well containing 100 l of cell 
culture medium. The plate was then incubated at 37C, 5%CO2 for 4 hr. The quantity 
of formazan product was determined by the amount of 490 nm absorbance. 
Determination of ICAM-1 expression on A549 cells using Enzymed-Linked 
Immunosorbent Assay (ELISA) 
A549 carcinomic human alveolar basal epithelial cells were cultured in F12K 
medium with 10% fetal bovine serum (FBS) and 1% Penicillin-Streptomycin (10,000 
U/ml) 37C, 5% CO2. Cell monolayers were incubated with TNF- (1,000 U/ml) or 
IFN- (100 U/ml) for 48 hr to activate the up-regulation of ICAM-1 on the cell 
surface.
20
ICAM-1 expression was measured using an indirect ELISA. A549 cells (8 x 
10
5 
cells/ml) were seeded in a 96 well-plate. Cells were fixed by using 2% 
formaldehyde in PBS (100 l/well) and incubated at room temperature for 1 hr. Cells 
were washed with PBS (200 l/well) and then non-specific adsorption was blocked 
by incubating with 1% BSA in PBS (120 l/well) for 30 min at room temperature. 
After washing with PBS, monoclonal anti-human CD54 (ICAM-1) domain D1 
(120l/well) was added and incubated 1 hr at 37ºC.  Goat anti-mouse IgG HRP (100 
l/well) was then added after washing with PBS and incubated for 1 hr at 37ºC. Cells 
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were washed three times with PBS and incubated with 3,3‟,5,5‟ tetramethylbenzidine 
as the substrate for 15 min at room temperature. The enzyme-substrate reaction was 
stopped by adding 1 N sulfuric acid. The absorbance was obtained by UV 
spectroscopy (Spectramax M5; max 450 nm) 
Binding and Uptake of Nanoparticles by A549 cells 
A549 cell monolayers were incubated with TNF- (1,000 U/ml) for 48 hr to over 
express ICAM-1 receptors. Cells were then washed three times with serum free F12K 
and then incubated with nanoparticles (with or without cLABL conjugated) 
suspended in serum free medium (0.5 mg/ml). Cells were incubated with 
nanoparticles for different time intervals to observe the uptake kinetics of particles. 
After incubation, cells were washed three times with ice-cold PBS and lysed with 
0.5% Triton X-100 in 0.2 M NaOH.
21
 cLABL-NP and NP associated with the cells 
were detected and compared using a fluorescence plate reader (Spectramax M5; ex: 
450 nm, em: 500 nm).
22
 
Inhibition of cLABL-NP binding to ICAM-1 
Various concentrations of free cLABL peptide or anti-ICAM-1 mAbs were incubated 
with activated A549 cells for 30 min, 37ºC, 5% CO2. Cells were then washed three 
times with serum free media and incubated with cLABL-NP or nanopartilces without 
peptide for 1 hr at the same condition. Cells were washed three times with ice-cold 
PBS, lysed with 0.5% Triton X-100 in 0.2 M NaOH. cLABL-NP and NP content 
bound to the cell surface or internalized into the cells were determined and compared 
by fluorescence spectroscopy (Spectramax M5; ex: 450 nm, em: 500 nm).  
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Intracellular trafficking of cLABL-NP to lysosomes 
ICAM-1 on A549 cells were activated using (1,000 U/ml) TNF- for 48 hr.  
Lysosomes were labeled with Texas Red dextran (10,000 Mw, lysine fixable) to 
indicate the location of lysosomes. Texas red dextran prepared in serum free F12K (1 
mg/ml) was incubated with activated A549 cells for 2 hr. Cells were then washed 
with serum free media for three times and further incubated with serum free media 
for up to 12 hr in order to chase the red fluorescent dye to localize in lysosomes.
23, 24
 
Cells were then incubated in the presence of cLABL-NP or NP containing the green 
fluorophore, coumarin-6, for 10 min. Cells were washed three times and incubated 
with serum free medium for each time point. After washing with ice-cold PBS, cells 
were fixed with 4% formaldehyde solution. Fluorescence emissions of nanoparticles 
and lysosomes were observed using FITC and rhodamine filter sets, respectively 
(Nikon Eclipse 80i microscope equipped for epifluorescence). Micrographs were 
captured using an Orca ER camera (Hamamatsu, Inc., Bridgewater, NJ). 
Colocalizations of nanoparticles and lysosomes were analyzed by Metamorph, 
version 6.2 (Universal Imaging Corp., West Chester, PA) 
Intracellular trafficking of doxorubicin and nanoparticles encapsulating 
doxorubicin  
TNF- activated A549 cells were incubated with free doxorubicin (0.5 mg/ml) or 
doxorubicin encapsulated in nanoparticles conjugated with cLABL (cLABL-DOX-
NP) or without cLABL (DOX-NP) (3.8 mg/ml) for 1 hr (for 1 hr observation) and 3 
hr (for 3 hr, 8 hr and 24 hr observation). Cells were then washed three times with ice-
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cold PBS and incubated with media with serum for each time period (8 hr and 24 hr). 
Cells were fixed with 4% paraformaldehyde. Nuclei were labeled with DAPI dilactate 
(blue) (300 nM, ex: 358 nm, em: 461 nm) for 5 min at 37ºC, 5%CO2. Micrographs 
were taken using the Nikon Eclipse microscope. 
For some studies, nanoparticles encapsulating doxorubicin contained the 
fluorophore, coumarin-6, to indicate the location of particles in the cells. cLABL-
DOX-NP and DOX-NP encapsulating coumarin-6 were incubated with cells for each 
time period (15 min, 30 min, 1 hr and 3 hr). Cells were washed three times with ice-
cold PBS and fixed with 4% paraformaldehyde. Nuclei were labeled with DAPI 
dilactate (blue) (300 nM, ex: 358 nm, em: 461 nm) for 5 min at 37ºC, 5%CO2. 
Micrographs were taken using the Nikon Eclipse microscope. 
Statistical analysis 
Statistical evaluation of data was performed using an analysis of variance (one-way 
ANOVA). Newman–Keuls was used as a post-hoc test to assess the significance of 
differences. To compare the significance of the difference between the means of two 
groups, the t-test was performed; in all cases, a value of p < 0.05 was accepted as 
significant. 
2.3 Results and Discussion 
Preparation of Carboxylated Pluronic
®
 F-127 
The hydroxyl groups of Pluronic
®
 F-127, HO(C2H4O)100(C3H6O)65(C2H4O)100H, were 
converted to carboxyl groups to facilitate the conjugation reaction of this surfactant 
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with the terminal amine of cLABL peptide.
25
 The 
1
H NMR spectrum displayed the 
absorption of methylene protons adjacent to the succinic moiety at  = 4.1 ppm and 
the proton of the carboxylic acid at  = 12 ppm (Figure 1).16 The COOH formation 
was confirmed by FTIR spectroscopy. The FTIR spectrum showed a strong C=O 
stretching absorption at  1,720 cm
-1
 and a very broad, strong absorption at         3,500 
cm
-1
,  which indicated the appearance of the hydroxyl of carboxylic acid (Figure 2). 
These results confirmed the formation of carboxylated Pluronic
®
 F-127. 
Preparation of PLGA nanoparticles encapsulating coumarin-6  
PLGA nanoparticles were prepared by a spontaneous solvent displacement method 
using carboxylated Pluronic
®
 F-127as an anionic surfactant. Dynamic light scattering 
showed that the size of nanoparticles encapsulating coumarin-6 was approximately 
225 nm in diameter with a low polydispersity suggesting a narrow size distribution, 
and that the zeta potential value was about -45 mV (Table 1). An increase in size and 
negative charge of nanoparticles after conjugation with cLABL peptide was 
observed, which was expected due to the pI value of cLABL peptide (pI~3.5). The 
size and charge of nanoparticles encapsulating coumarin-6 were comparable when 
either form of PLGA (0.22 dl/g or 0.67 dl/g) was used to formulate nanoparticles. 
The encapsulation efficiencies of coumarin-6 in both nanoparticles were reported in 
Table 2. As expected, the encapsulation efficiencies were diminished in both types of 
PLGA after the conjugation reaction. 
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Figure 1 (A) The proton NMR spectrum of Pluronic
®
 F127 (B) Proton NMR 
spectrum of carboxylated Pluronic
®
 F-127 displaying the absorption of methylene 
protons adjacent to the succinic moiety at  = 4.1 ppm and the proton of the 
carboxylic acid at  = 12 ppm. 
 
 
 
A 
B 
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Figure 2 (A) FTIR spectrum of Pluronic® F127. (B) Compared to unmodified 
Pluronic®, the FTIR spectrum showed a strong C=O stretching absorption at 1,720 
cm
-1
 and a very broad, strong absorption at 3,500 cm
-1 
which indicated the appearance 
of the hydroxyl of carboxylic acid. 
A 
B 
60 
 
Preparation of PLGA nanoparticles encapsulating doxorubicin 
A variety of mAbs have been identified for immunotherapy against a wide range of 
cancers.
26
 Peptides that can target the immunoglobulin receptor offer a simple 
alternative to mAbs. The cLABL peptide itself has a therapeutic effect, however, 
potency may be improved by using this ligand to target drug loaded nanoparticles. 
Nanocarriers often exhibit various benefits such as prolonged circulation and tumor 
localization via the enhanced permeability and retention effect.
17
 Doxorubicin, one of 
the most widely used anti-cancer drugs, was incorporated in nanoparticles in this 
study. 
 Nanoparticles encapsulating doxorubicin was prepared and characterized in this 
study. The size and charge of doxorubicin loaded nanoparticles increased after 
conjugation with the cLABL peptide (Table 1). The encapsulation efficiency of 
doxorubicin in nanoparticles was acceptable at 41 ± 4.8 % and 51 ± 7.6% when 
PLGA Mw~20 KDa and ~90 KDa were used to formulate nanoparticles, respectively 
(Table 2). After the conjugation reaction, the encapsulation efficiency was reduced by 
~54 and ~47% when PLGA Mw~20 KDa and ~90 KDa w ere reacted with cLABL, 
respectively. However, other studies have suggested that the encapsulation efficiency 
may be increased by an ester linkage of the carboxylic acid end group of PLGA and 
the hydroxyl group of doxorubicin, which results in retention of doxorubicin during 
the nanoparticle preparation procedure.
27
 Ultimately, doxorubicin serves as a 
convenient fluorescent marker for these studies and more hydrophobic drugs would 
likely offer improved encapsulation efficiencies. 
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Table 1 Nanoparticle properties prepared from PLGA 0.22 and 0.67 dl/g at specified formulation points 
Values are representative of three determinations (mean ± S.D.)
 Coumarin6-NP cLABL-coumarin6-NP DOX-NP cLABL-DOX-NP 
PLGA Inherent -
viscosity (dl/g) 
0.22 0.67 0.22 0.67 0.22 0.67 0.22 0.67 
Effective diameter 
(nm) 
224 ± 2.7 226 ± 4.5 243 ± 6.6 241 ± 0.8 264 ± 7.8 280 ± 15.4 303 ± 3.6 286 ± 10.3 
Polydispersity 0.11 ± 0.03 0.10 ± 0.05 0.05 ± 0.01 0.07 ± 0.04 0.14 ± 0.07 0.19 ± 0.01 0.15 ± 0.01 0.19 ± 0.09 
Zeta potential value 
(mV) 
-47 ± 3.1 -45 ± 2.8 -49 ± 3.8 
 
-59 ± 2.8 
 
-29 ± 0.4 -38 ± 3.0 -43 ± 0.6 -45 ± 3.2 
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Table 2 Encapsulation efficiency (%) of coumarin-6 and doxorubicin in nanoparticles  
 Encapsulation efficiency (%) 
Coumarin6-NP cLABL-
coumarin6-NP 
DOX-NP cLABL- 
DOX-NP 
PLGA 0.22 dl/g 51 ± 1.2 33 ± 5.0 41 ± 4.8 19 ± 2.1 
PLGA 0.67dl/g 60 ± 2.4 37 ± 1.3 51 ± 7.6 27 ± 5.4 
 Values are representative of three determinations (mean ± S.D.) 
 
Table 3 Density of cLABL on the surface of PLGA nanoparticles 
 Size (nm) Total surface area 
(m
2
/g of PLGA) 
Surface cLABL 
(pmol/cm
2
)
a
 
PLGA 0.22 dl/g 243 18.4 55 ± 0.8 
PLGA 0.67dl/g 241 18.6 51 ± 2.1 
Values are representative of three determinations (mean ± S.D.) 
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Conjugation of cLABL peptide on the surface of nanoparticles 
The efficiency of the coupling reaction between the amino group of cLABL and the 
carboxyl of Pluronic
®
 F-127-COOH coated on nanoparticles was determined. The 
amounts of free cLABL were analyzed (prior to and after the reaction) by reversed 
phase HPLC. The peptide density on the surface of nanoparticles encapsulating 
coumarin-6 was calculated from the total surface area assuming a normal Guassian 
particle size distribution.
28
 The density of peptide on both types of nanoparticle 
surfaces (0.22 dl/g and 0.67 dl/g) were comparable (Table 3). The calculation showed 
a higher density of cLABL conjugated compared to previous studies.
28
which 
conjugated the peptide with polyethylene glycol (PEG)-modified poly(ethylene-alt-
maleic acid) on the nanoparticle surface. This may be due to the more available 
carboxyl groups of Pluronic
®
-COOH coated on the nanoparticle surface. Therefore, 
the use of modified Pluronic
®
 may reduce the steps of the conjugation reaction, and 
also increase the density of peptide conjugated.
28
 
In vitro drug release study of nanoparticles encapsulating doxorubicin 
Generally the release of doxorubicin from the drug carriers was pH dependent 
probably due to the increase in solubility of doxorubicin at mildly acidic pH.
29, 30
 The 
release of the drug at pH 4 and 7.4 were determined for doxorubicin encapsulated in 
cLABL-NP and untargeted NP. These pH values were selected to represent 
extracellular and lysosomal pH values. The drug release from PLGA nanoparticles 
was determined using PLGA inherent viscosity 0.67 dl/g in acetate buffer at pH 4 and 
phosphate buffer at pH 7.4.  The release of doxorubicin from cLABL-DOX-NP 
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followed a biphasic profile regardless of pH (Figure 3). The release profile was 
characterized by a rapid release in the initial stage. The release of doxorubicin began 
with an initial burst of 35 ± 1.7% and 34 ± 2.8% from cLABL-DOX-NP at pH 4 and 
7.4, respectively, in the first three hours of the study. Drug burst may result from the 
large surface to volume ratio of nanoparticles and from rapid loss of drug via 
diffusion through the polymer matrix at or near the particle surface. The initial burst 
phase was followed by slow and sustained release. The slower phase likely resulted 
from continued diffusion through the PLGA matrix.
31
 
  A higher amount of doxorubicin was released from unmodified PLGA 
nanoparticles at pH 4 compared to at pH 7.4. The release profile of the drug from NP 
without peptide showed a greater initial burst at pH 4 and pH 7.4 in a comparison to 
the conjugated peptide, i.e., 76 ± 4.4% vs 35 ± 1.7% and 53 ± 2.7% vs 34 ± 2.8%, 
respectively, in first three hours. The rapid release at the initial state may be due to 
the high aqueous solubility of the protonated form of doxorubicin at the glycosidic 
amine in a low pH medium.
29, 30
 Interestingly, doxorubicin was released from 
cLABL-NP in a higher amount in higher pH medium (pH 7.4) compared with 
medium pH 4 as shown in Fig. 8 The more increasing release of doxorubicin from 
cLABL-DOX-NP in higher basic pH may have resulted from the agglomeration of 
the nanoparticles during the release study at pH 4. At higher pH, cLABL has higher 
negatively charge compared to at more acidic pH (pI~3.5). The high amount of 
doxorubicin released at this pH should be considered for drugs delivered by this 
nanoparticle formulation. The cLABL-NP would need to rapidly localize to the lung 
epithelium expressing ICAM-1 to avoid premature drug release supporting the 
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pulmonary delivery as a choice of the route of administration.  Furthermore, selection 
of more hydrophobic chemotherapeutic agents may be appropriate.  
 
 
 
 
 
 
 
Figure 3 The release of doxorubicin from cLABL-NP began with an initial burst of 
35.2±1.7% and 34.1±2.8% at pH 4 () and pH 7.4 (), respectively, in the first 3 h 
of the study. Data are presented as mean ± S.D. (n = 3).  
Cytotoxicity assay 
The cytotoxicity of doxorubicin HCl, cLABL-DOX-NP and DOX-NP to A549 cells 
was evaluated by using MTS assay. The IC50 value of free doxorubicin, doxorubicin 
released from cLABL-NP and doxorubicin released from unconjugated NP was 60, 
30 and 53 g/ml, respectively. The cytotoxicity of doxorubicin released from 
nanoparticles was comparable to that of free doxorubicin. The concentrations of 
doxorubicin in nanoparticles were calculated from the drug loading adjusted by the 
encapsulation efficiency. The relative IC50 value of doxorubicin from each 
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formulation suggested that the activity of drug encapsulated in nanoparticles were not 
affected by the encapsulation and conjugation reaction. The IC50 values of cLABL-
DOX-NP and DOX-NP were 3.1 and 3.3 mg/ml, respectively.  PLGA NP without 
doxorubicin did not show any cytotoxicity up to 10 mg/mL (data not shown) 
suggesting that the doxorubicin is slowly released from these non-cytotoxic carriers. 
Modification of PLGA NPs with cLABL díd not negatively affect the cell viability 
Uptake and Internalization of Nanoparticles 
Pro-inflammatory cytokines such as TNF- have previously been shown to 
upregulate the expression of ICAM-1.
20
 Incubating A549 cells with TNF- (1,000 
U/ml) or IFN- (100 U/ml) resulted in about 5 fold and 4 fold increase of ICAM-1, 
respectively, as determined by ELISA (Figure 4). This result confirmed the 
overexpressed of ICAM-1 and validated the use of this cell line as an inflammatory 
epithelial cell model. The binding and uptake of cLABL-NP to A549 cells were 
found to be significantly more rapid compared to untargeted NP. The increasing 
fluorescence intensity demonstrated the increasing amount of nanoparticles bound or 
taken up by cells (Figure 5). In the presence of cLABL-NP, the fluorescence intensity 
was 2.3 fold higher compared to the control nanoparticles after 5 min of incubation. 
The difference in the uptake extent diminished when the incubation time increased. 
This result may indicate saturation of ICAM-1 receptors. In addition, A549 cells have 
been shown to endocytose nanoparticles extensively, which may explain the 
significant uptake of unlabeled nanoparticles.
32
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 A blocking study demonstrated the inhibition of cLABL-NP binding to ICAM-1 
by free cLABL and anti-ICAM-1 mAbs. The depletion of fluorescence intensity 
showed that the binding of cLABL-NP to ICAM-1 was impeded when free cLABL 
was incubated with cells first (Figure 6A) suggesting a specific binding of cLABL-
NP to ICAM-1 on A549 cells.
33
In addition, a decrease in fluorescent intensity was 
shown when anti-ICAM-1 was pre-incubated with the cells; however, the difference 
was not statistically significant (Figure 6B).   
 
 
 
 
 
 
 
 
Figure 4 (A) Effect of IFN- on A549 ICAM-1 expression. Confluent monolayers of 
A549 cells were incubated 48 hr with IFN- (0-600 U/ml), and ICAM-1 expression 
was determined by ELISA. Data were presented as mean ± S.D. (n=3). (B) 
Expression of ICAM-1 activated by TNF- (1000 U/ml) was significantly higher 
A B 
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than IFN- (100 U/ml) and non-activated A549 cells. Data are presented as mean ± 
S.D. (n = 3). *** indicates p<0.001. 
 
 
 
 
 
 
 
 
Figure 5 Fluorescent intensity of cLABL-NP was significantly higher than 
untargeted NP for short incubation periods. Cells were incubated with nanoparticles 
(0.5 mg/ml) for different time intervals to observe the uptake particles. Cell lysates 
were analyzed by fluorescence spectroscopy. Data are presented as mean ± S.D. (n = 
3). ***p<0.001 and *p<0.05. 
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Figure 6 (A) The depletion of fluorescence intensity showed the inhibition of cLABL 
to the binding and internalization of cLABL-NP. Free cLABL peptide was incubated 
with cells for 30 min. Cell were then washed and incubated with nanoparticles for 1 
hr. Cell lysates were analyzed by fluorescence spectroscopy. (B) Anti-ICAM-1 pre-
incubated with cells reduced the fluorescent intensity but the difference was not 
statistically significant. Cells were treated with anti-ICAM-1 for 30 min, and then 
B 
A 
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incubated with nanoparticles for 1 hr. Cell lysates were analyzed by fluorescence 
spectroscopy. Data are presented as mean ± S.D. (n = 3). ***p<0.001 and **p<0.01. 
Intracellular trafficking of cLABL-NP to lysosomes 
The cLABL-NPs were observed to rapidly internalize into A549 cells after the 15 
min incubation period. This rapid internalization of ICAM-1 targeting nanoparticles 
agreed with internalization of nanocarriers targeted using anti-ICAM-1 monoclonal 
antibodies studied by Muro et al (15-30 min).
34
 The binding and internalization of 
cLABL-NP were likely induced by the multimeric nature of ICAM-1 ligands 
(cLABL) on the nanoparticle surface.
34
 In this study, cLABL-NPs were observed to 
accumulate in lysosomes at 1 hr after binding to the cell surface. Subsequently, the 
colocalization of cLABL-NP with lysosomes steadily decreased until no 
colocalization was observed at 24 hr (Figure 7). 
 The intracellular trafficking kinetics of cLABL-NP may have advantages in 
comparison to unconjugated NP or free drug.  Muro et al. report that the cLABL-NP 
spend more time in the early endosomes as described in the trafficking study of anti-
ICAM-1 nanoparticles into HUVECs.
34
  The result in this study revealed that 
internalized cLABL-NP may traffic away from lysosomes. The removal of cLABL-
NP, from lysosomes was probably not due to disruption of the lysosomes because 
there was no change in the distribution of Texas Red conjugated dextran during 24 hr 
of incubation observed in this study.
35
 Overall, the results suggested that the 
lysosomal degradation of cLABL-NP may be less pronounced by this intracellular 
trafficking pathway. The therapeutic activity of cytotoxic drugs may also be 
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prolonged by avoiding enzymatic degradation in the lysosomes by lysosomal 
sequestration.  
Untargeted nanoparticles merged with lysosomes at 2 hr after incubation but 
to a lower extent compared to ICAM-1 targeted NPs (Figure 8). This result suggested 
that nanoparticles without peptide may be taken up more slowly than targeted NP 
which agrees with the result of our uptake study described above. The accumulation 
of untargeted NPs was also not observed at a later time point of incubation. A 
mechanism of escape of PLGA-NP has been proposed previously by the fact that 
PLGA-NP may undergo charge neutralization during trafficking.
35
 The removal of 
particle charge was suggested to mediate membrane association leading to the escape 
of nanoparticles.
35 
 
 
 
 
 
 
 
 
 
72 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 Localization of cLABL-NP with lysosomes (red) was observed at 1 hr after 
incubation with cells. The extent of colocalization decreased thereafter. Cells were 
incubated in the presence of cLABL-NP for 10 min, washed and incubated with 
serum-free medium for each time point. Selected colocalizartions of NP and 
lysosomes are indicated by the white arrows.  
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Figure 8 Colocalization of untargeted NP with lysosomes was greatly decreased 
compared to ICAM-1 targeted NP. Selected colocalizations of NP and lysosomes are 
indicated by the white arrows. 
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Intracellular trafficking of doxorubicin and cLABL-NP encapsulating 
doxorubicin 
The cLABL-DOX-NP and DOX-NP were incubated with A549 cells to study 
intracellular trafficking. Intracellular localization of free doxorubicin, cLABL-DOX-
NP and DOX-NP were investigated using fluorescence microscopy. Free 
doxorubicin, which is fluorescent (red), was used as a control. The nuclei of cells 
were stained with the blue fluorescence dye, DAPI. The photographs of cLABL-
DOX-NP, DOX-NP and free doxorubicin were combined with the stained nuclei to 
observe the colocalization of the doxorubicin and the nuclei. The merged 
micrographs showed that free doxorubicin displayed rapid colocalization with the 
nuclei of A549 cells (in 1 hr) as expected (Figure 9A). Cells exposed to cLABL-
DOX-NP exhibited a small degree of colocalization of doxorubicin and nuclei in 
some cells during the first hour of the study (Figure 9B). This result suggested that a 
small amount of doxorubicin may be released and localized in the nuclei as indicated 
by the faint purple color in the nuclei. The colocalization of the drug and the nuclei 
shown from the color combination was further observed until 24 hr. In contrast, this 
colocalization of doxorubicin and the nuclei was observed at later time (3 hr) for the 
untargeted NP (Figure 9C). Doxorubicin was also observed to localize within the 
nuclei until 24 hrs. In a comparison to free doxorubicin, doxorubicin encapsulated in 
nanoparticles was slowly released and localized in the nuclei more gradually after 
cellular uptake. This result provided evidence to the capability of nanoparticles to 
offer targeted, intracellular delivery of this cytotoxic drug and suggested the 
prolonged retention of doxorubicin and sustained release of drug from nanoparticles. 
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Also, the yellow dots in overlaid pictures of cLABL-NP or NP (green) and 
doxorubicin (red) confirmed the retention of doxorubicin in nanoparticles 
encapsulating coumarin (green) (Figure 10A and B). The colocalization of dye and 
drug suggested that the images show the uptake of nanoparticles containing drug and 
not released drug.  
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Figure 9 (A) The colocalization of doxorubicin HCl and the nuclei was observed at 1 
hr after incubation of the drug with cells. (B) The colocalization of doxorubicin 
released from cLABL-DOX-NP was observed at 1 hr but with a less extent compared 
to free drug. (C) The released doxorubicin from untargeted NP localized in the nuclei 
was observed at 3 hrs. The white arrow indicates the colocalization. 
 
C 
78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
79 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 (A) Colocalization of doxorubicin co-encapsulated with coumarin-6 in 
cLABL-DOX-NP. (B) Colocalization of doxorubicin co-encapsulated with coumarin-
6 in DOX-NP. The white arrow indicates the colocalization of coumarin-6 and 
doxorubicin. 
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2.4 Conclusion 
This work has aimed to further develop the role of cLABL as a means of targeting 
PLGA NP to a molecular marker, ICAM-1, associated with inflammatory diseases 
and cancer. Targeted nanoparticles are of increasing interest because they may allow 
a reduction of adverse side effects and increase the efficacy of a drug by localizing it 
to the desired site of action. PLGA has advantages over other polymers due to its 
biodegradability, biocompatibility and approval by the FDA. Besides, PLGA NPs 
have provided controlled drug release in several studies, which lowered observed side 
effects.
15, 17, 35, 36
 Here, PLGA nanoparticles targeting the immunologically active 
receptor, ICAM-1, were formulated by attaching the cLABL peptide to the 
nanoparticle surface. The cLABL-NP displayed specific binding to ICAM-1 
compared to non-targeted NP. The cLABL-NPs were also more rapidly taken into 
A549 lung epithelial cells induced to overexpress ICAM-1. Intracellular trafficking 
studies showed that cLABL-NP accumulated in lysosomes for 1 hr and then left after 
3 hr. Conversely, untargeted NP accumulated in lysosomes more slowly (2 hr), and 
also left at a later time point. cLABL-NP encapsulating doxorubicin also accumulated 
quickly in A549 cells. Drug release studies indicated that the cLABL-NP formulated 
with a high Mw PLGA exhibited sustained drug release that depended on pH. Finally, 
the cytotoxicity study of cLABL-NP and NP compared to free doxorubicin HCl 
showed similar IC50 values suggesting that the activity of the drug released from 
nanoparticles was retained. These studies verified that cLABL can target 
nanoparticles to lung epithelial cells to deliver chemotherapeutics and provide 
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controlled release drug delivery. The effectiveness of targeted delivery in vivo must 
be inquired in future studies. 
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Chapter 3 
cIBR effectively targets nanoparticles to LFA-1 on acute lymphoblastic T cells 
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3.1 Introduction 
Leukocytes play an important role in disease defense and participate in the 
adaptive immune response. Under normal conditions, leukocytes circulate between 
the blood stream and the lymphatic system as non-adherent cells.
1
 Upon receiving 
signals from inflammatory mediators, various cell adhesion molecules are up-
regulated and leukocytes are recruited to the vascular endothelium.
1
 Leukocytes 
selectively accumulate at sites of inflammation via this multivalent adhesion 
mechanism and subsequently migrate into underlying tissues.
2
 Several adhesion 
molecules mediate the process including members of the integrin family and their 
immunoglobulin (Ig) superfamily ligands.
1, 3
 The recruitment of leukocytes from the 
blood stream to the inflammatory site involves a multistep adhesion cascade (e.g. 
tethering, rolling, activation and arrest). The integrins playing a major role during 
arresting and transmigration are LFA-1, 41 and 47 which bind to members of the 
immunoglobulin superfamily on endothelium such as ICAM-1.
4 
In inflammatory 
diseases, the extravasation of leukocytes into the inflammed tissues ultimately 
propagates further inflammation which may lead to a chronic disease state. LFA-1 
has emerged as an interesting target for treatment of inflammatory diseases and drug 
delivery. 
LFA-1 is constitutively expressed in a low affinity conformation on the 
plasma membrane of leukocytes.
5
The ligand binding activity of LFA-1 is tightly 
regulated. LFA-1 activation results in an increase in the affinity for ligand induced by 
a conformational change, and clustering of integrins on the cell surface.
4
 Rolling 
leukocytes respond to chemokines on vascular endothelial cells by expressing 
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specific receptors that transmit intracellular signals through G proteins.
4
 Chemokine 
receptor signaling changes the conformation of LFA-1 from a closed form (low 
affinity conformation) on the T-cell surface to open form (high affinity conformation) 
and hence enables T-cells to adhere and then migrate across the vascular wall. LFA-1 
clustering is initiated by lateral migration of integrins to form multivalent binding 
foci, thus strengthening the adhesion.
6
 
Leukocytes express molecules from the 2 integrin subfamily which includes 
leukocyte function associated antigen-1 (LFA-1, L2, CD11a/CD18), MAC-1 
(CD11b/CD18) and P150, 95 (CD11c/CD18). These molecules mediate binding to 
the intercellular adhesion molecule-1 (ICAM-1) Ig superfamily.
2, 3
 ICAM-1 (CD54) 
is the major LFA-1 ligand expressed on endothelial cells, epithelial cells and on 
antigen presenting cells (APC). ICAM-1 is up-regulated by proinflammatory 
cytokines such as IL-1, IL-4, IL-6, TNF- and IFN- during inflammation. LFA-1 
binds to ICAM-1 via specific interaction between the I domain of LFA-1 and domain 
1 (D1) of ICAM-1. Blockade of this molecular interaction using monoclonal 
antibodies has been shown be efficacious against acute inflammation
7
, and 
autoimmune diseases such as diabetes
8
, rheumatoid arthritis 
9
 and psoriasis
10, 11 
in 
addition to suppressing allograft rejection.
12, 13 
Here, a small peptide antagonist known to allosterically block binding of 
ICAM-1 to LFA-1 was used as a targeting ligand for nanoparticles.
14
 cIBR (cyclo 
1,12) Pen-PRGGSVLVTGC-OH is a cyclic peptide derived from D1 of ICAM-1. 
NMR, docking experiments and competitive inhibition by anti-LFA-1 have shown 
that the binding site of cIBR is on the I domain of LFA-1.
14-16
 cIBR has been 
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characterized to bind to the L site of the I domain of PMA activated LFA-1.
14
 This 
peptide has been shown to interfere with T cell homotypic and heterotypic adhesion 
and with mixed lymphocyte reaction.
16-18
 Interestingly, cIBR has been reported to be 
internalized by LFA-1 integrin on the surface of T cells, but not internalized into 
LFA-1 deficient cell lines
14-15, 19
, suggesting that cIBR could be used as a targeting 
ligand for selective intracellular drug delivery to leukocytes. 
LFA-1 mediated adhesion is mediated by integrin clustering in addition to the 
activation of this receptor. Although the mechanism of clustering remains to be 
clarified
6
, receptor clustering appears to be the consequence of an initial high affinity 
interaction of LFA-1 with multivalent ICAM-1.
5-6
 Multivalent interactions of 
multiple ligands on nanoparticles can increase the binding avidity by orders of 
magnitude.
20
 In this study, cIBR peptide was conjugated to the surface of 
nanoparticles to mimic the clustering of ICAM-1 and hence increase the avidity of 
binding to LFA-1 on T-cells. cIBR conjugated nanoparticles (cIBR-NPs) bound to 
LFA-1 on T-cells (Molt-3) more rapidly and to a greater extent compared to 
untargeted nanoparticles. In addition, cIBR-NPs were shown to block the adhesion of 
Molt-3 cells to A549 lung epithelial cells. These findings suggest a potential dual 
therapeutic mechanism for cIBR-NPs to control inflammatory diseases by blocking 
leukocyte adhesion and by targeting the delivery of drugs (e.g. anti-inflammatory 
agents). 
3.2 Materials and methods 
Materials 
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cIBR peptide (Cyclo(1,12)-Pen-PRGGSVLVTGC-OH) (Mw 1,174.5) was 
synthesized on a Pioneer peptide synthesizer (PerSeptive Biosystems, CA). Poly(DL-
lactic-co-glycolic acid) (50:50) with terminal carboxyl group (PLGA, inherent 
viscosity 0.67dL/g, Mw ~90 kDa) was purchased from LACTEL Absorbable 
Polymers International (Pelham, AL, USA). Pluronic
®
F-127, Texas Red Dextran 
(10,000 kDa, lysine fixable) and 2',7'-bis-(2-carboxyethyl)-5-(and-6)-
carboxyfluorescein, acetoxymethyl ester (BCECF, AM) were purchased from 
Invitrogen Molecular Probes, Inc. (Carlsbad, CA, USA). Coumarin-6 was obtained 
from Polysciences, Inc. (Warrington, PA, USA). Dialysis membrane (MwCO 
100,000) was purchased from Spectrum laboratory Products Inc. (Rancho 
Dominguez, CA, USA). RPMI 1640 medium, A549 cell line and the Molt-3 cell line 
were obtained from American Type Culture Collection (Manassas, VA, USA). 
Phorbol 12-myristate 13-acetate (PMA) was purchased from BIOMOL International, 
L.P. (Plymouth Meeting, PA). 
Methods 
PLGA nanoparticle preparation and characterization 
Nanoparticles encapsulating a fluorescent marker, coumarin-6, were formulated using 
a solvent displacement method.
21
 In brief, PLGA was dissolved in acetone (18 
mg/ml) containing coumarin-6 (50 g/ml). The solution was slowly transferred to a 
water phase containing 0.1% Pluronic
®
F-127-COOH (25 ml) under mild stirring (300 
RPM). Terminal hydroxyl groups on Pluronic
®
F-127 were converted to carboxyl 
groups according to a reported procedure.
22-23 
The nanoparticles spontaneously 
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formed due to the rapid removal of acetone. Excess surfactant was removed by 
dialysis against a 0.2% mannitol solution for 48 hrs.  
A series of PLGA nanoparticles encapsulating coumarin-6 were formulated 
according to the above procedure. For the preparation of nanoparticles coated with 
various ratios of carboxylic acid functional group of Pluroinic F127 surfactant, 0%, 
25%, 50% and 100% of 0.1% Pluronic
®
-COOH solution were mixed with 100%, 
75%, 50% and 0% of 0.1% Pluronic
®
-OH solution, respectively.  
Conjugation of cIBR peptide to PLGA-nanoparticles 
Pluronic
®
F-127-COOH coated PLGA nanoparticles (2.2 mg/ml) were buffered using 
2-(N-morpholino)ethanesulfonic acid (MES; pH 6.5). Nanoparticles were then 
incubated with 100 mM 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride (EDC) and 50 mM N-hydroxysulfosuccinimide (sulfo-NHS) for 15 
min.
23
The activated carboxyl terminus of Pluronic
®
 F127-COOH on the surface of 
nanoparticles was allowed to react with the amino terminus of the cIBR peptide (170 
M) at least 12 hrs at room temperature. Conjugated NPs were collected by 
centrifugation (16,089 g, 10 min) and washed three times with purified water. The 
size and charge of NPs and cIBR-NPs were characterized using dynamic light 
scattering (ZetaPALS, Brookhaven instrument Inc.). 
The amount of free cIBR after the reaction was quantified by gradient 
reversed phase HPLC (SHIMADZU) using a C18 column. The HPLC consisted of 
SCL-10A SHIMADZU system controller, LC-10AT VP SHIMADZU liquid 
chromatograph, SIL-10A XL SHIMADZU autoinjecter set at 10 l injection volume, 
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DGU-14A SHIMADZU degasser, sample cooler, and SPD-10A SHIMADZU UV-
Vis detector (220 nm). The HPLC-UV system was controlled by a personal computer 
equipped with SHIMADZU class VP Software. All separations were carried out 
using a Vydac® HPLC Protein and Peptide C18 column. Gradient elution was carried 
out at constant flow of 1 ml/min, from 100% A to 0% A (corresponding to 0% B to 
100% B) for 15 min, followed by an isocratic elution at 100% B for 3 min. Mobile 
phase compositions were (A) acetronitrile-water (5:95) with 0.1% TFA and (B) 
acetonitrile–water (90:10, v/v) with 0.1% trifluoroacetic acid (TFA). At the end of 
each analysis, the cartridge was re-equilibrated at 1 ml/min flow rate for 13 min with 
A. The density of peptide on the surface of nanoparticles was calculated from the 
total surface area assuming a normal Guassian particle size distribution. 
Stimulation of LFA-1 by phorbol 12-myristate 13-acetate (PMA) 
The Molt-3 cell line (1 x 10
6
 cells/ml) was stimulated using 0.4 µM of PMA for 20 
hrs. According to previous reports, PMA is able to activate LFA-1 and improve 
binding to ICAM-1.
24
 Cells at the same concentration were not activated and used as 
a control. Molt-3 cells, with or without PMA stimulation were incubated with anti-
LFA-1-FITC (0, 0.05 and 0.1 mg/ml) at 4 ºC for 45 min. Free antibodies were 
removed by rinsing three times with PBS after centrifugation (595 g, 1.5 min). The 
fluorescent intensity of cells was analyzed by flow cytometry. In addition, the 
specificity of anti-LFA-1-FITC was confirmed by incubation with A549 cells, which 
express ICAM-1 but not LFA-1. A549 were cultured as previously reported.
23
 Molt-3 
cells co-express LFA-1 and ICAM-1. Both cells were incubated with 0.4 M of PMA 
at 37C for 20 hrs. Anti-LFA-1-FITC (0.05 mg/ml) was incubated with Molt-3 cells 
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for 45 min at 4C. Cells were washed three times with PBS and centrifuged (595 
g,1.5 min) The fluorescent intensity of Molt-3 cells was determined by using a 
FACscan flow cytometer. Data analysis was performed using Cell Quest software 
(BD). 
Binding and uptake of cIBR-NPs into Molt-3 cells 
The binding and uptake of cIBR-NPs encapsulated fluorescent dye was studied by 
using flow cytometry. PMA stimulated Molt-3 cells (1 x 10
6
 cells/ml) were added in 
a 96 well-plate (200 l/well) containing CaCl2 (1.5 mM) and incubated with cIBR-
NPs or NPs encapsulating coumarin-6 (2.2 mg/ml, 90 l) at 37 C for 5, 15, 20 and 
35 min. Cells were then repeatedly centrifuged (460 g, 4C for 1 min) and washed 
three times with cold PBS and fixed with 4% paraformaldehyde. The fluorescent 
intensity of cells was measured using the FACscan flow cytometer. Data analysis was 
performed using Cell Quest software (BD). To investigate whether the uptake was 
dependent on the nanoparticle concentration, Molt-3 cells (1 x 10
6
 cells/ml, 100 l) in 
serum free media were added to a 96 well-plate containing CaCl2 (1.5 mM) followed 
by incubation with cIBR-NPs (70 l/well) at 37 C for 30 min at various 
concentrations (0.08, 0.16, 0.33, 0.66, 1.31, 2.63, 5.25 and 10.50 mg/ml). Cells were 
washed three times with cold PBS by centrifugation at 460 g, 4C for 1 min. The 
fluorescent intensity of the Molt-3 cells was again determined using the FACscan 
flow cytometer. Data analysis was performed as before. 
The binding and uptake of cIBR-NPs prepared by using various amounts of 
Pluronic
®
 F127-COOH by Molt-3 cells was observed and compared using flow 
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cytometry. Molt-3 cell line (2 x 10
6
 cells/ml) was stimulated using 0.4 µM of PMA to 
activate LFA-1 and improve binding to ICAM-1.
24
PMA stimulated Molt-3 cells (2 x 
10
6
 cells/ml) were added in microcentrifuge tubes (100 l) containing CaCl2 (1.5 
mM) and incubated with NPs or cIBR-NPs possessing various amounts of cIBR 
peptides (2.7 mg/ml, 100 l) at 37 C for 5, 15, 30 and 60 min. Cells were repeatedly 
centrifuged (460 g, 4C for 1 min) and washed three times with cold PBS and fixed 
with 4% paraformaldehyde. The fluorescent intensity of cells was measured using the 
FACscan flow cytometer.  
Inhibition of the binding of cIBR-NPs  
cIBR-NPs were hypothesized to bind to the I domain of LFA-1, a binding site of 
cIBR peptide.
14-16
 The binding site of cIBR-NPs was studied by blocking with cIBR. 
LFA-1 on Molt-3 (4 x 10
4 
cells/ml) was stimulated by PMA (0.4 M) for 20 hrs. 
Cells were added to a 96-well plate (100 l) containing CaCl2 (1.5 mM). Free cIBR at 
various concentrations (0.0, 0.31, 0.63, 1.2 and 2.5 mg/ml, 80 l) was incubated with 
cells for 40 min at 4C to inhibit the binding of cIBR-NPs or NPs to LFA-1. Cells 
were then incubated with cIBR-NPs or untargeted NPs (2.2 mg/ml, 80 l) at 4C for 
40 min. Cells were rinsed three times with cold PBS by centrifugation (460 g, 1 min, 
4C), fixed with 4% paraformaldehyde and again analyzed by flow cytometry . 
To further investigate whether the binding site of cIBR-NPs is LFA-1 I 
domain or not, free LFA-1 I domain was used to block the binding of cIBR-NPs to 
LFA-1 on plasma membrane of Molt-3 cells. The LFA-1 I domain was dissolved in 
water at various concentrations, 0, 0.31, 0.63 1.25 and 2.50 mg/ml and was mixed 
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with cIBR-NPs (2.1 mg/ml, 80 l) at 37 ºC for 1 hr. After incubation, Molt-3 cells 
(1x 10
6
 cells/ml) were added (100 µl) into the mixture and incubated at 37 ºC for 40 
min. Cells were pelleted by centrifugation (460 g, 1 min, 4C ) and free cIBR-NPs 
and the I domain were removed by three centrifugation/washing cycles. Cells were 
fixed using 4% paraformaldehyde. The binding of cIBR-NPs to the cells was 
determined from the fluorescent intensity analyzed by flow cytometry using the 
specified data analysis. 
The specificity of I domain in the inhibition of cIBR-NP uptake was 
investigated by incubating BSA (0, 0.31, 0.63 1.25 and 2.50 mg/ml) with cIBR-NP 
(2.1 mg/ml, 80 l) at 37 ºC for 1 hr. After incubation, Molt-3 cells (1x 106 cells/ml) 
were added (100 µl) into the mixture and incubated at 37 ºC for 40 min to allow 
binding of cIBR-NP to LFA-1 of cells. Free cIBR-NP and BSA were washed three 
times with PBS. Cells were fixed with 4% paraformaldehyde. The binding of cIBR-
NP to the cells was determined from the fluorescent intensity analyzed by flow 
cytometry.  
Temperature effects on the binding and internalization of cIBR-NPs and NPs  
The energy-dependent internalization of cIBR-NPs into Molt-3 cells was investigated 
in this study. Molt-3 cells (1.1 x 10
6 
cells/ml) were added to a 96 well plate (100 l 
/well) and incubated with serum free medium containing 1.5 mM CaCl2 for 40 min at 
4C and 37C followed by incubation with cIBR-NPs or NPs (2.2 mg/ml, 90 l/well) 
for 5, 15, 25, 35 and 45 min. Cells were then washed three times with PBS and fixed 
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with 4% paraformaldehyde. The uptake of cIBR-NPs or NPs by cells was determined 
from the fluorescent intensity analyzed using flow cytometry as before. 
Fluorescence microscopy of the uptake of cIBR-NPs by Molt-3 cells 
Fluorescence microscopy was performed to compare the extent of binding and uptake 
of cIBR-NPs and untargeted NPs in Molt-3 cells. Molt-3 cells (1 x 10
6 
cells/ml) were 
activated by using 0.4 M PMA for 24 hrs. Cells were then added to an 8-well plate 
containing CaCl2 (1.5 mM). cIBR-NPs or NPs (2.2 mg/ml) were incubated with the 
cells for  5, 15, 30 min and 1 hr at 37C, 5% CO2. Unbound nanoparticles were 
removed by washing three times with cold PBS and fixed with 4% paraformaldehyde. 
Fluorescence micrographs were acquired using the FITC filter set of a Nikon Eclipse 
80i microscope equipped for epifluorescence. Micrographs were captured using an 
Orca ER camera (Hamamatsu, Inc., Bridgewater, NJ) and analyzed by Metamorph, 
version 6.2 (Universal Imaging Corp., West Chester, PA). 
The binding of Molt-3 cells and cIBR-NPs prepared by using surfactant 
containing different ratios of Pluronic-COOH and Pluronic-OH was also observed by 
fluorescence microscopy. PMA activated Molt-3 cell line (2 x 10
6
 cells/ml) were 
incubated with cIBR-NPs bearing different amounts of cIBR peptide (2.7 mg/ml, 300 
l) for 40 min at 37C. Binding/uptake of cIBR-NPs and NPs with Molt-3 cells was 
evaluated using fluorescence microscopy (Nikon Eclipse 80i microscope equipped 
for epifluorescence). All fluorescence microscopy scans were performed using the 
same settings for the light source power and detector sensitivity, allowing direct 
comparison of the results obtained for the different incubations. 
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Lysosomal trafficking of cIBR-NPs in Molt-3 cells  
Fluorescence microscopy was utilized to investigate the intracellular fate of cIBR-
NPs and untargeted NPs in Molt-3 cells. Molt-3 cells (1 x 10
6 
cells/ml) were activated 
with 0.4 µM of PMA for 20 hrs. Cells were washed and dispersed in Texas red 
dextran (Mw 10,000, lysine fixable, 1 mg/ml) in serum free media and incubated for 
2 hrs at 37C, 5% CO2. Cells were washed three times with serum free medium. Cells 
were then incubated in serum free media at 37C, 5% CO2 for 12 hrs to allow the dye 
to traffic lysosomes. Cells were then added to an 8 well plate containing CaCl2 (1.5 
mM). Then cIBR-NPs or NPs (100 l, 2.2 mg/ml) were added to cells and incubated 
for 10 min at 37C, 5% CO2. Unbound nanoparticles were removed by washing three 
times with serum free medium. Cells were then incubated in serum free medium for 
each time period (30 min, 1 hr, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs and 24 hrs.). Cells were 
washed by centrifugation at 856 g for 1 min and fixed with 4% paraformaldehyde. 
Fluorescence emissions of nanoparticles and lysosomes were observed using FITC 
and rhodamine filter sets, respectively (Nikon Eclipse 80i microscope equipped for 
epifluorescence). Micrographs were captured using an Orca ER camera. Co-
localizations of nanoparticles with lysosomes were analyzed by Metamorph, version 
6.2. 
Inhibition of heterotypic adhesion by cIBR-NPs 
cIBR-NPs were hypothesized to bind to LFA-1 of Molt-3 cells, hence blocking the 
binding of LFA-1 of Molt-3 cells and ICAM-1 of A549 lung epithelial cells. The 
inhibition of LFA-1 and ICAM-1 adhesion by cIBR-NPs was monitored in this study. 
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A549 cells (8 x 10
5
 cells/ml) were incubated with TNF- (1,000 U/mL) for 48 hrs to 
activate the expression of ICAM-1 as reported previously. 
23
 LFA-1 on Molt-3 cells 
was activated by 0.4 M of PMA in serum free medium for 20 hrs. Molt-3 cells were 
labeled with a fluorescent dye, 2',7'-bis-(2-carboxyethyl)-5-(and-6)-
carboxyfluorescein, acetoxymethyl ester (BCECF, AM) (5 l, 2 mM), in 20 ml of 
PBS for 15 min at 37C. Cells were washed three times with PBS and resuspended in 
5 ml of PBS (final concentration of cells was 5.5 x 10
5 
cells/ml). Molt-3 cells were 
then transferred to a 96-well plate (200 l/well) and incubated with various 
concentrations of cIBR-NPs (0, 0.38, 0.75 and 1.50 mg/ml) at 37C for 30 min. Molt-
3 cells were then transferred to A549 culture on 8 well plates to evaluate the 
interaction between ICAM-1 on A549 cells and LFA-1 on Molt-3 cells at 37C, 5% 
CO2 for 45 min. After incubation, unbound Molt-3 cells were washed away with cold 
PBS three times and the culture was fixed with 4% paraformaldehyde. The binding of 
Molt-3 to A549 cells was quantified by counting the bound Molt-3 in four images 
taken with the Nikon Eclipse 80i microscope.  
Statistical analysis 
Statistical evaluation of data was performed using an analysis of variance (one-way 
ANOVA). Newman–Keuls was used as a post-hoc test to assess the significance of 
differences. To compare the significance of the difference between the means of two 
groups, a t-test was performed; in all cases, a value of p < 0.05 was accepted as 
significant. 
3.3 Results  
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PLGA nanoparticle preparation and characterization 
PLGA nanoparticles were prepared using a solvent displacement method.
23
 
Nanoparticles were formed from PLGA, which served as a hydrophobic core to 
encapsulate the poorly water soluble dye, coumarin-6.
23
The diameter of nanoparticles 
was approximately 200 nm with a low polydispersity suggesting a narrow size 
distribution. Modified Pluronic
®
 F -127 bearing carboxylic acid termini yielded 
negatively charged NPs. The zeta potential value was about -23 mV (Table 1). It is 
probable that the strong negative charge provided some electrostatic stabilization to 
reduce agglomeration and maintain particle size. Furthermore, free carboxylic acid 
groups on the modified surfactant allowed conjugation of the targeting peptide.  
Conjugation of cIBR peptide to PLGA-nanoparticles 
The cIBR peptide was covalently attached to the carboxylic acid end groups of 
modified Pluronic
®
 F-127 on the nanoparticle surface using carbodiimide 
chemistry.
23
The conjugation efficiency was determined by quantifying the 
unconjugated ligand remaining in the reaction medium after nanoparticle separation. 
The amount of free cIBR peptide measured by RP-HPLC decreased during the 
reaction (0-20 hrs) (Figure 1A). The peptide density on the surface of nanoparticles 
after reaction was calculated assuming a normal Guassian particle size distribution 
(Table 2).
 23
 The conjugation reaction was also performed in the absence of EDC to 
observe any possible adsorption (electrostatic or hydrophobic interaction) of cIBR 
peptide to the nanoparticles. The result showed that the adsorption of peptide was 
negligible since the amount of unconjugated peptide in the reaction medium analyzed 
102 
 
by RP-HPLC did not decrease when peptide was incubated with nanoparticles 
without activation of COOH (Figure 1B).
 
Table 1 Nanoparticle Properties at Specified Formulation Points 
 Effective diameter 
(nm) [Mean ± SD ] 
Polydispersity 
[Mean ± SD ] 
Zeta potential 
value (mV) [Mean 
± SD ] 
NP 199 ± 8.0 0.08 ± 0.04 -22.5 ± 1.4 
cIBR- NP 248 ± 10 0.08 ± 0.05 -25.7 ± 1.8 
Values are representative of three experiments. 
Table 2 Density of cIBR on the Surface of PLGA Nanoparticles 
 Size 
(nm) 
Total surface area 
(m
2
/g of PLGA) 
Surface cIBR 
(pmol/cm
2
)
 
cIBR-NP 248 18.1 39.0 ± 9.6 
Values are representative of three experiments (mean ± S.D.). 
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Figure 1 (A) Measurement of cIBR peptide reacted with nanoparticles over the time. 
The amount of cIBR peptide conjugated on nanoparticle surface increased with 
incubation time indicating reaction to nanoparticles. (B) The amount of peptide on 
nanoparticle was constant when the reaction was performed without EDC. Data are 
presented as mean ± S.D. (n = 3), *** indicates p< 0.001, ** indicates p< 0.01 and * 
indicates p< 0.05. 
The degree of cIBR peptide conjugation to NP surface depends on the density of 
carboxylic acid groups of surfactant 
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The density of carboxylic acids coated on NPs was varied by increasing ratio of 
Pluronic
®
 F127-COOH to Pluronic
®
 F127-OH used as a surfactant in aqueous 
solution when preparing PLGA nanoparticles. The results from dynamic light 
scattering and Zeta Pals have shown that the negatively charge of NPs increased with 
increasing percent of Pluronic
®
 F127-COOH (Figure 2A), whereas the size of 
nanoparticles were not changed significantly (~170 nm) (Figure 2B). The size and 
charge of cIBR-NPs prepared from different ratios of Pluronic
®
 F127-COOH were 
characterized using DLS. The negative charge of the resulting cIBR-NPs increased 
with increasing ratio of Pluronic
®
 F127-COOH in surfactant solution except for 
cIBR-NPs prepared from 100% Pluronic
®
 F127-COOH (Figure 2A). cIBR-NPs 
prepared from 100% Pluronic
®
 F127-COOH had a less negative charge than other 
formulations probably as a result of charge masking by the cIBR peptide, which has a 
neutral net charge. Furthermore, the use of different ratios of Pluronic
®
 F127-COOH 
coated on NPs yielded different amounts of cIBR peptide conjugated on NPs (Figure 
3). The amounts of cIBR conjugated on NPs were analyzed by reversed phase HPLC. 
The results demonstrated that the amount of cIBR on NPs is related to the amounts of 
carboxylic acid groups. NPs prepared by using 100% of Pluronic
®
 F127-COOH 
yielded the highest density of cIBR on NP surface, followed by NPs prepared by 
using 50%, 25% and 0% of Pluronic
®
 F127-COOH, respectively (Figure 3). The 
results of HPLC demonstrated some extent of cIBR peptide conjugation to NPs 
prepared from 0% Pluronic
®
 F127-COOH (100% Pluronic
®
 F127-OH). This result 
suggested that the hydroxyl groups of Pluronic
®
 F127-OH upon activation using EDC 
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Figure 2 (A) Zeta potential value of NPs and cIBR-NPs (B) size of coumarin loaded 
PLGA nanoparticles at different percent of Pluronic
®
 F127-COOH used as a 
surfactant in NP preparation. Data are presented as mean ± S.D. (n = 3). 
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Figure 3 Measurement of cIBR peptide reacted with nanoparticles at different 
percent of Pluronic
®
 F127-COOH used as a surfactant to prepare NP. The amount of 
cIBR peptide conjugated on nanoparticle surface increased with percent of Pluronic
®
 
F127-COOH indicating the importance of carboxylic acid groups on NP in the 
conjugation reaction. The amount of cIBR peptide conjugated on NP was very low 
the absence of EDC in the conjugation reaction (control). Data are presented as mean 
± S.D. (n = 3), ** indicates p< 0.001 and * indicates p< 0.05. 
PMA stimulates aggregation of Molt-3 cells 
Molt-3 cells were found to aggregate in response to PMA (Figure 4A). Although 
some homotypic adhesion of Molt-3 cells occurred in the absence of PMA, PMA 
stimulated Molt-3 cells exhibited much larger cell clusters. In previous reports, PMA 
was shown to increase the avidity of LFA-1 via rhoA protein which works as an 
intracellular transducer of protein kinase C activation leading to integrin activation 
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and cell aggregation.
25
Immunofluorescence flow cytometry showed that the 
expression of LFA-1 on Molt-3 cells was not changed when incubated with PMA 
suggesting that PMA did not induce expression of LFA-1 (Figure 4B). This result 
was previously observed in other LFA-1 bearing cells.
26
As a control, A549 lung 
carcinomic epithelial cells, expressing ICAM-1, but not LFA-1 were incubated with 
PMA and also incubated with anti-LFA-1-FITC. The fluorescent intensity measured 
by flow cytometry was negligible compared with Molt-3 cells since A549 cells lack 
LFA-1 (Figure 4C).    
cIBR-NPs exhibit interaction with Molt-3 cells 
The binding and uptake of cIBR-NPs by Molt-3 cells were monitored using flow 
cytometry. The interaction of cIBR-NPs and Molt-3 cells was substantially greater 
than that of untargeted NPs (Figure 5A). Molt-3 cells showed ~5 fold higher 
fluorescence when incubated with targeted nanoparticles. The fluorescent intensity of 
Molt-3 cells increased with time for both particle types but to a larger extent for 
cIBR-NPs. These results suggested that cIBR-NPs bound to Molt-3 cells more 
quickly and to a greater extent when compared to untargeted NPs. Furthermore, the 
binding of cIBR-NPs was also concentration dependent; uptake increased with 
increasing nanoparticle concentration (Figure 5B). 
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Figure 4 (A) Stimulation of LFA-1 on Molt-3 cells by PMA. Aggregation of PMA 
stimulated Molt-3 cells was evident compared to unstimulated Molt-3 cells. (B) 
Binding of anti-LFA-1 to LFA-1 on stimulated and unstimulated LFA1-1. Anti-LFA-
1-FITC labeling of LFA-1 revealed that the expression of LFA-1 was unchanged for 
PMA-stimulated compared to unstimulated Molt-3 cells. (C) Negligible fluorescent 
intensity of anti-LFA-1-FITC was observed when incubated with cells lacking LFA-1 
(A549 cells). Data are presented as mean ± S.D., (n = 3), * indicates p< 0.001 
compared to 0 mg/ml of anti-LFA-1-FITC. 
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Figure 5 (A) Binding of cIBR-NP to Molt-3 cells. cIBR-NP interaction with Molt-3 
cells was significantly greater than untargeted NPs at all time points. The 
fluorescence of Molt-3 cells incubated with cIBR-NPs increased with time. (B) The 
dependence of cIBR-NP concentration on the binding to Molt-3 cells. The 
fluorescence of Molt-3 cells increased as the concentration of cIBR-NPs increased. 
Data are presented as mean ± S.D. (n = 3), * indicates p < 0.001. 
Free cIBR and the LFA-1 I domain inhibited the binding of cIBR-NPs to Molt-3 
cells 
Inhibition of cIBR-NPs was investigated by incubating Molt-3 cells with free cIBR 
peptide followed by incubation with cIBR-NPs or NPs. The fluorescent intensity of 
cells incubated with cIBR-NPs decreased significantly compared to cells incubated 
with untargeted NPs (Figure 6A). Disrupting of the binding of cIBR-NPs to Molt-3 
cells by cIBR peptide suggested cIBR-NPs targeted LFA-1. The binding of 
untargeted NPs was again very low.  
A B 
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To further validate binding specificity, cIBR-NPs were allowed to bind to the 
I domain of LFA-1 prior to incubation with Molt-3 cells. The I domain was expected 
to bind to cIBR on targeted NPs and block the binding of targeted NPs to LFA-1 on 
Molt-3 cells.  As the concentration of the LFA-1 I domain increased, the binding of 
cIBR-NPs correspondingly decreased (Figure 6B). The binding of cIBR-NPs was 
reduced to ~60% when 2.5 mg/ml of the I domain was used with cIBR-NPs 
compared to the absence of the I domain whereas there was no significantly reduction 
of the cIBR-NP binding to Molt-3 cells when BSA was firstly mixed with cIBR-NP 
(Figure 6C). This result further supported the specific binding of cIBR-NPs to the I 
domain of LFA-1. Previous reports indicated that cIBR peptide has a PRGG sequence 
with the -turn structure of the D1 of ICAM-1, the binding site of LFA-1.
14-15
 
Furthermore, Anderson and Siahaan elucidated the binding specificity of cIBR 
peptide and showed that cIBR-FITC binding to soluble LFA-1 can be competitively 
inhibited by an anti-CD11a antibody as an indicator of specific binding of cIBR to the 
I domain of LFA-1.
14
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Figure 6 (A) The inhibition of cIBR peptide to the binding of cIBR-NP to Molt-3 
cells. The interaction of cIBR-NPs with Molt-3 cells decreased as free cIBR peptide 
concentration increased suggesting that cIBR competitively inhibits binding to LFA-1 
on Molt-3 cells. Data are presented as mean ± S.D. (n = 3), ** indicates p < 0.001. 
(B) The inhibition of LFA-1 I domain to the binding of cIBR-NP to Molt-3 cells. The 
interaction of cIBR-NPs with Molt-3 cells was also competitively inhibited by the I 
domain of LFA-1. The I domain was added to the NPs prior to addition of cells. (C) 
B 
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The uptake of cIBR-NP pretreated with BSA by Molt-3 cells did not significantly 
decrease in the presence of BSA. Data are presented as mean ± S.E., (n = 3), ** 
indicates p< 0.01 and *indicates p< 0.05.  
Uptake of cIBR-NPs is temperature dependent 
Molt-3 cells were incubated with cIBR-NPs at 4 C and 37 C to determine the effect 
of temperature on the uptake of nanoparticles and to learn whether the mechanism of 
cIBR-NPs entry into Molt-3 cells was energy dependent. The uptake of cIBR-NPs 
decreased significantly at 4 C (Figure 7A), suggesting that cIBR-NPs uptake was 
indeed energy dependent. Furthermore, the fluorescent intensity of cells incubated 
with cIBR-NPs at 37 C increased over time. At low temperature, cIBR-NPs binding 
was similar to binding at 37 C; however, the increase in fluorescent intensity 
occurred more slowly suggesting that endocytosis was slowed at low temperature. 
The dependence of temperature on the uptake of untargeted nanoparticles was also 
investigated. The uptake of nanoparticles without peptide was also decreased at low 
temperature but to a lesser extent (Figure 7B) confirming an energy dependent 
endocytic process observed previously.
27
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Figure 7 The dependence of temperature on the binding of cIBR-NP to Molt-3 cells. 
The binding and uptake of (A) cIBR-NPs and (B) NPs were slowed at low 
temperature (4 C), which suggested energy dependent endocytosis of nanoparticles. 
Data are presented as mean ± SD., (n = 3), * indicates p< 0.05, ** indicates p< 0.01 
and *** indicates p< 0.001. 
Fluorescence microscopy of Molt-3 cells and nanoparticles 
The uptake of cIBR-NPs and NPs by Molt-3 cells was examined by fluorescence 
microscopy. The association of cIBR-NPs and NPs with Molt-3 cells was clearly 
demonstrated by fluorescence micrographs. The fluorescent intensity of cells 
incubated with untargeted NPs was far less than cells incubated with targeted NPs 
(Figure 8). The fluorescent intensity of cells incubated with NPs slowly increased 
with incubation time and showed the greatest intensity at the longest time, whereas 
the fluorescent intensity of cells incubated with cIBR-NPs was quite high initially. 
These results supported the kinetics of cIBR-NPs incubated with Molt-3 cells 
B 
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determined by flow cytometry. Both suggest the rapid binding and internalization of 
cIBR-NPs and may suggest receptor saturation.  
 
 
 
 
 
 
 
 
 
 
 
Figure 8 Micrograph of Molt-3 cells incubated with cIBR-NP or NP encapsulating 
fluorescence dye. Interaction of cIBR-NPs with Molt-3 cells occurred more quickly 
and to a greater extent compared to untargeted NPs at each incubation time as shown 
by fluorescence micrographs.  
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cIBR-NPs prepared by using 100% Pluronic® F127-COOH exhibited the most 
rapid binding to Molt-3 cell line. 
The purpose of this experiment is to quantify the effect of cIBR density on NP 
surface on the binding of cIBR-NPs to LFA-1 expressing cell line (Molt-3 cells). 
Nanoparticles with different amounts of cIBR peptide grafted on the surface were 
incubated with Molt-3 cells to investigate the effect of cIBR density on binding of 
cIBR-NPs by Molt-3 cells. The flow cytometry data showed that fluorescent intensity 
of Molt-3 cells incubated with cIBR-NPs prepared from 100% Pluronic
®
 F127-
COOH was higher than cells incubated with cIBR-NPs prepared from 50%, 25% and 
0% Pluronic
®
 F127-COOH, respectively at all incubation times. Fluorescence 
intensity of Molt-3 cells incubated for 60 minutes with cIBR-NPs prepared from 
100%, 50% and 25% Pluronic
®
 F127-COOH were ~1.7, 1.3 and 1.0 fold greater than 
cIBR-NPs prepared from 0% Pluornic-COOH, respectively, suggesting the 
importance of cIBR peptide density in the binding to LFA-1 on Molt- 3 cells (Figure 
9A).  
cIBR-NPs with different degrees of cIBR peptide conjugated and untargeted 
NPs binding to LFA-1 expressing cells was also examined on Molt-3 cell lines using 
fluorescence microscopy. Fluorescence microscopy clearly demonstrated binding of 
cIBR-NPs to Molt-3 cells. Molt-3 cells incubated with untargeted NPs exhibited low 
level of green fluorescence, while Molt-3 cells incubated with cIBR-NPs 
demonstrated higher fluorescence intensity indicating the greater degree of cell 
association with cIBR-NPs (Figure 9B). Binding of cIBR-NPs was shown to depend 
on cIBR density on NPs as fluorescence intensities of Molt-3 cells increased upon the 
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increase in percent of Pluronic
®
 F127-COOH used to prepare NPs. These results 
indicated that increasing cIBR density on NP mediated by increasing carboxylic acid 
groups on NP surface are of potential importance in modulating the interaction of 
cIBR-NPs with LFA-1 expressing cell line. 
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Figure 9 (A)Micrograph of Molt-3 cells incubated with cIBR-NP or NP 
encapsulating fluorescence dye. Interaction of cIBR-NPs with Molt-3 cells occurred 
more quickly and to a greater extent compared to untargeted NPs at each incubation 
time as shown by fluorescence micrographs. (B) Binding of cIBR-NP to Molt-3 cells. 
The association of cIBR-NP prepared from 100% of Pluronic
®
 F127-COOH with 
Molt-3 cells was significantly greater than cIBR-NPs prepared from surfactant 
NP cIBR-NP 
0% 
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containing lower percent of Pluronic
®
 F127-COOH at all time points. Data are 
presented as mean ± S.D. (n = 3), * indicates p < 0.001. 
Trafficking of cIBR-NPs to lysosomes 
Lysosomes are acidic and contain hydrolytic enzymes where nanoparticles or drugs 
in nanoparticles may be degraded. To inviestigate whether cIBR-NPs traffick to the 
lysosomes or not, co-localozation of lysosomes and nanoparticles was monitored. The 
lysosomal compartments of Molt-3 cells were stained with Texas red-dextran (lysine 
fixable) to track cIBR-NPs and NPs uptake. Then, cells were treated with cIBR-NPs 
or NPs encapsulating the green fluorescent dye. The intracellular localization of 
nanoparticles was tracked at different time points and lysosomal accumulation was 
indicated by yellow fluorescence in merged images (Figure 10). The co-localization 
of cIBR-NPs with lysosomal vesicles was not evident over 24 hrs. The co-
localization of untargeted NPs with lysosomes was undetectable at 6 hrs and was 
detected at 24 hrs. These results implied that cIBR-NPs did not traffic to lysosomes 
but untargeted NPs slowly accumulated in lysosomes.  
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Figure 10 Micrographs of Molt-3 cells incubated with cIBR-NP or NP in the 
presence of Texas red-dextran. Intracellular trafficking of cIBR-NPs and NPs (green) 
to lysosomal compartments (red) of Molt-3 cells. The co-localization (yellow 
fluorescence) of cIBR-NPs with lysosomes was generally not observed over 24 hrs, 
whereas co-localization of NPs with lysosomes was first observed at 6 hrs and slowly 
increased over 24 hrs. 
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cIBR-NPs inhibit the adhesion of Molt-3 cells and lung epithelial cells. 
Leukocyte recruitment to endothelial and epithelial tissues requires interaction of 
LFA-1 and ICAM-1.
14, 28
cIBR peptide alone has been shown to inhibit homotypic and 
heterotypic cell interactions via binding LFA-1.
17, 19, 29
 The interaction of LFA-1 on 
PMA-stimulated Molt-3 cells and ICAM-1 expressed on lung carcinomic epithelial 
cells activated with TNF- resulted in heterotypic cell adhesion and was investigated 
by fluorescence microscopy. Micrographs allowed quantification of the number of 
adhered Molt-3 cells (stained with a green fluorescent dye) to A549 cells (Figure 
11A). Pretreatment of Molt-3 cells with cIBR-NPs was investigated as a means to 
inhibit this heterotypic cell adhesion. When PMA-stimulated Molt-3 cells were pre-
incubated with cIBR-NPs, significant inhibition was observed (Figure 11B). 
Pretreatment of Molt-3 cells with cIBR-NPs yielded up to a ~73% decrease in 
adhered cells suggesting that cIBR-NPs bound to LFA-1 of Molt-3 cells blocked the 
availability of LFA-1 integrins to bind to ICAM-1 on A549 cells. Furthermore, cIBR-
NPs may decrease the availability of LFA-1 on the cell surface via endocytosis of this 
receptor.
14
The result of this study revealed the potential of cIBR-NPs to inhibit 
lymphocyte recruitment during inflammatory responses. 
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  A 
 
 
 
 
 
 
  B 
 
 
 
 
 
Figure 11 The inhibition of cIBR-NP to the interaction of LFA-1 and ICAM-1 on 
Molt-3 cells and A549 cells. (A) Optical micrographs of the adhesion of Molt-3 cells 
(green) to A549 lung epithelial cells at various concentrations of cIBR-NPs. (B) 
cIBR-NPs inhibited the heterotypic adhesion of Molt-3 cells to A549 cells in a dose 
dependent manner. Data are presented as mean ± S.D., (n = 3), * indicates p< 0.001 
compared with 0 mg/ml of cIBR-NPs. 
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3.4 Discussion 
The interaction of LFA-1 and ICAM-1 plays a vital role in leukocyte recruitment and 
migration across the vasculature during normal leukocyte circulation through lymph 
nodes and during recruitment in the response to inflammatory signals. LFA-1 also 
participates in the „immunological synapse‟ between T lymphocytes and antigen 
presenting cells (APC).
6
 In recent decades, potential therapeutic agents used to block 
the binding of LFA-1 to ICAM-1 to treat immunological and inflammatory disorders 
have focused on monoclonal antibodies and small molecules designed to antagonize 
interactions between these proteins.
30-31
 However, hypersensitivity reactions and 
unpredictable half-lives are often encumbrances for immunotherapy using 
monoclonal antibodies.
29, 31, 32
 In comparison to monoclonal antibodies, cyclic 
peptides have been shown to offer improved safety, physicochemical stability and 
may even improve selectivity to the targeted site.
3, 33
 
cIBR, a cyclic peptide derived from domain 1 of ICAM-1, has demonstrated 
specific binding to isolated LFA-1 and to the surface of T cells.
9, 10
 Previous research 
showed that cIBR conjugated to the fluorescent dye FITC entered cells via 
endocytosis; however, cIBR conjugated to doxorubicin mainly passively diffused 
through the cell membrane of HL-60 cells.
29
 Passive diffusion of cIBR-doxorubicin 
may be a result of the increased hydrophobicity of the conjugate, a change in the 
conformation of the cIBR peptide after conjugation and/or steric hindrance of 
doxorubicin at the recognition site of the cIBR peptide.
29
 Regardless, these findings 
suggested that the delivery of some drugs may be improved if the drugs were 
encapsulated. 
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In the present study, cIBR was conjugated to the surface of PLGA 
nanoparticles. The physical incorporation of drug in the particle matrix may mask the 
hydrophobicity of the drug and mitigate potential off-target passive diffusion into 
cells driven by the poorly water soluble compound. Furthermore, the grafting of cIBR 
to the end of a long chain surfactant on the nanoparticle surface can reduce steric 
hindrance at the cIBR binding site which may have occurred in a single drug-peptide 
conjugate. 
The importance of multivalency in the LFA-1/ICAM-1 interaction and the 
activation of high avidity LFA-1 in some types of LFA-1 expressing cells have been 
reported.
34
 LFA-1 is exclusively expressed on leukocytes but these cells do not 
adhere to ICAM-1 unless activated (e.g. by PMA).
6, 35
 Furthermore, Welder et al have 
demonstrated that monovalent soluble intercellular cell adhesion molecule-1 
(sICAM-1) is unable to bind efficiently to LFA-1 expressed on cells unless it is first 
rendered multivalent by coupling to polystyrene microspheres, thus, illustrating the 
importance of multivalency.
36
 Pyszniak et al have demonstrated that sICAM-1-coated 
microspheres specifically bind to activated LFA-1 but not to the low avidity state.
35
 
The distribution of high avidity LFA-1 on the cell surface was observed to be highly 
localized on some types of LFA-1 expressing cells, whereas the low avidity state was 
more evenly distributed. They also reported that only after activation with PMA, 
isolated splenic T cells and murine T cell hybrodoma T28 bound the sICAM-1 
microspheres and the binding was inhibited by anti-LFA-1 mAb. Therefore, utilizing 
a high density of cIBR ligands on nanoparticles may improve binding efficiency of 
cIBR-NPs to activated LFA-1 due to multivalent ligand receptor interactions.  
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In the present study, grafting cIBR peptide to biodegradable PLGA 
nanoparticles increased selectivity, the rate, and the extent of binding of untargeted 
nanoparticles and internalization by activated LFA-1 on acute lymphoblastic 
leukemia T cells (Molt-3). The uptake of targeted nanoparticles was concentration 
and temperature dependent suggesting receptor-mediated endocytosis. The partial 
inhibition of nanoparticle uptake at low temperature (4 C) suggested that the 
internalization of the cIBR-NPs likely occurred via an energy dependent endocytic 
pathway.  
Lysosomesare acidic intracellular compartments that contain a variety of 
hydrolytic enzymes. Texas red-dextran is internalized by fluid phase endocytosis and 
accumulates in lysosomes due to its acid hydrolase-resistant nature.
37
The fate of 
nanoparticles was investigated by studying the colocalization of nanoparticles and 
lysosomes via fluorescence microscopy. Virtually no colocalization of cIBR-
nanoparticles and lysosomes was observed suggesting that LFA-1 targeted 
nanoparticles do not traffic to lysosomes. The internalization and recycling of LFA-1 
to the plasma membrane has been reported.
38
 The exocytosis cycle of several types of 
integrins has also been shown in polymorphonuclear cells including neutrophils.
38
 
The recycling process of integins is functional to retrieve these receptors and, as they 
cleave their ligands, to recycle them as adhesion molecules on the plasma 
membrane.
38
 It is possible that cIBR-NPs bound to LFA-1 may enter this receptor 
recycling process.
38
 Regardless, cIBR-NPs may have advantages over untargeted NPs 
for drug delivery because they can avoid hydrolytic degradation in lysosomes.  
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3.5 Conclusion 
Targeted drug delivery has emerged as an important strategy to improve the efficacy 
and reduce the adverse effects of drugs. In the present study, cIBR-NPs were 
characterized as a potential drug delivery system targeting the receptor, LFA-1 
integrin, on leukocytes. cIBR-NPs were bound and internalized by LFA-1 on Molt-3 
T-cells much more rapidly and to a greater extent than untargeted nanoparticles. 
Furthermore, cIBR-NPs bound specifically to LFA-1 on the Molt-3 cell line as 
confirmed by competitive inhibition assays. cIBR-NPs did not appear to traffic to 
lysosomal compartments suggesting that encapsulating drugs in this type of NPs may 
offer some protection from lysosomal degradation. The adhesion between T cells and 
lung epithelial cells expressing LFA-1 and ICAM-1, respectively was significantly 
inhibited by cIBR-NPs. These studies suggest the plausibility of using LFA-1 as a 
target molecule with the potential of a dual therapeutic effect by blocking leukocyte 
recruitment and targeting immunomodulators or anti-inflammatory drugs to 
leukocytes.  
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Chapter 4 
Nanoparticles Targeting Dendritic Cell Surface Molecules Effectively  
 
Block T cell Conjugation and Shift Response 
 
 
 
 
 
 
 
 
 
133 
 
4.1 Introduction 
Professional antigen presenting cells (APC) such as dendritic cells (DCs) help 
orchestrate immune responses to foreign antigens by capturing antigen and loading it 
onto major histocompatibilty complex (MHC) class II. The antigen-primed APC then 
present the antigen to naïve CD4+T cells which express cognate T cell receptors.
1
 
The resulting immunological synapse formed between T cells and APCs often 
initiates signaling events for T cell proliferation and effector function such as 
cytokine production.
2
 Leukocyte function-associated antigen-1 (LFA-1; primarily on 
T cells) binding to intercellular adhesion molecule 1 (ICAM-1; primarily on DCs) can 
prolong the immunological synapse and support T cell activation.
3-5
 Targeting of 
these molecules is known to modify T cell activation.
6
 
Molecules that mediate cell adhesion or signaling are typically present in 
large numbers at the cell-cell interface. Several studies have shown that multivalency 
can enhance the binding of ligands to these types of receptors and shift the response 
of targeted cells.
7-10
 For example, multivalent presentation of anti-CD20 monoclonal 
antibody fragments can enhance the targeting of B cell antigen CD20.
10
 Similarly, 
multiple copies of peptide ligands on a polymer backbone can improve binding to 
CD21 on B cells when compared to free ligand.
11
Arrays of RGD peptides on micelles 
have been consistently found to dramatically enhance binding to v3 receptors in 
contrast to free RGD peptides.
12
 
The response of cells targeted by multivalent ligands is often unexpected. 
Antigen valency has been found to be a key parameter affecting binding to B cells 
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and cellular response.
13
 High valency antigen arrays induced antibody production by 
B cells, while low valency antigen arrays did not.
13
 Multivalent ligands induced 
calcium influx in a dose dependent manner, whereas the same molar concentration of 
free ligand did not.
13 
Ligand valency also affects the response of leukocytes 
undergoing rolling adhesion. For example, multivalent L-selectin ligands clustered L-
selectin and induced L-selectin shedding, but the corresponding monovalent ligands 
did not.
14-15
Thus, multivalent ligands can affect cell response in addition to enhancing 
ligand binding. 
The binding of LFA-1 and ICAM-1 is also controlled by changes in avidity 
resulting from receptor clustering.
16-17
 Cell adhesion mediated by ICAM-1 and LFA-
1 involves multivalent interaction between these two molecules on opposing cells 
(APC and T cell). LABL (ITDGEATDSG) is a peptide modeled after the I domain of 
LFA-1 which is the binding site of ICAM-1. cIBR (cyclo 1,12 Pen-
PRGGSVLVTGC) is a cyclic peptide derived from domain 1 of ICAM-1 which binds 
to the I domain of LFA-1.
18-19 
LABL and cIBR peptides inhibit homotypic and 
heterotypic T cell adhesion as well as mixed lymphocyte reactions.
20-22
 
Nanoparticles modified with these peptides (cLABL-NPs and cIBR-NPs) 
were previously used to specifically target ICAM-1 and LFA-1 expressing cells, 
respectively.
23-25
 NPs targeting these receptors were found to bind cells and rapidly 
internalize via receptor-mediated endocytosis. In addition, cIBR-NP blocked the 
adhesion of T cells to lung epithelial cells expressing a high level of ICAM-1.
23 
Since 
the oligomeric states of LFA-1 and ICAM-1 molecules contribute to their ability to 
regulate T cell responses, it was hypothesized that these nanoparticles may bind with 
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high avidity to ICAM-1 or LFA-1 on DCs.  Such targeted NPs were suspected to be 
better inhibitors of T cell conjugation to DCs compared to free ligands and a potential 
tool to alter cell response. 
4.2 Materials and Methods 
Materials 
LABL peptide (ITDGEATDSG, Mw 964.95) and cIBR peptide (cyclo 1,12 Pen-
PRGGSVLVTGC, Mw 1174.50) were synthesized on a Pioneer peptide synthesizer 
(PerSeptive Biosystems, CA). Poly(DL-lactic-co-glycolic acid) (50:50) with terminal 
carboxyl group (PLGA, inherent viscosity 0.67dL/g, Mw ~90 kDa) was purchased 
from Lakeshore Biomaterials (Birmingham, AL, USA). Pluronic
®
F-127 was obtained 
from BASF Corporation. (Mount Olive, NJ, USA). 1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride (EDC), N-
hydroxysulfosuccinimide (sulfo-NHS) and 2- mercaptoethanol were purchased from 
Thermo Fisher Scientific Inc. (Rockford, IL, USA). Coumarin-6 was purchased from 
Polysciences, Inc. (Warrington, PA, USA). Dialysis membrane (MwCO 100,000) 
was purchased from Spectrum laboratory Products Inc. (Rancho Dominguez, CA, 
USA). RPMI-1640 medium was obtained from Cellgro (Manassas, VA, USA). 
Tumor Necrosis Factor- (TNF-) was purchased from Promega (Madison, WI, 
USA). Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) was 
purchased from Peprotech Inc. (Rocky Hill, NJ, USA). Carboxyfluorescein diacetate 
succimidyl ester (CFSE) and 5-(and-6)-(((4cloromethyl) 
enzoyl)amino)tetramethylrhodamine (Orange CMTMR)were purchased from 
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Invitrogen Corporation, (Carlsbad, CA). Monoclonal anti-human CD54 (ICAM-1) 
Domain 1 and Monoclonal anti-LFA-1 were purchased from Ancell (Bayport, MN, 
USA). CellTiter 96
®
 AQueous Non-Radioactive Cell Proliferation Assay (MTS) was 
purchased from Promega (Madison, WI, USA).  Ovalbumin was purchased from 
Sigma (St. Louis, MO). Penicillin, streptomycin and L-glutamine were purchased 
from Cellgro (Manassas, VA, USA). IL-2 was generously provided by Dr. Christophe 
Nicot at the University of Kansas Medical Center. B6.129S7-
Rag1
tm1Mom
Tg(TcraTcrb)425Cbn mice were purchased from Taconic Farms (Hudson, 
NY). C57BL/6 wildtype mice were purchased from Jax labs (Bar Harbor, ME). 
Methods 
Cell culture and isolation 
Bone marrow derived dendritic cells were generated from C57BL/6 wildtype mice as 
described.
26
  Briefly, 2 x 10
6
 cells were isolated from bone marrow, plated on 
bacterial Petri dishes and cultured in 10 ml DC media (RPMI-1640, 10% heat 
inactivated fetal bovine serum, 100 µg/ml penicillin-streptomycin, 50 µM β-
mercaptoethanol, 20 ng/ml murine granulocyte macrophage colony stimulating factor 
(GM-CSF) (R&D), and 2 nM L-glutamine.  At 72 hours (Day 3), 10 ml of fresh DC 
media was added to each dish.  On days 6 and 8, 10 ml of supernatant and cells were 
removed, cells recovered by centrifugation (90 x g) and added back to the dish with 
fresh DC medium.  On day 9 non-adherent cells were collected, labeled with (5 M) 
5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester (CFSE) for 10 minutes at 
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37°C, washed, primed with 50 µg/ml ovalbumin, and matured overnight with 100 
ng/ml TNF-α.    
On day 10, T cells were isolated from B6.129S7-
Rag1
tm1Mom
Tg(TcraTcrb)425Cbnmice spleens by passing spleens through a wire 
mesh.  T cells were purified using a negative selection, mouse T cell enrichment kit 
according to manufacturers‟ directions (EasySep).   
PLGA nanoparticle preparation and characterization 
PLGA nanoparticles and nanoparticles loaded with coumarin-6 were prepared by a 
solvent displacement method. In brief, PLGA was dissolved in acetone (18 mg/ml) 
containing coumarin-6 (50 g/ml). The solution was gently infused into 0.1% 
Pluronic
®
F-127-COOH (25 ml) under mild stirring (300 RPM). Terminal hydroxyl 
groups on Pluronic
®
F-127 were converted to carboxyl groups according to a reported 
procedure.
27
The resultant nanoparticle suspension was dialyzed (100,000 MWCO) 
against a 0.2% mannitol solution for 48 hrs to remove excess surfactant. Particle size 
and zeta potential of nanoparticles were characterized using dynamic light scattering 
(ZetaPALS, Brookhaven instrument Inc.). 
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Figure 1 T cell conjugation to DCs maybe blocked by the binding of cIBR-NP to 
LFA-1 or LABL-NP to ICAM-1 on DCs.  
Conjugation of LABL and cIBR peptides to PLGA-nanoparticles 
The N-terminus of peptide was covalently linked with the carboxyl groups of 
Pluronic
®
F-127-COOH coated on PLGA nanoparticles by carbodiimide chemistry.
23
 
Specific binding of the LABL and cIBR peptides suggests they are radially pointing 
away from the particles surface (Figure 1).Nanoparticles (2.2 mg/ml) were buffered 
using 2-(N-morpholino)ethanesulfonic acid (MES; pH 6.5) and incubated with 100 
mM 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) and 50 
mM N-hydroxysulfosuccinimide (sulfo-NHS) for 15 min. EDC was used to react with 
a carboxyl group on PLGA NPs and formed an amine-reactive O-acylisourea 
intermediate. Sulfo-NHS was added to stabilize this intermediate, hence increasing 
the efficiency of coupling reaction. Excess EDC and sulfo-NHS were removed by 
centrifugation (16,089 g, 10 min). Then, cIBR or LABL peptides (0.4 mg) were 
added and allowed to react with Pluronic
®
F-127-COOH on nanoparticles for 12 hrs at 
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room temperature. Peptide conjugated NPs were collected by centrifugation (16,089 
g, 10 min) and washed three times with purified water.  
The conjugation efficiency was determined by quantifying the unconjugated 
ligand remaining in the reaction medium after nanoparticle separation. The peptide 
density on the surface of nanoparticles after reaction was calculated assuming a 
normal Guassian particle size distribution.
23, 25
The amount of free peptides in reaction 
medium was analyzed by gradient reversed phase HPLC (SHIMADZU) using a C18 
column. The HPLC consisted of SCL-10A SHIMADZU system controller, LC-10AT 
VP SHIMADZU liquid chromatograph, SIL-10A XL SHIMADZU autoinjecter set at 
30 l injection volume, DGU-14A SHIMADZU degasser, sample cooler, and SPD-
10A SHIMADZU UV-Vis detector (220 nm). The HPLC-UV system was controlled 
by a personal computer equipped with SHIMADZU class VP Software. All 
separations were carried out using a Vydac® HPLC Protein and Peptide C18 column. 
Gradient elution was carried out to determine the amount of LABL peptide at 
constant flow of 1 ml/min, from 0% B to 8% B for 5 min, followed by 14.3% B at 
17.5 min, 50% at 23 min and 70% B at 24 -35 min. HPLC gradient system was 
programmed to separate cIBR peptide at constant flow of 1 ml/min, from 25% B for 5 
min, 55% B at 25 min and 100%B at 25.1 -30 min. Mobile phase compositions were 
(A) acetronitrile-water (5:95) with 0.1% TFA and (B) 100% acetonitrile with 0.1% 
trifluoroacetic acid (TFA).  
LFA-1 and ICAM-1 expression on dendritic cells and T cells 
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The relative expression of LFA-1 and ICAM-1 on T cells and DCs were qualitatively 
assessed using flow cytometry (FACScan).  DCs (4 x 10
5
 cells/ml) were matured with 
TNF- (1,000 U/ml) and primed with ovalbumin (OVA) (50 g/ml) for 24 hrs. DCs 
were isolated by centrifugation, and incubated 45 minutes on ice with 80 l of anti-
ICAM-1 (0.05 mg/ml) or anti-LFA-1 (0.25 mg/ml) conjugated with FITC at 1:50 
dilution. Cells were washed three times and analyzed by flow cytometry.   
Splenic C57BL/6-TgN(OT-II.2a)-Rag1  T cells (2.2 x 10
6
 cells/ml) were 
incubated with 80 l of anti-ICAM-1-FITC (0.05 mg/ml) or anti-LFA-1-FITC (0.25 
mg/ml) on ice for 45 min. Unbound antibodies were removed by rinsing three times 
with PBS after centrifugation (16,089 g, 2.5 min). The fluorescent intensity of cells 
was measured by a FACscan flow cytometer. Data analysis was performed using Cell 
Quest software (BD). 
Binding and uptake of LABL-NPs and cIBR-NPs into DCs 
The binding and uptake of LABL-NPs and cIBR-NPs encapsulated fluorescent dye 
was monitored using flow cytometry. DCs (1 x 10
5
 cells/ml) were added and allowed 
to adhere on a 96 well-plate (200 l/well) for 24 hr in the presence of TNF- (1,000 
U/ml) and OVA (50 g/ml). DCs were washed three times with PBS and incubated 
with NPs, LABL-NPs or cIBR-NPs (2.2 mg/ml, 100 l) at 37 C for 15, 30, 45 and 
60 min. Cells were washed three times with PBS and trypsinized for 3 min at 37C. 
Then DCs were transferred to microcentrifuge tube and washed once with PBS by 
centrifugation (600 g, 2 min). The fluorescent intensity due to DC uptake of 
141 
 
fluorescent NPs was measured using the FACscan flow cytometer. Data analysis was 
performed using Cell Quest software (BD).  
Fluorescence microscopy of DCs binding/uptake with LABL-NPs or cIBR-NPs 
Dendritic cells (1 x 10
6 
cells/ml, 300 l) were added into an 8-well plate and 
stimulated by TNF- (1,000 U/ml) and OVA (50 g/ml) for 24 hrs. Cells were 
washed with PBS and then incubated with NPs, LABL-NPs or cIBR-NPs (2.2 mg/ml, 
300 l) for  40 min at 37C. Unbound nanoparticles were removed by washing three 
times with PBS and cells were fixed with 4% paraformaldehyde. Fluorescence 
micrographs were acquired using the FITC filter set of a Nikon Eclipse 80i 
microscope equipped for epifluorescence. Micrographs were captured using an Orca 
ER camera (Hamamatsu, Inc., Bridgewater, NJ) and analyzed by Metamorph, version 
6.2 (Universal Imaging Corp., West Chester, PA). All images were corrected for 
variations in excitation light intensity. 
In vitro cellular cytotoxicity of LABL-NPs and cIBR-NPs 
MTS cell viability assays were performed to provide an assessment of the toxicity of 
LABL-NPs and cIBR-NPs on T cells and TNF- stimulated and OVA primed DCs. 
Briefly, T cells (3.2 x 10
6
 cells/ml) and DCs (1 x 10
5
 cells/ml) were seeded on 96-
well plates and incubated with various concentrations of LABL-NPs and cIBR-NPs 
for 24 hr. A tetrazolium salt MTS was applied and the incubation was continued for 
additional 4 hrs. MTS was converted by mitocondrial dehydrogenase enzyme in 
living cells to form a colored formazan product. The absorbance of the formazan 
product was recorded at 490 nm using a 96-well plate reader (Spectramax M5).  
142 
 
DCs and T cell conjugate formation 
DCs (4 x 10
5
 cells/ml) were stained by incubating with 5 ml of CFSE in PBS (10 M) 
for 10 min at 37 C in PBS. The staining was quenched by the addition of 25 ml of 
complete culture medium and incubation at 4C for 10 min. The remaining dye was 
washed away by three washes with complete culture medium. T cells were incubated 
with 10 l of CMTMR orange fluorescent dye (5 M) in 10 ml of PBS for 30 min at 
37C. The reaction of the dye was quenched by incubating with complete culture 
medium for 30 min at 37C. T cells were washed three times with complete culture 
medium. Untreated DCs were used as a positive control. Dendritic cells (4 x 10
5
 
cells/ml) primed with OVA (50 g/ml) and matured in the presence of TNF- (1,000 
U/ml) were incubated with anti-ICAM-1 (1 g/ml), anti-LFA-1 (5 g/ml), NPs (2.2 
mg/ml), LABL peptide (0.095, 0.19 and 0.38 mM), LABL-NPs (1.1, 2.2 and 4.4 
mg/ml), cIBR peptide (0.012, 0.024 and 0.048 mM) or cIBR-NPs (1.1, 2.2 and 4.4 
mg/ml) for 30 min at 37 C. DCs were washed three times with PBS and incubated 
with T cells (2 x 10
6
 cells/ml) for 2 hr at 37 C.  After incubation, DCs were washed 
three times with PBS and fixed with 4% paraformaldehyde. Cells were imaged using 
an Orca ER camera (Hamamatsu, Inc., Bridgewater, NJ) and imaged using 
Metamorph, version 6.2 (Universal Imaging Corp., West Chester, PA). Dendritic 
cells and T-cells attached to dendritic cells were measured by using Image J software 
per condition from all images. The analysis was performed by using color 
segmentation (RGB channel separation), which was made binary and followed by 
measurement of the area of R and G channels. Similar threshold limiting was applied 
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to all images and colors. The results were reported by the percent of ratio of R 
channel area (corresponds to T cells) to G channel area (corresponds to DC). The 
percentage of T cell-conjugates was calculated. 
% T cell conjugated to DC = Area of T cells binding DCs    x 100 
                                    Area of DCs  
T cell proliferation assay 
Primary T cells isolated from C57BL/6-TgN(OT-II.2a)-Rag1 mice were labeled with 
carboxyfluorescein succinimidyl ester (CFSE) (5 M) for 10 min at 37 C, 5% CO2 
to observe the dye dilution by cell division. The staining was quenched by the 
addition of 5 volumes of culture medium into T cells and incubated 10 min at 4C. 
DCs (4 x 10
5
 cells/ml) were matured in the presence of TNF- (1,000 U/ml) and 
primed with OVA (50 g/ml) for 24 hrs in 24-well plate. DCs were treated with anti-
ICAM-1 (1 g/ml), anti-LFA-1 (5 g/ml), unconjugated NPs (2.2 mg/ml), LABL 
peptide (0.095, 0.19 and 0.38 mM), LABL-NPs (1.1, 2.2 and 4.4 mg/ml), cIBR 
peptide (0.012, 0.024 and 0.048 mM) or cIBR-NPs (1.1, 2.2 and 4.4 mg/ml) for 30 
min, at 37 C, 5% CO2 and washed three times with PBS. T cells (2 x 10
6
 cells/ml) in 
serum free RPMI-1640, IL-2 and 1% penicillin-streptomycin were incubated with 
DCs 7 days at 37C, 5% CO2.T cells collected after 24 hrs (1 day) and 168 hrs (7 
days) were centrifuged at 16,089 gfor 2 minutes and fixed with 4% 
paraformaldehyde. The CFSE dilution was measured by using FACScan flow 
cytometer. The percent of T cell proliferation was analyzed by calculating the percent 
of cells with diluted CFSE using FlowJo software. 
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Quantification of cytokines in cell culture supernatants by ELISA 
DCs were matured in the presence of TNF- (1,000 U/ml) and primed with OVA (50 
g/ml) for 24 hrs in 24-well plate. DCs were treated with anti-ICAM-1 (1 g/ml), 
anti-LFA-1 (5 g/ml), unconjugated NPs (2.2 mg/ml), LABL peptide (0.095, 0.19 
and 0.38 mM), LABL-NPs (1.1, 2.2 and 4.4 mg/ml), cIBR peptide (0.012, 0.024 and 
0.048 mM) or cIBR-NPs (1.1, 2.2 and 4.4 mg/ml) for 30 min, at 37 C, 5% CO2 and 
washed three times with PBS. T cells (2 x 10
6
 cells/ml) in serum free RPMI-1640, IL-
2 and 1% penicillin-streptomycin were incubated with DCs 7 days at 37C, 5% 
CO2.Supernatants of cell cultures were collected for cytokine detection. Secreted 
TNF-, IL-2, IL6 and IL-17 were measured by ELISA assay (Cytokine Core Lab, 
Baltimore, Maryland).  ELISA was performed in Nunc Maxisorb ELISA strips 
freshly coated with capture antibody for 16 hours before the assay was performed. 
Detecting antibody and the streptavidin- peroxidase conjugate were added into 
standard, all samples and controls. Premixed substrate solution (Neogen) was then 
added. The plate was read on a Molecular Divices ELISA plate reader. Curve fitting 
was selected among linear, quadratic and 4-point based on the best regression 
coefficient using the SoftPro software package. 
Statistical analysis 
Statistical evaluation of data was performed using an analysis of variance (one-way 
ANOVA). Newman–Keuls was used as a post-hoc test to assess the significance of 
differences. To compare the significance of the difference between the means of two 
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groups, a t-test was performed; in all cases, a value of p < 0.05 was accepted as 
significant. 
4.3 Results 
Characterization of nanoparticles and peptide-conjugated nanoparticles  
A variety of targeted and control NPs were synthesized. The size of all PLGA NP 
formulations was less than 200 nm and NPs possessed a negative zeta potential 
(Table 1). Low polydispersity values (<0.1) suggested a relatively narrow particle 
size distribution.  LABL and cIBR peptides were successfully conjugated to PLGA-
NPs. The zeta potential of LABL-NPs was more negative than unconjugated NPs, 
presumably due to the LABL peptide having a net charge of -3. cIBR-NPs had a less 
negative charge than unconjugated NPs. Pluronic
®
 F127-COOH groups were 
probably masked by the cIBR peptide, which has a net charge of +1. The amounts of 
LABL and cIBR peptides attached to NPs were determined by quantifying the 
unconjugated peptide remaining in the medium after the conjugation reaction.
23
 
LABL was conjugated with a high density, while cIBR density closely matched a 
previous publication (Table 2).
 23
 
Relative expression of ICAM-1 and LFA-1 on DCs and T cells 
Expression levels of ICAM-1 and LFA-1 on activated bone marrow derived dendritic 
cells (DCs) matured with TNF- and primed with OVA were determined using 
fluorescent anti-ICAM-1 and anti-LFA-1. DCs expressed both ICAM-1 and LFA-1 
indicating that either LABL or cIBR could be used to target these adhesion molecules 
on DCs (Figure 2A). For these studies we used primary CD4+ T cells, which express 
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an ovalbumin specific T cell receptor (OT-II). Flow cytometry data showed minimal 
expression of ICAM-1 on primary OT-II T cells but high expression of LFA-1 as 
expected (Figure 2B). Although NPs were not directly incubated with OT II T cells, 
the relative expression of these two receptors was provided for reference. 
Table 1 Nanoparticle properties of specified formulations
*
 
 NP LABL-NP cIBR-NP 
Effective diameter (nm)  154.6 ± 10.0 172.6 ± 2.5 171.9 ± 4.3 
Polydispersity 0.026 ± 0.030 0.070 ± 0.039 0.055 ± 0.005 
Zeta potential (mV)  -21.4 ± 0.4 -34.7± 2.0 -13.9 ± 0.8 
*
Values are representative of three experiments (mean ± S.D.). 
Table 2 Density of peptides on the surface of nanoparticles
*
 
 Size 
(nm) 
Total surface area 
(m
2
/g of PLGA) 
peptide density 
(pmol/cm
2
)
 
LABL-NP 172.6 25.9 265.5 ± 78.5 
cIBR-NP 171.9 26.1 39.5 ± 3.0 
*
Values are representative of three experiments (mean ± S.D.) 
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Figure 2 (A) ICAM-1 and LFA-1 expression on dendritic cells and on (B) T cells. 
OVA-primed DCs and T cells were incubated with anti-ICAM-1 and anti-LFA-1 for 
45 min on ice. Cells were washed and analyzed by flow cytometry.  ** indicates 
p<0.001 and * indicates p<0.05.  
Both LABL-NPs and cIBR-NPs exhibited rapid binding to DCs 
LABL peptide binds specifically to the domain 1 of ICAM-1, whereas cIBR peptide 
binds the I domain of LFA-1.
18-19
 LABL-NPs, cIBR-NPs and unconjugated NPs were 
incubated with DCs to investigate the binding by DCs. Immature DCs were 
stimulated with TNF- and primed with OVA for 24 hrs prior to addition of NPs.  In 
comparison to untargeted NPs, fluorescent intensities of DCs incubated with LABL-
NPs or cIBR-NPs were much higher than cells incubated with untargeted NPs at all 
incubation times. Fluorescence intensities of DCs incubated 45 minutes with LABL-
NPs or cIBR-NPs were ~2 and ~2.3 fold greater than NPs, respectively, indicating 
BA
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that the interactions of LABL-NPs and cIBR-NPs with DCs occurred more rapidly 
and to a greater extent compared to untargeted NPs (Figure 3). 
 
 
 
 
 
 
 
 
Figure 3 Binding of NPs, LABL-NPs or cIBR-NPs to dendritic cells. NPs, LABL-
NPs and cIBR-NPs were incubated with OVA-primed and TNF- activated DCs for 
15, 30, 45 or 60 min at 37 C and analyzed by flow cytometry. The interaction of 
cIBR-NPs with dendritic cells was significantlygreater than LABL-NPs and 
untargeted NPs at all time points. The fluorescence of dendritic cells incubated with 
each of the NP types increased with time. * indicates p< 0.05, ** indicates p< 0.01 
and *** indicates p< 0.001.  
Fluorescence microscopy of DCs binding nanoparticles 
The binding of NPs, LABL-NPs or cIBR-NPs by DCs was also followed using 
fluorescence microscopy. Nanoparticle fluorescence rapidly localized to DCs (Figure 
4A). Images collected using MetaMorph were analyzed using ImageJ software and 
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showed ~2 times greater fluorescence intensity of DCs incubated with LABL-NPs 
compared to untargeted NPs at 40 min (Figure 4B), thus supporting flow cytometry 
results. DCs treated with cIBR-NPs demonstrated even higher fluorescent intensities. 
These results indicated that LABL-NPs and cIBR-NPs effectively targeted DCs.  
The internalization of LABL-NPs and cIBR-NPs was supported by the 
punctate fluorescence pattern observed in the micrographs. Similar patterns were also 
reported for the uptake of untargeted NPs and cLABL-NPs in lung epithelial cells 
(A549 cells) and endothelial cells (HUVECs) expressing high levels of ICAM-1 in 
previous reports.
24-25
 The punctate pattern of cIBR-NPs appeared slightly more 
evident than LABL-NPs and untargeted NPs at 40 min of incubation (Figure 4A). 
These results supported the flow cytometry data.  
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Figure 4 (A) Fluorescent micrographs of DCs in medium (untreated), DCs incubated 
with untargeted NPs, DCs incubated with LABL-NPs and DCs incubated with cIBR-
NPs for 40 min. Punctate fluorescence patterns suggested the accumulation of NPs 
with the cells (B) Mean fluorescent intensities of DCs incubated with NP, LABL-NP 
and cIBR-NP were quantified from micrographs using ImageJ software. DCs were 
stimulated by TNF- and primed with OVA for 24 hrs prior to the study. DCs were 
then incubated with NPs, LABL-NPs and cIBR-NPs for 40 min at 37 C. * indicates 
p< 0.001. 
In vitro cellular cytotoxicity of LABL-NPs or cIBR-NPs 
Cell viability studies indicated that LABL-NPs and cIBR-NPs were minimally 
cytotoxic to DCs and T cells. The average cell viability was greater than 95% at all 
concentrations tested when LABL-NPs and cIBR-NPs were incubated with DCs for 
24 hrs (Figure 5A and 5B). For reference, the viability of T cells exposed to LABL-
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NPs and cIBR-NPs relative to untreated cells was also evaluated. After 24 hrs of 
treatment, a decrease in T cell viability was observed at LABL-NPs concentrations 
higher than 16 mg/ml (IC50 = 25.6 mg/ml). The IC50 of cIBR-NPs with T cells was 
3.4 mg/ml. From our results, we inferred that DCs were highly viable after incubation 
with these particles for 30 min in the conjugation study. DC cultures were washed to 
remove any free NPs prior to addition of primary T cells; therefore, T cell 
cytotoxicity data is only offered for references. 
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Figure 5 Dendritic cell and T cell viability in the presence of (A) LABL-NPs or (B) 
cIBR-NPs. LABL-NPs and cIBR-NPs were minimally cytotoxic to DCs and T cells 
at the concentrations used for ensuing studies.    
Peptide-NPs significantly inhibited the conjugation of DCs and T cells. 
The induction of cell proliferation and cytokine production in resting T cells requires 
binding of LFA-1 on T cells and its receptor, ICAM-1 on DCs to allow prolonged 
signaling.
3-5
 The effect of LFA-1/ICAM-1 blockade on conjugate formation between 
T cells isolated from B6.129S7-Rag1
tm1Mom
Tg(TcraTcrb)425Cbnmice and mature 
DCs primed with OVA was investigated. LABL-NP blockade of ICAM-1 on DCs led 
to a substantial decrease in the number of T cells bound to DCs (Figure 6). 
Pretreatment of DCs with LABL-NPs resulted in up to a 76% decrease in T cell 
binding to DCs compared to T cells incubated with untreated DCs. From these 
results, we inferred that LABL-NPs bound ICAM-1 expressed on DCs and blocked 
B 
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the availability of ICAM-1 to interact with LFA-1 on T cells. The number of T cells 
interacting with DCs pretreated with cIBR-NPs was decreased up to 78% compared 
to T cells incubated with untreated DCs. Untargeted NPs decreased the T cell 
conjugation to DCs by only 23%.  
In addition, free peptides were incubated at molar concentrations 
corresponding to the molar amount of peptides presented on the surface of 
nanoparticles. Peptide-conjugated nanoparticles blocked the binding of T cells to DCs 
significantly better than free peptides.  Furthermore, inhibition of the T cell 
conjugation to DCs was further enhanced by increasing LABL-NP or cIBR-NP 
concentration. These data were also analyzed by counting T cells conjugated to DCs 
(Figure 6C) and the results were in agreement with the analysis reported here using 
Image J software. 
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Figure 6 (A) Blocking of DC-T cell conjugate formation.  LABL-NPs and cIBR-NPs 
inhibited the binding of T cells to DCs to a much greater extent than free LABL and 
cIBR peptides. (B) Micrographs of T cells (red) binding DCs (green). LABL-NPs and 
cIBR-NPs exhibited greater inhibition of T cell conjugation to Dcs than LABL 
peptides, anti-ICAM-1, anti-LFA-1, NPs and untreated DCs. DCs were incubated 
with TNF and primed with OVA for 24 hrs prior to incubation with samples. DCs 
were washed and T cells were cocultured for 2 hours and T cells and DCs were 
imaged and counted. (C) LABL-NPs and cIBR-NPs inhibited the binding of T cells to 
DCs to a much greater extent than free LABL and cIBR peptides. DCs were 
incubated with samples for 30 min, washed and cocultured with T cells for 2 hours. T 
cells and DCs were imaged and counted. *** indicates p<0.001.  
C 
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Effects of LABL-NPs and cIBR-NPs on T cell proliferation 
To examine the effect of NPs on T cell proliferation, carboxyfluorescein diacetate 
succimidyl ester (CFSE) fluorescence dilution in OVA-specific T cells was analyzed 
after co-incubation with DCs for 24 hrs (1 day) and 168 hrs (7 days). DCs were 
pretreated with untargeted nanoparticles (NPs), antibodies, free peptides or peptide-
conjugated NPs. The three different molar concentrations of free peptides matched 
the molar concentration of peptide conjugated to NPs. Division of cells was 
calculated from the percentage of cells having diluted fluorescent intensity using 
Flowjo software. Untargeted NPs and cIBR-NPs incubated with DCs led to a 
substantial increase in the number of T cells undergoing division. We observed that 
89%, 78% and 41% of T cells divided following co-incubation with DCs which had 
been pretreated with NPs (2.2 mg/ml) or cIBR-NPs (4.4 and 2.2 mg/ml) for 7 days, 
respectively. In contrast, T cells incubated with untreated DCs only proliferated ~6%.  
The proliferation of T cells incubated with DCs pretreated with anti-ICAM-1, 
anti-LFA-1, LABL peptide, LABL-NPs (4.4, 2.2 and 1.1 mg/ml) or cIBR peptide 
were not substantially altered by the treatments (Figure 7). There were no significant 
differences in the levels of T cell proliferation between the groups of DCs treated 
with these samples when compared to untreated DCs. T cells alone without DCs were 
used as a negative control and yielded a T cell proliferation of only ~1.8%. 
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Figure 7 The proliferation of T cells after coculture with DCs treated with samples. 
The percent of T cells dividing after incubation for 24 hrs (1 day) and 168 hrs (7 
days) was determined by flow cytometry. DCs incubated with TNF and primed with 
OVA were incubated with samples for 30 min at 37 C. After removing samples, 
OVA specific T cells were added and incubated with DCs for 7 days. cIBR-NPs and 
untargeted NPs stimulated the proliferation of OTII T cells but other samples did not 
significantly alter T cell proliferation. *** indicates p<0.001 and * indicates p<0.05. 
Cytokine production of DCs and OT-II T cells 
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One marker for DC maturation and T cell stimulation is the production of cytokines. 
Cytokines are produced by both antigen presenting cells such as DCs and by T cells. 
DCs predominantly produce TNF-, IL-1 and IL-6.28 IL-2 is produced by CD4+ T 
cells.
28
 To observe cytokine production of DCs after treatment with peptides or 
nanoparticles, DCs matured with TNF- and primed with OVA were incubated with 
LABL peptide, cIBR peptide, LABL-NPs, cIBR-NPs, or NPs for 30 min. DC cultures 
were washed and then OT-II T cells were cocultured with DCs for 7 days and 
cytokine production was determined by enzyme-linked immunoassay (ELISA). DCs 
incubated with LABL-NPs, cIBR-NPs or NPs secreted significantly higher amounts 
of TNF- (4-5 fold), relative to untreated DCs. In contrast, the amounts of TNF- 
produced by DCs treated with LABL and cIBR peptide solutions were very low 
similar to untreated DCs (Figure 8A).  
Furthermore, the amount of IL-6 produced by coculture of T cells with DCs 
pretreated with untargeted NPs was not significantly different from the coculture of 
untreated DCs and T cells. Conversely, the amount of IL-6 produced by coculture of 
T cells with DCs pretreated with LABL peptide, cIBR peptide, LABL-NPs or cIBR-
NPs were lower than coculture of untreated DCs and T cells (Figure 8B). These 
results suggested that LABL peptide, cIBR peptide, LABL NPs and cIBR-NPs, did 
not stimulate IL-6 production, which is predominantly produced by DCs.
28 
Untargeted NPs did not alter IL-6 production relative to untreated DCs suggesting 
that these particles neither bound specifically to cell adhesion molecules nor blocked 
the activation of the OTII T cells.  
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Proliferation of naïve CD4+ T cells into effector T cells is also regulated by 
mature DCs. Coculture of OT-II T cells with DCs that had been pre-incubated with 
untargeted NPs enhanced T cell proliferation and production of IL-17, when 
compared to other treatments or controls (Figure 8C). From these results we 
concluded the presence of untargeted NPs promotes activation of T cells and may 
increase production of TGF, which is normally considered immunosuppressive. Yet, 
in the presence of IL-6, TGF- promotes the expression of IL-17 and the 
differentiation of Th17 CD4 cells.
 30
These findings are further supported by the low 
levels of IL-6 produced by LABL, cIBR, LABL-NPs and cIBR-NPs treatments which 
correlate with the production of IL-17 since IL-6 in combination with TGF- induces 
Th17 differentiation from naïve CD4+ T cells.
30
 Finally, the amount of IL-2 was 
undetectable in all media of DCs cocultured with OT-II T cells.  
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Figure 8 The production of cytokines in cocultures where DCs were pretreated with 
LABL-NPs, cIBR-NPs, untargeted NPs, LABL peptide or cIBR peptide. (A) All 
nanoparticles increased the secretion of TNF- compared to untreated DCs. (B) 
LABL-NPs, cIBR-NPs, LABL and cIBR peptides decreased the amount of IL-6 
detected in the coculture of DCs and T cells relative to untreated DCs. Untargeted 
B 
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NPs increased the level of IL-6 production in the coculture of DCs and T cells (C) 
Untargeted NPs induced the production of IL-17 from activated OT-II T cells. 
LABL-NPs, cIBR-NPs, LABL and cIBR peptides did not stimulate the production of 
IL-17. *** indicates p<0.001 and ** indicates p<0.01. 
4.4 Discussion  
A critical step in the development of an immune response is the activation of T cells. 
This process transitions naïve CD4+ T cells into effector cells. T cell activation 
begins with antigen recognition through a highly specific interaction between T cell 
receptor (TCR) and antigenic peptide presented by major histocompatibility complex 
(MHC) molecules on the surface of antigen presenting cells.
1
 The activation of a T 
cell by an APC requires the reorganization of receptors and ligands to form an 
immunological synapse. This dynamic and highly organized structure maintains the 
cell-cell interaction.
31
The immunological synapse is formed by a re-arrangement of 
receptors that form supramolecular activation clusters. The central cluster is 
comprised of TCR-peptide-MHC interaction which is surrounded by LFA-1 and 
ICAM-1 adhesion molecules, among others, in the mature immunological synapse.
32
 
The binding of TCRs to peptide-MHC complexes further activates LFA-1 on T cells 
that recognize and bind ICAM-1 on APC.
2
 This interaction strengthens the 
conjugation of APC and T cells and completes the immunological synapse which can 
lead to efficient T cell activation.
29-30
 
ICAM-1 belongs to the immunoglobulin superfamily and is expressed 
constitutively at low levels on APC, endothelial cells, and other cell types.
16
 The 
upregulation of ICAM-1 can be induced by inflammatory mediators such as IL-1.
31
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Generally, the binding of cell adhesion molecules is enhanced by oligomerization and 
clustering of the adhesion molecules.
16
 ICAM-1 rearranges into non-covalent 
homodimers on the cell surface via interactions between domain 4 (D4).
16
 Moreover, 
D4-D4 dimers can then be non-covalently linked by interaction of domain 1, resulting 
in a “W” shaped tetramer that forms linear arrays that are likely bent into circular 
arrays. This organization of ICAM-1 influences formation of the immunological 
synapse (Figure 1).
16
 
The binding of LFA-1 to ICAM-1 is also tightly regulated. The interaction of 
LFA-1 to ICAM-1 is driven by cluster formation and a change in LFA-1 
conformation leading to higher avidity and affinity, respectively.
17 
Binding of TCRs 
to peptide-MHC complexes generates intracellular signals leading to an increase in 
avidity of LFA-1 binding by forming a cluster.
17, 34
 The adhesion of DCs and T cells 
involves LFA-1 and ICAM-1 clusters, made up of thousands of molecules.
16
 The high 
densities of ICAM-1 on APCs and LFA-1 on T cells are necessary for firm, long-
lasting conjugation. Thus, the nature of T cell conjugation to DCs suggests that 
multivalent inhibitors may pose an interesting intervention.  
LABL and cIBR peptides have been shown to bind specifically to ICAM-1 
and LFA-1, respectively.
19-20
 These peptides also specifically bind their respective 
ICAM-1 and LFA-1 receptors when conjugated to nanoparticles.
23, 25 
Presenting these 
as multivalent arrays on the nanoparticle surface was hypothesized to provide more 
potent intervention strategies due to enhanced binding avidity, triggered endocytosis 
of receptors, and changes in cell response (Figure 1).
35-36 
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In this study, pretreatment of DCs with LABL-NPs yielded up to a ~76% 
decrease in T cell conjugate formation with DCs suggesting that LABL-NPs bound to 
ICAM-1 on DCs and blocked the availability of ICAM-1 to interact with LFA-1 on T 
cells. Similar results were obtained when DCs were pre-treated with cIBR-NPs. The 
quantity of T cells binding to DCs treated with cIBR-NPs was reduced by 78% when 
compared to untreated control. LABL-NPs and cIBR-NPs blocked T cell conjugation 
to DCs to a greater extent than LABL peptide, cIBR peptide, anti-ICAM-1 antibody, 
anti-LFA-1 antibody and unconjugated NPs.  
Inhibition of T cell conjugation to DCs was most likely due to an increase in 
the binding avidity of multivalent peptides and perhaps internalization of cell 
adhesion molecules facilitated by the nanoparticles.
35-36
 Multiple copies of LABL or 
cIBR peptide conjugated to the surface of nanoparticles were hypothesized to induce 
the clustering of LFA-1 and ICAM-1, hence enhancing the binding avidity of 
peptides to activated, high-density receptors. Welder et al has shown that monovalent 
soluble ICAM-1 is unable to bind efficiently to LFA-1 expressing cells unless it is 
rendered multivalent by coupling to polystyrene microspheres.
36
 Furthermore, the 
peptide-NPs were suspected to sustain inhibition by inducing receptor internalization. 
Internalization of clustered ICAM-1 on endothelial cells is known to be triggered by 
multimeric anti-ICAM-1 conjugated on microspheres, whereas monomeric anti-
ICAM-1 was not efficiently internalized.
35
 LABL-NPs and cIBR-NPs have also been 
shown to be internalized into lung epithelial cells and HUVEC cells expressing 
ICAM-1 and T cells expressing LFA-1, respectively.
23-25 
Here, the punctate staining 
166 
 
patterns observed in DCs treated with NPs indicated uptake, and presumably receptor 
internalization. 
 
 LABL-NPs, cIBR-NPs, and NPs induced TNF- production which may result 
from endocytosis or processing of particles in DCs.
37
 Indeed, PLGA nanoparticles 
have been shown to induce proinflammatory cytokine production and increase T cell 
proliferation.
38-40 
Co-incubation of T cells with DC that had been pretreated with 
untargeted NPs led to high levels of TNF-, IL-6 and IL-17 and augmented T cell 
proliferation relative to untreated DCs. A similar observation was previously reported 
in DCs treated with PLGA microspheres.
41
 LABL-NPs decreased the production of 
IL-6 from DCs and/or OT-II T cells and also resulted in a decrease the amount of IL-
17, presumably by inhibiting T cell differentiation into Th17 cells.  
DCs pretreated with cIBR-NPs also induced TNF- production and 
proliferation of OT-II T cells in a dose dependent manner. Significantly lower levels 
of IL-6 and IL-17 were produced when comparing cIBR-NPs to other NPs or to 
untreated coculture. In addition, it was unclear whether the T cells that proliferate 
following stimulation of T cells with cIBR-NP treated DC were Th1, Th2 or Th17 
cells. Based on previous reports, LFA-1 does not seem to deliver a costimulatory 
signal but improves engagement of TCR by promoting adhesion of T cells to APC.
3 
Blockade of LFA-1 on DCs would, therefore, not be expected to inhibit T cell 
activation by DCs. However it could change the T cell differentiation by changing the 
microenvironment of T cell during activation. Although cIBR-NPs blocked T cell 
conjugation to DCs initially, this effect was most likely transient, since substantial T 
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cell proliferation was observed at day 7. Data also showed that increasing cIBR-NP 
dose ultimately increased T cell proliferation. 
4.5 Conclusion     
Chemical conjugation of LABL and cIBR peptides to PLGA NPs generated efficient 
targeting to ICAM-1 and LFA-1 receptors on DCs, respectively. LABL-NPs and 
cIBR-NPs were found to be effective inhibitors of T cell conjugation to DCs. LABL-
NPs and cIBR-NPs blocked T cell conjugation to DCs more efficiently than 
untargeted NPs, free peptides and antibodies. Compared to controls, T cell 
proliferation was arrested when T cells were incubated in the presence of DCs treated 
with LABL-NPs, whereas DCs treated with cIBR-NPs or untargeted NPs 
dramatically stimulated the division of T cells. These findings suggested the potential 
of LABL-NPs to change the character of mature DCs, yet block immunological 
synapse formation without stimulating T cell proliferation and point to cIBR-NPs as 
inducers of T cell expansion. All NPs increased the production of TNF- compared 
to free ligands or untreated controls, but the amount of IL-6 or IL-7 depended on NP 
type. Collectively, results suggested that LABL-NPs and cIBR-NPs function as 
distinct immune modulators that dramatically differ from soluble peptide inhibitors of 
ICAM-1 or LFA-1.  
 
 
 
 
168 
 
References 
1         Dustin ML, Shaw AS (1999) Costimulation: Building An Immunological 
Synapse. Science, 283, 649-650. 
2. Dustin ML (2008) T-cell Activation Through Immunological Synapses and 
Kinapses. Immunol Rev, 221,77-89. 
3. Bachmann MF, McKall-Faienza K, Schmits R, Bouchard D, Beach J, Speiser 
DE, Mak TW & Ohashi PS (1997) Distinct Roles for LFA-1 and CD28 
During Activation of Naive T cells: Adhesion Versus Costimulation. 
Immunity,  7,549-557. 
4. Van Seventer GA, Shimizu Y, Horgan KJ, Shaw S (1990) The LFA-1 Ligand 
ICAM-1 Provides An Important Costimulatory Signal for T cell Receptor-
Mediated Activation of Resting T cells. J Immunol , 144, 4579-4586. 
5. Springer TA, Dustin ML, Kishimoto TK, Marlin SD (1987) The Lymphocyte 
Function-Associated LFA-1, CD2, and LFA-3 Molecules: Cell Adhesion 
Receptors of The Immune System. Annu Rev Immunol, 5, 223-252. 
6. Lunsford KE, Koester MA, Eiring  AM, Horne PH, Gao D, Bumgardner GL 
(2005) Targeting LFA-1 and CD154 Suppresses The In Vivo Activation And 
Development of Cytolytic (CD4-Independent) CD8+ T cells. J Immunol., 175, 
7855-66. 
169 
 
7.  Simnick AJ, Valencia A, Liu R, Chilkoti (2010) A. Morphing Low-Affinity 
Ligands into High-Avidity Nanoparticles by Thermally Triggered Self-
Assembly of a Genetically Enclosed Polymer. ACS Nano, 4, 2217-2227. 
8.  Stukel JM, Li RC, Maynard HD, Caplan MR (2010) Two-Step Synthesis of 
Multivalent Cancer-Targeting Constructs. Biomacromolecules, 11, 160-167. 
9.  Hong  A, Leroueil PR,  Majoros IJ, Orr BG, Baker JR, Banaszak Holl  MM 
(2007) The Binding Avidity of a Nanoparticle-Based Multivalent Targeted 
Drug Delivery Platform. Chemistry and Biology, 14, 107-115. 
10.    Johnson RN, Kopeckova P, Kopecek J (2009) Synthesis and Evaluation of 
Multivalent Branched HPMA Copolymer-Fab‟ Conjugates Targeted to the B-
Cell Antigen CD20. Bioconjugate Chem., 20, 129-137. 
11.    Ding H, Prodinger  WM, Kopecek  J (2006) Identification of CD21-Binding 
Peptides with Phage Display and Investigation of Binding Properties of 
HPMA Copolymer-Peptide Conjugates. Bioconjugate chem., 17, 514-523. 
12.  Carlson CB, Mowery P, Owen RM, Dykhuizen EC,  Kiessling LL (2007) 
Selective Tumor Cell Targeting Using Low-Affinity, Multivalent Interactions. 
ACS Chem Biol., 2, 119-27. 
13.      Puffer EB, Pontrello JK, Hollenbeck JJ, Kink  JA, Kiessling LL (2007) 
Activating B Cell Signaling with Defined Multivalent Ligands. ACS Chem 
Biol., 2, 252-62. 
170 
 
14.      Gordon EJ, Sanders WJ, Keissling LL (1998) Synthetic Ligands Point to Cell 
Surface Strategies. Nature, 392, 30-31. 
15.    Mowery P, Yang ZQ, Gordon EJ, Dwir O, Spencer AG, Alon R,Kiessling LL 
(2004) Synthetic Glycoprotein Mimics Inhibit L-Selectin-Mediated Rolling 
and Promote L-Selectin Shedding.Chem Biol., 11, 725-32. 
16.  Lebedeva T, Dustin ML, Sykulev Y (2005) ICAM-1 Co-stimulates Target 
Cells to Facilitate Antigen Presentation. Curr Opin Immunol, 17, 251-258. 
17.  Hogg N, Laschinger M, Giles K, McDowall A (2003) T-cell Integrins: More 
Than Just Sticking Points. J Cell Sci, 116, 4695-4705. 
18.  Anderson ME, Siahaan TJ (2003) Targeting ICAM-1/LFA-1 Interaction for 
Controlling Autoimmune Diseases: Designing Peptide and Small Molecule 
Inhibitors. Peptides, 24, 487–501. 
19. Anderson ME, Siahaan TJ (2003) Mechanism of Binding and Internalization 
of ICAM-1-Derived Cyclic Peptides by LFA-1 on The Surface of T cells: A 
Potential Method for Targeted Drug Delivery. Pharm Res, 20, 1523-1532. 
20. Jois SDS, Siahaan TJ (2003) A Peptide Derived from LFA-1 That Modulates 
T-cell Adhesion Binds to Soluble ICAM-1 Protein. J. Biomol. Struc. Dyn, 20, 
635-644. 
21.  Tibbetts SA, Seetharama JD, Siahaan TJ, Benedict SH, Chan MA (2000) 
Linear and Cyclic LFA-1 and ICAM-1 Peptides Inhibit T cell Adhesion and 
Function. Peptides, 21,1161-1167. 
171 
 
22. Tibbetts SA, Chirathaworn C, Nakashima M, Jois DS, Siahaan TJ, Chan MA 
& Benedict SH (1999) Peptides Derived from ICAM-1 and LFA-1 Modulate 
T cell Adhesion and Immune Function in A Mixed Lymphocyte Culture. 
Transplantation, 68, 685-692. 
23.  Chittasupho C, Manikwar P, Krise JP, Siahaan TJ, Berkland C (2010) cIBR 
Effectively Targets Nanoparticles to LFA-1 on Acute Lymphoblastic T cells. 
Mol Pharm, 7,146-155. 
24.    Zhang N, Chittasupho C, Duangrat C, Siahaan TJ, Berkland C (2008) PLGA 
Nanoparticle-Peptide Conjugate Effectively Targets Intercellular Cell-
Adhesion Molecule-1. Bioconjug Chem, 19 , 145-152. 
25.  Chittasupho C,  Xie S, Baoum A, Yakovleva T, Siahaan TJ, Berkland C 
(2009) ICAM-1 Targeting of Doxorubicin-Loaded PLGA Nanoparticles to 
Lung Epithelial Cells. European Journal of Pharmaceutical Sciences, 37, 
141-150. 
26.   Lutz MB, Kukutsch N, Ogilvie AL, Rössner S, Koch F, Romani N & Schuler G 
(1999) An Advanced Culture Method for Generating Large Quantities of 
Highly Pure Dendritic Cells from Mouse Bone Marrow. J Immunol Methods, 
223,77-92. 
27.    Guerrouache M, Karakasyan C, Gaillet C, Canva M, Millot MC (2006) 
Immobilization of A Functionalized Poly(ethylene glycol) onto -
Cyclodextrin-Coated Surfaces by Formation of Inclusion Complexes: 
172 
 
Application toThe Coupling of Proteins. J Applied Polym Sci., 100, 2362-
2370. 
28.     Commins SP, Borish L, Steinke JW (2010) Immunologic Messenger     
Molecules: Cytokines, Interferons, and Chemokines. J Allergy Clin Immunol, 
125, S53-72. 
29.   Zhu J, Yamane H, Paul WE (2010) Differentiation of Effector CD4 T cell 
Populations. Annu Rev Immunol, 28, 445-489. 
30.  Miossec P, Korn T, Kunchroo VK (2009) Mechanisms of Disease 
Interleukin-17 and Type 17 Helper T Cells. Th e new england journal of 
medicine, 361, 888-898. 
31. Dustin ML (2005) A Dynamic View of The Immunological Synapse. Semin 
Immunol, 17, 400-410. 
32. Dustin ML (2009) Modular Design of Immunological Synapses and Kinapses. 
Cold Spring Harbor Perspect Biol, 1, a002873. 
33.  Rothlein R, Dustin ML, Marlin SD, Springer TA (1986) A Human 
Intercellular Adhesion Molecule (ICAM-1) Distinct from LFA-1. J Immunol, 
137, 1270-1274. 
34.  Dustin ML, Springer TA (1989) T-cell Receptor Cross-Linking Transiently 
Stimulates Adhesiveness Through LFA-1. Nature, 341, 619-624. 
173 
 
35.  Muro S, Wiewrodt R, Thomas A, Koniaris L, Albelda SM, Muzykantov 
VR, Koval M (2003) A Novel Endocytic Pathway Induced by Clustering 
Endothelial ICAM-1 or PECAM-1. J Cell Sci., 116, 1599-609. 
36.  Welder CA, Lee DHS, Takei F (1993) Inhibition of Cell Adhesion by 
Microspheres Coated with Recombinant Soluble ICAM-1. Journal of 
Immunology, 150, 2203-2210. 
37.  Yoshida M, Babensee JE (2006) Molecular Aspects of Microparticle 
Phagocytosis by Dendritic Cells. J. Biomater. Sci. Polymer, 17, 893-907.  
38.  Semete B, Booysen LIJ, Kalombo L, Venter JD, Katata B, Ramalapa JA, 
Verschoor JA, Swai H (2010) In Vivo Uptake and Acute Immune Response to 
Orally Administered Chitosan and PEG Coated PLGA Nanoparticles. 
Toxicology and Applied Pharmacology. (e-published) 
39. Molavi O, Mahmud A, Hamdy S, Hung RW, Lai R, Samuel J, Lavasanifar A 
(2009) Development of a Poly(D,L-lactic-co-glycolic acid)Nanoparticle 
Formulation of STAT3 Inhibitor JSI-124:Implication for Cancer 
Immunotherapy. Molecular Pharmaceutics, 7, 364-374. 
40.  Steenblock  E, Fahmy TM (2008) A Comprehensive Platform for Ex Vivo T-
cellExpansion Based on Biodegradable PolymericArtificial Antigen-
presenting Cells. Molecular Therapy, 16, 765-772. 
41.  Yoshida M, Babensee JE (2006) Molecular Aspects of Microparticle 
Phagocytosis by Dendritic Cells. J. Biomater. Sci. Polymer, 17, 893-907.  
174 
 
 
 
 
 
 
 
Chapter 5 
Targeting ICAM-1 and LFA-1 by hyaluronic acid conjugates for potential 
treatment of autoimmune diseases 
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5.1 Introduction  
An ideal therapeutic intervention for autoimmune diseases would target the 
cells that are actively involved in the pathogenesis of the autoimmune disease while 
keeping protective immune responses intact. Since APCs express many different 
antigens, it may be possible to selectively block an MHC molecule that is associated 
with each autoantigen. In this approach, targeting only the subpopulation of offending 
T cells could minimize global immunosuppression. To this end, antigen-specific 
inhibition of the immunological synapse (IS) by simultaneously blocking antigen 
recognition (Signal 1) and costimulation (Signal 2) has been explored.
1, 2
 
A number of antigen peptide analogs have been shown to bind to MHC 
molecules resulting in inhibition of antigen presentation to antigen specific T cells 
and also a reduction in T cell proliferation.
3
 In addition, receptors participating in 
adhesion or costimulation have become attractive targets for immune suppression. 
Cell-cell communication at the IS includes both of these signals, orchestrated in 
thousands of receptor-ligand interactions. Valency, geometry, and duration of the IS 
are well known affect T cell activation.
4-8
 
The choice of material for multivalent ligand presentation is also important. 
Some polymeric materials used for drug delivery have been shown to modulate 
immune responses. For example, the synthetic polymers poly(lactic acid) (PLA) and 
poly(lactic-co-glycolic acid) (PLGA) are biodegradable and biocompatible, but their 
hydrophobicity has been shown to cause immune responses.
9, 10
 Studies have also 
shown that PLGA nanoparticles coated with polyethylene glycol were efficiently 
176 
 
taken up by phagocytes such as macrophages resulting in an increase in T cell 
proliferation and proinflammatory cytokine production.
11, 12
 In the previous chapter, 
untargeted PLGA NPs also induced T cell activation by stimulating T cell 
proliferation and the production of proinflammatroy cytokines including TNF-, IL-6 
and IL-17.  
Furthermore, dendritic cells treated with chitosan or PLGA films increased 
DC maturation by inducing expression of costimulatory molecules (CD86 and CD40) 
similar to LPS-matured dendritic cells. In contrast, DCs treated with alginate or 
hyaluronic acid (HA) films decreased the expression levels of these same 
molecules.
13
 
In this study, an ovalbumin (OVA) antigen and a peptide targeting ICAM-1 
(LABL) were conjugated to hyaluronic acid (HA). HA conjugates with OVA antigen, 
LABL, or a 1:1 ratio of these peptides were studied to determine DC binding, T cell 
proliferation and cytokine production.  
5.2 Materials and Methods 
Materials 
LABL peptide (ITDGEATDSG, Mw 964.95) and OVA peptide 
(ISQAVHAAHAEINEAGR, Mw 1773.93) were synthesized on a Pioneer peptide 
synthesizer (PerSeptive Biosystems, CA). Hyaluronic acid (HA, Mw ~31 kDa) was 
purchased from Lifecore (MN, USA). RPMI 1640 medium was obtained from 
Cellgro (Manassas, VA, USA). Tumor Necrosis Factor- (TNF-) was purchased 
from Promega (Madison, WI, USA). Granulocyte Macrophage-Colony Stimulating 
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Factor (GM-CSF) was purchased from Peprotech Inc. (Rocky Hill, NJ, USA). 
Carboxyfluorescein diacetate succimidyl ester (CFSE) and 5-(and-6)-
(((4cloromethyl) enzoyl)amino)tetramethylrhodamine (Orange CMTMR)were 
purchased from Invitrogen Corporation, (Carlsbad, CA). Ovalbumin was purchased 
from Sigma (St. Louis, MO). Penicillin, streptomycin and L-glutamine were 
purchased from Cellgro (Manassas, VA, USA). IL-2 was generously provided by Dr. 
Christophe Nicot at the University of Kansas Medical Center.  C57BL/6-TgN(OT-
II.2a)-Rag1 mice were purchased from Taconic Farms (Hudson, NY). C57BL/6 
wildtype mice were purchased from Jax labs (Bar Harbor, ME). 
Methods 
Cell culture and isolation 
Bone marrow derived dendritic cells were generated from C57BL/6 wildtype mice as 
described
36
.  Briefly, 2 x 10
6
 cells were isolated from bone marrow, plated on 
bacterial Petri dishes and cultured in 10 ml DC media (RPMI 1640, 10% heat 
inactivated fetal bovine serum, 100 µg/ml penicillin-streptomycin, 50 µM β-
mercaptoethanol, 20 ng/ml murine granulocyte macrophage colony stimulating factor 
(GM-CSF) (R&D), and 2 nM L-glutamine.  At 72 hours (Day 3), 10 ml of fresh DC 
media was added to each dish.  On days 6 and 8, 10 ml of supernatant and cells were 
removed, cells recovered by centrifugation (90 x g) and added back to the dish with 
fresh DC medium.  On day 9 non-adherent cells were collected.  
On day 10, T cells were isolated from C57BL/6-TgN(OT-II.2a)-Rag1 spleens by 
passing spleens through a wire mesh.  T cells were purified using a negative 
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selection, mouse T cell enrichment kit according to manufacturers‟ directions 
(EasySep).  
Conjugation of LABL and OVA peptide to HA polymer 
The aminooxy group of peptide was linked to amide group of hyaluronic acid. 
Peptides were mixed in a 1:2 molar ratio to the polymer reactive sites. Peptide-HAs 
were prepared by dissolving HA polymer (10 mg) in acetate buffer solution (20 mM, 
5 ml) of pH 5.5 ± 0.1. Then, LABL peptide (13.9 mg) or OVA peptide (24.7 mg) was 
added and mixed gently. Reaction solutions were then stirred at 500 RPM using 
magnetic stir bars for 24 hrs at room temperature. LABL-OVA-HA was prepared by 
adding LABL (6.9 mg) and OVA (12.4 mg) peptides simultaneously. The solution of 
peptide conjugated with HA (peptide-HA) was then transferred to dialysis bags 
(MWCO 3500 Da) and was dialyzed for 24 hrs with changing of water at least once 
to remove free peptides. The peptide-HAs were lyophilized.  
Characterization of LABL and/or OVA conjugated HA 
The amount of LABL and OVA peptides conjugated on HA were quantified by 
determination of free peptides in reaction medium by gradient reversed phase HPLC 
(SHIMADZU) using a C18 column. The HPLC consisted of SCL-10A SHIMADZU 
system controller, LC-10AT VP SHIMADZU liquid chromatograph, SIL-10A XL 
SHIMADZU autoinjecter set at 30 l injection volume, DGU-14A SHIMADZU 
degasser, sample cooler, and SPD-10A SHIMADZU UV-Vis detector (220 nm). The 
HPLC-UV system was controlled by a personal computer equipped with 
SHIMADZU class VP Software. All separations were carried out using a Vydac® 
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HPLC Protein and Peptide C18 column. Gradient elution was carried out to determine 
the amount of LABL and OVA peptide at constant flow of 1 ml/min. Gradient elution 
was carried out to determine the amount of LABL peptide at constant flow of 1 
ml/min, Mobile phase compositions were (A) acetronitrile-water (5:95) with 0.1% 
TFA and (B) 100% acetonitrile with 0.1% trifluoroacetic acid (TFA).  
Binding and uptake of HA, LABL-HA, OVA-HA and LABL-OVA-HA into DCs 
The binding and uptake of HA, LABL-HA, OVA-HA and LABL-OVA-
HAconjugated with FITC was monitored using fluorescence microscopy. DCs (1 x 
10
5
 cells/ml) were added in an 8 well-plate (200 l/well) and matured with TNF- 
(1,000 U/ml) and primed with OVA (50 g/ml) for 24 hrs. DCs were washed with 
PBS and incubated with HA, OVA-HA, LABL-HA and LABL-OVA-HAconjugated 
with FITC (2 mg/ml, 300 l) at 37 C for 15 min. Cells were washed three times with 
PBS and fixed with 4% paraformaldehyde. Fluorescence micrographs were acquired 
using the FITC filter set of a Nikon Eclipse 80i microscope equipped for 
epifluorescence. Micrographs were captured using an Orca ER camera (Hamamatsu, 
Inc., Bridgewater, NJ) and analyzed by Metamorph, version 6.2 (Universal Imaging 
Corp., West Chester, PA). All images were corrected for variations in excitation light 
intensity. Mean fluorescent intensity of cells incubated with HA conjugates was 
determined by using ImageJ software. 
The binding/uptake of HA conjugates into DCs was also determined and 
analyzed by using fluorescence plate reader. DCs were matured with TNF- (1,000 
U/ml) and primed with OVA (50 g/ml) for 24 hr. Cells were washed three times 
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with serum free RPMI1640 and incubated with HA, OVA-HA, LABL-HA and 
LABL-OVA-HA in serum free medium (2 mg/ml) for 15 min. After incubation, cells 
were washed three times with ice-cold PBS.  HA conjugates associated with the DCs 
were detected and compared using a fluorescence plate reader (Spectramax M5; ex: 
450 nm, em: 500 nm).  
T cell proliferation assay 
Primary T cells isolated from C57BL/6-TgN(OT-II.2a)-Rag1 mice were labeled with 
CFSE (5 M) for 10 min at 37 C, 5% CO2 to observe cell division by CFSE dilution. 
The dye reaction was quenched by the addition of 5 volumes of culture medium into 
T cells and incubated 10 min at 4C. DCs (4 x 105 cells/ml) were matured with TNF-
 (1,000 U/ml) and primed with OVA (50 g/ml) for 24 hrs in 24-well plate. DCs 
were treated with HA, LABL-HA, OVA-HA and LABL-OVA-HAconjugated with 
FITC (2 mg/ml) for 30 min, at 37 C, 5% CO2 and washed three times with PBS. T 
cells (2 x 10
6
 cells/ml) in serum free RPMI1640, IL-2 and 1% penicillin-streptomycin 
were incubated with DCs 7 days at 37C, 5% CO2.T cells collected after 24 hrs (1 
day) and 168 hrs (7 days) were centrifuged at 16,089 gfor 2 minutes and fixed with 
4% paraformaldehyde. The CFSE dilution was measured by using FACScan flow 
cytometer. The percent of T cell proliferation was analyzed by calculating the percent 
of cells with diluted CFSE using FlowJo software. 
Quantification of cytokines in cell culture supernatants by ELISA 
DCs were matured with TNF- (1,000 U/ml) and primed with OVA (50 g/ml) for 
24 hrs in 24-well plate. DCs were treated with HA, LABL-HA and LABL-OVA-HA 
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(2 mg/ml) for 30 min, at 37 C, 5% CO2 and washed three times with PBS. T cells (2 
x 10
6
 cells/ml) in serum free RPMI1640, IL-2 and 1% penicillin-streptomycin were 
incubated with DCs 7 days at 37C, 5% CO2.Supernatants of cell cultures were 
collected for cytokine detection. Secreted IFN-, TNF-, IL-4, IL-10 and IL-17 were 
measured by ELISA assay (Cytokine Core Lab, Baltimore, Maryland).  ELISA was 
performed in Nunc Maxisorb ELISA strips freshly coated with capture antibody for 
16 hours before the assay was performed. Detecting antibody and the streptavidin- 
peroxidase conjugate were added into standard, all samples and controls. Premixed 
substrate solution (Neogen) was then added. The plate was read on a Molecular 
Divices ELISA plate reader. Curve fitting was selected among linear, quadratic and 
4-point based on the best regression coefficient using the SoftPro software package. 
Statistical analysis 
Statistical evaluation of data was performed using an analysis of variance (one-way 
ANOVA). Newman–Keuls was used as a post-hoc test to assess the significance of 
differences. To compare the significance of the difference between the means of two 
groups, a t-test was performed; in all cases, a value of p < 0.05 was accepted as 
significant. 
5.3 Results and Discussion 
Characterization of peptide-HAs 
The conjugation of peptides to HA was based on a novel N-oxime reaction scheme. 
Peptides capped with an aminooxy group at the N-terminus were reacted to the 
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carbonyl group of N-acetyl amides on HA. Both LABL and OVA peptides were 
successfully grafted to HA using this conjugation reaction. The amounts of unreacted 
LABL and OVA peptides were quantified after the conjugation reaction. The 
conjugation efficiency of LABL and OVA peptides were greater than 80% in all 
cases according to HPLC data (Table 1). For these studies, the total peptide 
concentration was held constant for all reactions; therefore, LABL-OVA-HA had a 
~1:1 ratio of grafted peptide, but the same total peptide content.   
 
Table 1 Percent of peptide conjugated to HA polymer. 
 
 OVA-HA LABL-HA LABL-OVA-
HA 
% conjugation of 
LABL 
- 80.9 ± 2.7 88.2  ± 0.5 
% conjugation of 
OVA 
93.0  ± 0.2 - 89.8  ± 4.8 
 
Binding of peptide-HAs to DCs 
The binding of HA, LABL-HA, OVA-HA and LABL-OVA-HA to DCs was 
investigated in vitro by fluorescence microscopy and fluorescence spectroscopy. DCs 
were matured with TNF- and primed with OVA for 24 hrs prior to addition of HA 
conjugates labeled with the fluorophore FITC. Fluorescence microscopy revealed that 
DCs incubated for 15 min with LABL-HA and LABL-OVA-HA exhibited ~2 and 2.5 
fold higher fluorescent intensities than DCs incubated with HA, respectively. DCs 
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incubated with LABL-OVA-HA were significantly more fluorescent than those 
treated with LABL-HA (Figure 1A and B). The result was confirmed by fluorescence 
spectroscopy. Incubating DCs with LABL-HA and LABL-OVA-HA resulted in a 
significant increase in fluorescence intensity of DCs when compared to HA (Figure 
1C).  
Unanue et al. reported that free synthetic peptides can also bind directly to 
class II MHC molecules and be recognized by T cells specific for this antigen.
15-17
 
The higher fluorescence induced by LABL-OVA-HA suggested that a binding event 
involving the OVA peptide may augment the fluorescence achieved by LABL-OVA, 
whereas the OVA alone did not bind DC efficiently. These result suggested that OVA 
conjugated on HA and OVA conjugated on LABL-OVA-HA may bind MHC 
molecules with different conformations. The internalization of these peptide-HAs will 
need to be further studied. 
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Figure 1 Binding of HA conjugates to dendritic cells matured with TNF- and 
primed with OVA. (A) Micrographs of DCs incubated with HA conjugates for 15 
min. (B) Fluorescent intensities of DCs as quantified from fluorescence micrographs. 
(C) Fluorescent intensities of DCs were confirmed using fluorescence specotroscopy. 
B 
C 
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Data presented as mean ± S.D. (n=3). *** indicates p<0.001 and ** indicates p<0.05 
and * indicates p<0.01. 
T cell proliferation was reduced by the peptide-HA conjugates 
The degree of T cell proliferation was determined after coculture of DCs matured 
with TNF-α and primed with OVA and OVA-specific T cells. DCs were pretreated 
with HA, LABL-HA or LABL-OVA-HA for 30 min and then cocultured with OVA 
specific T cells. After 24 hrs (day 1) and 168 hrs (day 7), OVA-specific T cell 
proliferation was measured by dilution of fluorescent dye (CFSE) using FACScan 
flow cytometer. The percent of T cell proliferation was analyzed by calculating the 
percent of cells with diluted CFSE using FlowJo software. LABL-OVA-HA and 
LABL-HA incubated with DCs led to a statistically significant decrease in the 
number of T cells undergoing division compared to the untreated group (Figure 2). 
There were no significant differences in the level of T cell proliferation between DCs 
treated with HA compared to untreated DCs. T cells alone without DCs were used as 
a negative control and yielded a T cell proliferation of only ~0.6%.  
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Figure 2 Proliferation of T cells cocultured with DCs for 1 day and 7 days. T cell 
proliferation was determined by using flow cytometry. Data presented as mean ± S.D. 
(n=3). ** indicates p<0.01 and * indicates p<0.05. 
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Figure 3 (A) The production of TNF- in cocultures where DCs were pretreated with 
HA, LABL-HA or LABL-OVA-HA. HA and peptide-HAs decreased the secretion of 
TNF- compared to untreated DCs. *** indicates p<0.001 and ** indicates p<0.01. 
(B) The production of IL-17 in coculture of DC and T cells. The amount of IL-17 in 
coculture of T cells and DCs pretreated with HA, LABL-HA and LABL-OVA-HA 
were undetectable. Data presented as mean ± S.D. (n=3). 
HA and peptide-HAs reduced cytokine production of DCs and OT-II T cells. 
Blocking of T cell proliferation by HA and peptide-HAs suggested that HA and 
peptide-HAs may also regulate cytokine production. To determine the effect of HA 
and peptide-HAs on cytokine production, DCs matured with TNF- and primed with 
OVA were pretreated with HA, LABL-HA and LABL-OVA-HA for 30 min, washed 
with PBS, and cocultured with primary OT II T cells for 7 days. TNF- , IFN-, IL-4, 
B 
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IL-10 and IL-17 were then quantified by ELISA (Table 2). After 7 days, all 
cocultures of DCs and T cells showed undetectable levels of IFN-, IL-4, and IL-10. 
HA and peptide-HAs did not induce the production of IFN-, IL-4 and IL-6 
suggesting that HA and peptide-HAs had no effect on DC and T cell 
activation.Compared with untreated DCs, the levels of TNF- and IL-17 were 
significantly reduced in the presence of HA, LABL-HA and LABL-OVA-HA. The 
amount of TNF- in the medium of cells exposed to HA, LABL-HA and LABL-
OVA-HA was reduced from 10.9 (untreated) to 3.7, 4.1 and 8.2 ng/ml, respectively. 
This result suggested that the production of TNF- by DCs, which can induce 
inflammation, was inhibited in the presence of HA and peptide-HAs.
18
 Since TNF- 
promotes inflammatory responses, dysregulation of TNF-can lead to the 
pathogenesis of various inflammatory and autoimmune diseases.
19
 Blockade of TNF-
 has shown therapeutic efficacy in a number of T cell-dependent autoimmune 
diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, Crohn‟s disease, 
inflammatory bowel disease and psoriasis.
19, 20
 
IL-17 has been associated with the pathogenesis of a wide range of 
inflammatory and autoimmune diseases including asthma, psoriasis, rheumatoid 
arthritis (RA), inflammatory bowel disease, systemic sclerosis and systemic lupus 
erythematosus (SLE).
21, 22
 IL-17 produced from untreated cells was 13.9 ± 0.7 ng/ml, 
whereas the amount of this cytokine secreted from cells in the presence of HA and 
peptide-HAs was undetectable. The decrease in cytokine production suggested that 
HA and peptide-HAs inhibited the differentiation of Th17 CD4 cells. The binding of 
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HA and peptide-HAs to DC inhibited T cell and DC conjugate formation, hence 
inhibiting T cell proliferation and any ensuing cytokine production.  
The binding of peptide-HAs to DCs, the reduction of T cell proliferation, the 
suppression of TNF- and IL-17 production, and the lack of IFN-, IL-4 and IL-6  
suggested that these HA conjugates may be useful for targeting dendritic cells 
involved in inflammatory and autoimmune diseases. The fact that HA and peptide-
HA were not able to induce proinflammatory cytokines (IFN-, IL-4 and IL-6) 
suggested that LABL-HA and LABL-OVA-HA have potential as a multivalent, 
antigen-specific immune modulator. 
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Table 2 Summary of assayed cytokines and their functions. 
Cytokines Cell expression Functions 
TNF- Mononuclear phagocytes 
(major) and T cells 
(minor) 
18, 23
 
-Induces leukocyte extravasation 
-Upregulates adhesion molecules on endothelial 
cells  
-Regulates maturation and migration of APCs.
18
 
IFN- Effector T cells (Th1 
cells) (major) and DCs 
and Natural Killer (NK) 
cells (minor)
31
 
 
-Increases MHC class I and II expression and 
stimulates antigen presentation and cytokine 
production by APCs. 
-Stimulates the adherence and phagocytosis of 
mononuclear phagocytes
31
 
IL-4 Th2 cells (major) and 
basophils, NK T cells, 
eosinophils and mast 
cells (minor)
31
 
-Stimulates T cellproliferation and 
differentiation
31
 
IL-10 Regulatory T cells, 
monocytes and B cells
24
 
-Inhibits cytokine production from T cell and 
mononuclear phagocytes.  
-Inhibits the expression of the costimulatory 
molecules CD80 and CD86 by DCs and other 
APCs.
24
 
IL-17 Activated T cells, 
particularly Th17 cells
21, 
22
 
-Induces expression of a variety of cytokines 
and chemokines such as IL-6, IL-11, 
granulocyte colony-stimulating factor, GM-CSF 
and TGF- from non-hematopoietic cells.24 
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5.5 Conclusion     
A novel N-oxime chemistry was successfully used to conjugate LABL, OVA and 
both ligands (LABL and OVA) to HA.  HA and peptide conjugated HA rapidly 
bound to DCs. DCs treated with HA, LABL-HA, and LABL-OVA-HA significantly 
suppressed T cell proliferation and reduced the production of proinflammatory 
cytokines TNF- and IL-17 compared to untreated cells. These results suggested that 
HA serves as an effective backbone for multivalent ligand presentation. In addition, 
multivalent display of both antigen and a Signal 2 inhibitor (LABL) may ultimately 
provide antigen-specific disruption of cellular signaling leading to autoimmunity.  
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Chapter 6 
Conclusion and Future directions 
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Multivalent receptor-ligand interactions regulate many important biological 
responses. In cell-cell recognition events, pairs of receptors and ligands often occur in 
arrays and elicit a cellular response dictated by valency.
1
 For example, the 
immunological synapse (IS) requires sustained conjugate formation between T cells 
and APCs mediated by a large member of binding events, due in part to the low 
affinity and high dissociation rate of the T cell receptor. Therefore, ligands and 
receptors are clustered and arranged in an orderly manner to prolong the duration of T 
cell signaling. Multivalent ligand strategies have been shown to increase avidity of 
ligands conjugated to nanoparticles.
2 
In addition, multivalent conjugates can 
potentially improve the ligand binding specificity, induce ligand-receptor 
endocytosis, and induce unique cell responses.
3-6
 Attaching multiple copies of ligand 
to polymeric nanoparticles is one of the ways to achieve such multivalency.  
The goal of this thesis has been to develop nanoparticles that could be used to 
target specific cell surface receptors. PLGA nanoparticles (NPs) coated with PEG 
were synthesized and multiple copies of targeting ligands were attached to a reactive 
terminus of the PEG. Multiple copies of ICAM-1 or LFA-1 ligands conjugated to 
NPs were shown to enhance binding and uptake of NPs compared to untargeted NPs, 
and blocking studies established the specificity of these targeted NPs to ICAM-1 or 
LFA-1, respectively. In vitro studies of cocultures of DCs with T cells also showed 
the ability of both LABL-NPs and cIBR-NPs to shift cell responses due to NP 
binding and internalization. NPs did, however, consistently show the production of 
the proinflammatory cytokine TNF-, which led to some final studies on water 
soluble multivalent polymers. 
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HA and peptide conjugated HA also have potential to target receptor/ligand 
interactions in the IS and could inhibit T cell proliferation and cytokine production 
(IL-4, IL-6, IFN-, TNF- and IL-17). These findings have significant implications 
for the development of new therapeutic strategies in autoimmune diseases or 
inflammatory diseases in which T cell activation may play an important role. The 
actions of HA on the immune response are dependent on HA size and the 
mechanisms remain unknown. HA fragments in the 200-500 KDa range were 
reported to induce inflammatory cytokines by interacting with CD44 and TLR.
7-9
 HA 
fragments that are smaller than 100 KDa showed various effects. Low molecular 
weight HA fragments have shown to induce cytokine, chemokine and enzyme 
production by alveolar and bone marrow derived macrophages.
7, 10 
In contrast, 
Kanawa et al. reported that low Mw HA (3, 22 KDa) did not significantly affect the 
proinflammatory cytokine production by bone marrow macrophages.
11
 In addition, in 
LPS-treated macrophages, IL-6 and TNF- production levels were significantly 
reduced by the addition of low Mw HA (3 and 22 KDa), indicating the inhibitory 
effect on of low Mw HA on Toll-like receptor (TLR) signaling.
11
 Yamasaki et al. also 
found that large Mw HA induced L-1 release by macrophages, whereas extracellular 
small HA oligosaccharides did not.
12
 In chapter 5, low Mw (31 KDa) HA was used to 
conjugate targeting peptides. The results have shown that this molecular weight of 
HA did not stimulate T cell proliferation or proinflammatory cytokine production 
indicating that HA might be useful as a polymeric multivalent peptide carrier. 
Future work with this multivalent ligand targeted drug delivery systems 
should further investigate the use of HA to inhibit the immunological synapse 
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formation. This would include the blockade of DC and T cells conjugate formation by 
using LABL-OVA-HA. Furthermore, the binding mechanism of this peptide-HA 
could be determined by using anti-MHC antibody and/or anti-ICAM-1 antibody to 
block the binding of OVA and LABL, respectively to examine the binding sites of 
this conjugate. In addition, the internalization of peptide-HAs should be determined 
since it could not be excluded from the mechanism of blocking the IS. Future work 
should examine the use of peptide-HAs to deplete the clinical scores and symptoms 
of autoimmune disease animal models to evaluate the clinical efficacy of this 
conjugate. Furthermore, HA could also be conjugated to other costimulatory 
molecule ligands expressed on DC including B7, OX40L and LFA-1 to examine the 
other possibilities to block the IS.  
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